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│General introduction, aims, and outline of this thesis  _______________________________ 
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Chronic kidney disease 
Chronic kidney disease (CKD) is a major public health problem worldwide with a prevalence 
around 10% in the United States, Europe (including The Netherlands), and Asia.
1-5
 CKD is 
characterized by a progressive loss of renal function over a period of months or years, leading 
to inadequate removal of fluid and waste products from the body.
5
 CKD is defined as 
persistent renal damage (detected by a renal biopsy or markers of renal damage) and/or a 
glomerular filtration rate (GFR) smaller than 60 ml/min/1.73 m
2
 for three months or longer. 
CKD can be classified into five clinical stages based on renal damage and GFR, as shown in 
Figure 1.
5
 Once CKD progresses to stage 5 (end-stage renal disease, ESRD) initiation of renal 
replacement therapy (RRT), defined as the start of dialysis or receiving a kidney transplant, 
should be considered. 





















The prevalence of CKD, with mainly diabetes mellitus and hypertension as underlying cause, is 
rising.
1;6;7
 This rise can be explained by the ageing population and lifestyle changes (e.g. 





Once having developed CKD, the prevalence of cardiovascular events is higher compared with 
people with a normal renal function.
10;11
 CKD patients are even more likely to die of 
cardiovascular causes than to reach ESRD.
12
 This high cardiovascular burden supports the 
need for optimal cardiovascular risk-management in CKD patients. Despite the fact that only a 
small proportion of patients reach ESRD, the prevalence and incidence of ESRD patients 
receiving RRT has increased dramatically.
13;14
 In the United States, it is expected that ESRD 
incidence counts will increase with 29% and prevalence counts with 47% in the period 2007 to 
2020.
6
 These increasing numbers support the need for actions to slow down progression to 
ESRD. These actions are preferably initiated in the earlier stages (1-2) of CKD. Unfortunately, 
CKD is often diagnosed in moderate (stage 3) to advanced stages (4-5) when disease-related 
symptoms become present.
15
 Patients with stage 3 CKD should be under the care of a 
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nephrologist and treated according to guidelines
5;16
 to slow down progression to ESRD. In The 
Netherlands, once having progressed to advanced stages of CKD, patients are referred to 
outpatient clinics for specialized pre-dialysis care (Figure 1). 
Pre-dialysis care 
Pre-dialysis care in The Netherlands is an intensive and multidisciplinary care program for CKD 
stage 4 (GFR 15-30 ml/min/1.73 m
2
) and 5 (GFR <15 ml/min/1.73 m
2
) patients, not receiving 
RRT.
17
 A nephrologist, dietician, nurse, and social worker will treat and guide these patients in 
the last phase before starting RRT. During pre-dialysis care, patients are regularly seen by 
these healthcare workers. Due to the regular check-ups, possibly increasing to once a month 
in CKD stage 5, individualized care can be provided. The main goals of pre-dialysis care are to 
slow down renal function decline, prevent and treat metabolic complications (including 
cardiovascular diseases), and prepare patients for the start of RRT. The effectiveness of 
multidisciplinary pre-dialysis care on several clinical outcomes has been proven.
18-21
 To 
illustrate, patients following a multidisciplinary pre-dialysis program had a lower systolic 
blood pressure and lower mortality and hospitalization rates once having started dialysis, 
compared with patients receiving standard care. 
Slowing down renal function decline can be achieved by treating risk factors of disease 
progression, such as hypertension, proteinuria, and hyperglycemia. Metabolic complications 
treated during pre-dialysis care are anemia, hyperkalemia, mineral bone disorders, and 
metabolic acidosis. Cardiovascular risk-management focuses on both the risk factors of 
disease progression as metabolic complications, but also on hyperlipidemia and lifestyle 
factors, such as nutrition, physical activity and smoking. Current treatment options and 
targets for patients on pre-dialysis care are summarized in guidelines
22
 and an overview of 
these Dutch guidelines is presented in Table 1. Preparing patients for the start of RRT includes 
education on clinical, psychological, and social consequences of different RRT modalities (such 
as hemodialysis, peritoneal dialysis, and transplantation), or conservative treatment. This 
guidance contributes to making the best choice for each individual patient and thereby 
increases the quality of care. 
The current Dutch guidelines for pre-dialysis care
22





 CKD guidelines and partly on clinical experience in The Netherlands. For current 
pre-dialysis guidelines, the evidence used is mainly based on studies performed in CKD 
patients with earlier stages of CKD and not on studies performed in the specific population of 
patients on pre-dialysis care. Furthermore, most studies mainly focused on objective 
progression outcomes, such as renal function decline and progression to RRT/ESRD. Evidence 
is lacking on the effect of risk factors of disease progression and metabolic complications on 
more direct patient-related outcomes, such as self-assessed symptoms and health-related 
quality of life. Improving health-related quality of life is important because starting dialysis 
with a better health-related quality of life increases survival.
23;24
 Besides this, not all 
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guidelines are specified for certain important subgroups (e.g. age), despite the fact that 
patients receiving specialized pre-dialysis care are a very heterogeneous population. 
Table 1: Pre-dialysis guidelines: treatment strategies 
Progression factor / 
complication 
Target Treatment options 
Hypertension Blood pressure <130/80 mmHg Anti-hypertensive drugs, dietary changes 
(<2.4 g sodium/day, <6 g salt/day), 
lifestyle changes 
Proteinuria Urinary protein excretion <1 g/24h Anti-hypertensive drugs (ACEi/ARB), 
dietary changes (<2.4 g sodium/day, 
 0.8 g/kg protein/day) 
Hyperglycemia HbA1c <7% Balancing medication, diet and lifestyle 
factors (such as physical activity) 
Anemia Hemoglobin 6.8-7.4 mmol/l, avoid ≥8.0 
mmol/l, serum ferritin 100-500 µg/l 
Erythropoiesis stimulating agents, iron 
supplements, dietary changes 
Mineral bone disorders Calcium 2.1-2.37 mmol/l, phosphate  
0.7-1.3 mmol/l, PTH ~2-7 pmol/l 
Phosphate binders, bisphosphonates, 
calcium supplements, vitamin D, dietary 
changes 
Metabolic acidosis Serum HCO3 20-22 mmol/l Dietary changes (<2.4 g sodium/day, 0.8 
g/kg protein/day), sodium bicarbonate 
Hyperkalemia Potassium <5.5 mmol/l Dietary changes (2-3 g potassium/day), 
diuretics, cation-exchangers 
Hyperlipidemia LDL <2.5 mmol/l, non-HDL <3.4 mmol/l, 
HDL >1 mmol/l, triglycerides 2.25-4.5 
mmol/l 
Statins, dietary changes (<10 energy% 
and <1 energy% trans fatty acids) 
Lifestyle factors Stop smoking, balancing nutrition and 
physical activity 
Education ‘self-management’ 
ACEi/ARB: angiotensin-converting enzyme inhibitor/angiotensin-II receptor blocker; HbA1c: hemoglobin A1c; PTH: 
parathyroid hormone; HCO3: bicarbonate; LDL: low density lipoprotein; HDL: high density lipoprotein. 
Clinical studies used in this thesis 
PRE-dialysis PAtient REcord study (PREPARE) 
The PRE-dialysis PAtient REcord (PREPARE) study consists of a multi-center retrospective 
(PREPARE-1) and prospective (PREPARE-2) cohort study. Both studies included incident adult 
patients referred to an outpatient clinic for specialized pre-dialysis care (547 and 502 patients 
respectively). In practice, this refers to patients with an estimated GFR of <20-30 ml/min/1.73 
m
2
 and a progressive loss of renal function. For the PREPARE-1 study, patients were included 
between 1999 and 2001 and followed until the start of RRT, death, or January 1, 2008. For the 
PREPARE-2 study the inclusion period started in 2004 and ended in 2011 and follow-up of 
patients is still ongoing. In both studies, demographic, anthropometric, and clinical 
characteristics were collected at baseline and at the end of follow-up. In PREPARE-1 these 
data were extracted from medical records and in PREPARE-2 information was prospectively 
collected by the medical staff of each participating center. Additional in PREPARE-2, a health-
related quality of life questionnaire was filled in and blood and urine samples were collected. 
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Besides this, in both studies laboratory values were extracted from the electronic hospital 
information systems during the whole period of pre-dialysis care. Furthermore, in PREPARE-2 
demographic, anthropometric, and clinical characteristics were also collected each six-month 
interval. 
Leiden Longevity Study (LLS) 
The Leiden Longevity Study was designed to identify genetic determinants of familial 
longevity.
25;26
 In total, 421 Dutch families were included, with at least two alive long-lived 
siblings of 89 years or older for males and 91 years or older for females. Along with the long-
lived siblings, 1671 offspring of these families and 744 partners of these offspring, all 
Caucasian, were included. From these offspring and their partners, non-fasting blood serum 
samples were drawn and additional information was collected on self-reported lifestyle, 
information on medical history from the participants’ general practitioner, and information 
on medication use from the participants’ pharmacy. 
Objective of this thesis 
The main objective of this thesis was to estimate the effect of several important risk factors 
on disease progression in patients on specialized pre-dialysis care.  Disease progression was 
assessed objectively, as renal function decline and time until the start of RRT, and 
subjectively, as disease-related symptoms and health-related quality of life. These results can 
provide supporting evidence for current pre-dialysis guidelines or give indications to adapt 
the guidelines. 
The second objective of this thesis was to provide insight in (un)known mechanisms that 
influence renal function decline. These results may unravel new treatment strategies to slow 
down disease progression in pre-dialysis patients. 
Outline of this thesis 
Chapters 2-5 describe the effect of several risk factors on objectively assessed disease 
progression. In chapter 2 the effect of reaching the blood pressure target, according to 
current guidelines for pre-dialysis care, on disease progression is estimated. It was 
hypothesized that the effect of blood pressure may change in elderly patients due to the age-
related increase of the cardiovascular burden. Therefore, chapter 3 focuses on the effect of 
blood pressure on disease progression in elderly (≥65 year) patients. Whether proteinuria is 
still a risk marker for disease progression in patients on pre-dialysis care is presented in 
chapter 4. Furthermore, the prescription of proteinuria-lowering medication – angiotensin-
converting enzyme inhibitor and angiotensin-II receptor blocker – during pre-dialysis care is 
described. The idea is that discontinuation of these medications during pre-dialysis care may 
increase residual renal function and thereby postpone the start of RRT.
27
 For treating 
hyperlipidemia evidence is weak and contradictory, and therefore in chapter 5 the effect of 
lipid levels on disease progression is estimated. 
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Chapters 6 and 7 describe the subjectively assessed outcomes. Evidence is lacking on the 
course of symptoms and health-related quality of life during pre-dialysis care. This 
information is necessary to decide whether these outcomes are good indicators for disease 
progression and may be useful as risk markers. Therefore, chapter 6 describes the course of 
symptoms and health-related quality of life. Besides this, current guidelines state that 
targeting high hemoglobin levels in anemic CKD patients increases the risk of mortality and 
morbidity.
28
 However, studies on this topic show contradictory effects on health-related 
quality of life.
29
 Therefore, more evidence is necessary and chapter 7 estimates the effect of 
high hemoglobin levels on health-related quality of life. 
The aim of chapters 8 and 9 is to unravel (un)known mechanisms of renal function decline. 
Race (black versus white), chapter 8, and familial longevity (longevity versus non-longevity 
families), chapter 9, are associated with renal function decline. Both familial circumstances 
comprise of genetic and early environmental factors that can influence renal function decline. 
These populations are therefore ideal for revealing new mechanisms. 
All previous chapters may contribute to develop more evidence-based guidelines in the near 
future. However, guidelines can only improve quality of care for CKD patients when these 
guidelines are actually achieved. In chapter 10 we comment on an audit-based education 
program that may increase guideline achievement.   
Chapters 11 and 12 are based on methodological issues experienced in the previous chapters. 
The theoretical and practical principles of multiple imputation, a method that can be used 
when data is missing, is presented in chapter 11. Missing data were encountered in every 
analysis performed. We experienced that the method of multiple imputation performed 
better than other conventional methods, such as complete case analysis and mean 
substitution, when the reason for data being missing was dependent on patient 
characteristics. Therefore, we used this method in many chapters and the acquired 
knowledge is illustrated in the educational article presented in this chapter. Chapter 12 
contains a letter to the editor, commenting on statistical analyses performed in an article 
about the association of body mass index with disease progression in non-diabetic CKD 
patients.  
Chapter 13 discusses and interprets the results presented in all previous chapters. 
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Abstract 
Background:  To investigate whether high blood pressure accelerates renal function decline 
in patients with advanced chronic kidney disease (CKD), we studied the association of systolic 
(SBP) and diastolic blood pressure (DBP) with decline in renal function and time until the start 
of renal replacement therapy (RRT) in patients with CKD stages 4-5 on pre-dialysis care. 
Methods:  In the PRE-dialysis PAtient REcord-1 (PREPARE-1) cohort 547 incident pre-dialysis 
patients, referred as part of the usual care to outpatient clinics of eight Dutch hospitals, were 
included between 1999 and 2001 and followed until the start of RRT, mortality, or end of 
follow-up (January 1, 2008). Main outcomes were rate of decline in renal function, estimated 
as the slope of available eGFR measurements, and time until the start of RRT.  
Results:  A total of 508 patients, 57% men and median (boundaries of interquartile range) 
age of 63 (50-73) years, were available for analyses. Mean ± standard deviation decline in 
renal function was 0.35 ± 0.75 ml/min/1.73 m
2
/month. Every 10 mmHg increase in SBP or DBP 
resulted in an accelerated decline in renal function (adjusted additional decline 0.04 [95% 
confidence interval (CI) 0.02;0.07] and 0.05 [95% CI 0.00;0.11] ml/min/1.73 m
2
/month 
respectively) and an earlier start of RRT (adjusted hazard ratio (HR) 1.09 [95% CI 1.04;1.14] 
and 1.16 [95% CI 1.05;1.28] respectively). Furthermore, patients with SBP and DBP above the 
BP target of <130/80 mmHg experienced a faster decline in renal function (adjusted 
additional decline 0.31 [95% CI 0.08;0.53] ml/min/1.73 m
2
/month) and an earlier start of RRT 
(adjusted HR 2.08 [95% CI 1.25;3.44]), compared with patients who achieved the target (11%). 
Comparing the decline in renal function and rate of starting RRT between patients with only 
SBP above the target (≥130 mmHg) and patients with both SBP and DBP below the target 
(<130/80 mmHg), showed that the results were almost similar as compared with patients 
with both SBP and DBP above the target (adjusted additional decline 0.31 [95% CI 0.04;0.58] 
ml/min/1.73 m
2
/month and adjusted HR 2.24 [95% CI 1.26;3.97]). Therefore, it seems that 
especially having SBP above the target is harmful. 
Conclusion:  In pre-dialysis patients with CKD stages 4-5, having blood pressure (especially 
SBP) above the target for CKD patients (<130/80 mmHg) was associated with a faster decline 
in renal function and an earlier start of RRT. 
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Background 
Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are major public health 
problems worldwide because of rapidly increasing numbers of prevalent and incident cases.
1-3
 
The demand for pre-dialysis care is growing due to the increasing number of patients with 
late-stage CKD. Patients on pre-dialysis care need to be treated to slow down decline in renal 
function and to postpone the start of renal replacement therapy (RRT; dialysis and 
transplantation).  
High blood pressure is an important independent predictor of decline in renal function in the 
general population
4
 and in several subgroups
5-8
. Furthermore, high blood pressure is also a 




 in the general population. Once a 
person has developed early-stage CKD, blood pressure has a persisting detrimental effect on 
decline in renal function resulting in an accelerated progression to ESRD.
15-19
 However, little is 
known about the association of blood pressure with decline in renal function in patients with 
CKD stages 4-5 on pre-dialysis care. 
Therefore, it is important to study the association of blood pressure with progression of CKD 
in patients with CKD stages 4-5 on pre-dialysis care. Guidelines from the Kidney Disease 
Outcomes Quality Initiative (K/DOQI), Seventh Report of the Joint National Committee (JNC 
7), and the American Heart Association (AHA) propose a blood pressure treatment target of 
<130/80 mmHg through all stages of CKD.
20-22
 Because the use of this proposed treatment 
target of <130/80 mmHg in pre-dialysis patients is not evidence-based, it is important to 
investigate whether this target is indeed beneficial in this specific population. Therefore, the 
aim of our study was to investigate the association of systolic (SBP) and diastolic blood 
pressure (DBP) with progression of CKD as assessed by decline in renal function and time until 
the start of RRT in patients with CKD stages 4-5 on pre-dialysis care. 
Methods 
Study design and participants 
The PRE-dialysis PAtient REcord-1 (PREPARE-1) study is a follow-up study in which consecutive 
incident adult patients with CKD stages 4-5 were included from outpatient clinics of eight 
Dutch hospitals when referred for pre-dialysis care between 1999 and 2001. Patients had 
been referred to these outpatient clinics if creatinine clearance was below 20 ml/min. 
Furthermore, in these patients the need for RRT was expected within one year. Patients who 
spent less than one month on pre-dialysis care and patients with prior RRT were excluded. 
The clinical course of pre-dialysis patients was followed through the medical charts until the 
start of dialysis, transplantation, death, or January 1, 2008, whichever was earliest. 
Predefined data on demography, anthropometry, and clinical symptoms were extracted from 
medical charts at inclusion. All available data concerning laboratory measurements during 
pre-dialysis care were extracted from the hospital information systems. The study was 
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approved by the Institutional Review Boards of the participating hospitals and conducted in 
concordance with Good Clinical Practice Guidelines. 
Measurements and definitions 
Blood pressure and variables used for adjustment in multivariable analyses were assessed at 
the first pre-dialysis visit (baseline) and measured according to the standard care applied in 
each individual hospital. The standard procedure for measuring blood pressure is using a 
device dependent on cuff occlusion of the arm, with the patient in sitting or lying position. 
The blood pressure treatment target was defined as SBP <130 mmHg and DBP <80 mmHg 
according to the K/DOQI, JNC 7, and AHA guidelines.
20-22
 Estimated glomerular filtration rate 
(eGFR) was calculated using the four-variable Modification of Diet in Renal Disease (MDRD) 
formula, taking into account age, sex, race, and serum creatinine.
23
 Baseline serum creatinine 
measurement was defined as the measurement closest to the start of pre-dialysis care, within 
90 days before and 14 days after the start. 
Outcomes 
For the present analyses, the first year of pre-dialysis care was used as follow-up time 
because blood pressure was only assessed at baseline and blood pressure levels can change 
during pre-dialysis care. Therefore, we expect that the effect of baseline blood pressure on 
progression of CKD weakens after several years of follow-up. Outcomes were decline in renal 
function and time until the start of RRT. The rate of decline in renal function was estimated by 
fitting a regression line through the available eGFR measurements for each individual patient. 
This resulted in slopes expressing the monthly loss of eGFR. eGFR measurements between 
one month prior to inclusion and one year after inclusion were used and at least two 
measurements had to be available to estimate the rate of decline. Patients with eGFR 
measurements only available between one month prior to inclusion and one month 
thereafter were excluded from the analyses for decline in renal function (n=20). The start of 
RRT was defined as starting dialysis or being transplanted within the first year of pre-dialysis 
care. 
Statistical analyses 
Continuous data were expressed as mean ± standard deviation (SD) and skewed data as 
median (boundaries of interquartile range, IQR). Baseline characteristics were presented for 
the total study population and stratified in patients below or above the blood pressure 
treatment target. SBP and DBP were both analyzed in steps of 10 mmHg increase and in 
categories. We used clinically relevant categories for SBP (<130 (reference group), 130-149, 
150-169, 170-189, and ≥190 mmHg) and for DBP (<80 (reference group), 80-89, 90-99, and 
≥100 mmHg). The reference categories chosen were based on the treatment target of 
<130/80 mmHg. Furthermore, the range of the SBP and DBP categories (steps of 10 and 20 
mmHg respectively) were selected by using the distribution of these variables, to end up with 
enough power in each category. Additionally, SBP and DBP were combined based on the 
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treatment target of <130/80 mmHg. The additional effect of having DBP above 80 mmHg on 
top of having SBP above 130 mmHg, compared with the single effect of SBP ≥130 mmHg or 
DBP ≥80 mmHg, was investigated. For this analysis, patients were stratified in four categories 
based on the combination of SBP and DBP (<130/<80 (reference group), ≥130/<80, <130/≥80, 
and ≥130/≥80 mmHg). 
A linear regression analysis was used to assess the association of blood pressure with decline 
in renal function during the first year of follow-up. Multivariable analyses were used to adjust 
for the possible confounders age, sex, race, smoking, primary kidney disease, presence of 
cardiovascular disease (CVD; angina pectoris, coronary disease, and/or myocardial infarction), 
and presence of diabetes mellitus (DM).  
The Kaplan-Meier method was used to estimate the crude rate and a Cox proportional hazard 
regression analysis was used to estimate the adjusted rate of starting RRT during the first year 
of pre-dialysis care. The rate of starting RRT was adjusted for the same confounders used in 
the multivariable linear regression analyses. The time from the first pre-dialysis visit until the 
start of RRT or end of the first year of follow-up was used in the Cox proportional hazard 
regression as follow-up time. Mortality and lost to follow-up were censored events. All  
p-values are two-tailed and p<0.05 was considered statistically significant. Data were 
analyzed with PASW/SPSS version 17. 
Multiple sensitivity analyses were performed. First, sensitivity analyses were performed with 
only the first six months or with complete follow-up (until January 1, 2008) instead of the first 
year of follow-up, to investigate whether differences in follow-up time lead to different 
results. Second, a sensitivity analysis was performed with SBP and DBP stratified in quartiles 
and quintiles to make sure that the associations found are robust and not dependent on the 
choice of categories. Third, it can be argued that our analyses should be additionally adjusted 
for proteinuria, hemoglobin, and baseline eGFR. However, data regarding proteinuria, 
hemoglobin, and baseline eGFR were not available for all patients included in the analyses 
(n=405, n=444, and n=445 respectively). Therefore, adjusting for these variables was only 
performed as a sensitivity analysis, in order to maintain power. 
Results 
Baseline characteristics 
From the 547 incident pre-dialysis patients included, 525 patients had no prior RRT and spent 
more than one month on pre-dialysis care. SBP and DBP measurements at baseline were 
present for 508 patients and for 436 patients two or more eGFR measurements were 
available to estimate the rate of decline in renal function. Of these 508 patients, 89% had SBP 
and/or DBP above the blood pressure treatment target (SBP ≥130 mmHg and/or DBP ≥80 
mmHg). Most of the patients on pre-dialysis care were referred by nephrologists (76%). This 
percentage was the same in patients below and patients above the target (78% and 76% 
respectively, Table 1). Patients with SBP and/or DBP above the target were older, smoked 
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more, had a slightly higher body mass index (BMI), lower eGFR, higher levels of proteinuria, 
and a higher prevalence of CVD (Table 1). At baseline, patients with an available estimated 
rate of decline in renal function (n=436) were slightly older, had a higher eGFR, lower levels of 
proteinuria, and less co-morbidities, than patients without available eGFR data (n=72). 
Table 1: Demographic, anthropometric, and clinical characteristics at baseline for the total study population and 











Age (years) 63 (50-73) 55 (45-71) 64 (50-73) 
Sex (% men) 57 57 56 
Race (not Black, %) 97 97 96 




26 ± 5 25 ± 4 26 ± 5 
Smokers / quitters (%) 56 50 57 
Primary kidney disease (%)    
     Diabetes mellitus 17 16 17 
     Glomerulonephritis 10 14 9 
     Interstitial nephritis 16 17 15 
     Renal vascular disease/nephrosclerosis 23 17 23 




13.1 ± 5.8 14.0 ± 6.0 13.0 ± 5.7 
Proteinuria (g/24h)
4
 2.0 (0.7-3.9) 1.1 (0.6-2.9) 2.2 (0.8-4.0) 
Hemoglobin (g/dl)
5
 11.3 ± 1.6 11.4 ± 1.8 11.3 ± 1.6 
Co-morbidities (%)
 
   
     Anemia
6
 47 46 47 
     Cardiovascular disease
7
 36 28 37 
     Diabetes mellitus 27 24 27 
     Malignancy 11 10 11 
Referral to pre-dialysis care by nephrologist (%) 76 78 76 
Median with boundaries of interquartile range is given for age and proteinuria and for the other continuous variables 
mean ± standard deviation is given. 
1 
Below the target was defined as systolic blood pressure (SBP) <130 and diastolic 
blood pressure (DBP) <80 mmHg and above the target as SBP ≥130 and/or DBP ≥80 mmHg. 
2
 Available for 472 
patients. 
3
 Estimated glomerular filtration rate (eGFR) calculated with the four-variable Modification of Diet in Renal 
Disease formula and available for 445 patients. 
4
 Available for 405 patients. 
5
 Available for 444 patients.
 6
 Defined as a 
hemoglobin level <11 g/dl. 
7
 Defined as the presence of angina pectoris, coronary disease, and/or myocardial 
infarction. 
Of all patients, 92% were treated with anti-hypertensive drugs at baseline. Patients below the 
blood pressure treatment target were primarily prescribed angiotensin-converting enzyme 
(ACE) inhibitors and/or diuretics whereas patients above the target were prescribed calcium-
antagonists and beta-blockers just as often (Table 2). Angiotensin-II inhibitors were prescribed 
the least. Furthermore, the number of anti-hypertensive drug types was higher in patients 
above the blood pressure treatment target than in patients below the target. Of the patients 
treated with anti-hypertensive drugs, only 11% achieved the blood pressure treatment target 
of <130/80 mmHg. 
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Table 2: Blood pressure characteristics at baseline for the total study population and stratified by reaching the blood 











Systolic blood pressure (mmHg)
 
152 ± 27 114 ± 12 157 ± 25 
Diastolic blood pressure (mmHg)
 
83 ± 14 68 ± 8 85 ± 13 
Anti-hypertensive drug types (%)    
     ACE-inhibitor 43 60 40 
     Angiotensin-II inhibitor 20 10 21 
     Beta-blocker 39 31 40 
     Calcium antagonist 45 22 48 
     Diuretics 48 52 48 
     Other
2
 14 7 15 
Number of anti-hypertensive drug types (%)    
     0 8 9 8 
     1 26 35 24 
     2 28 33 28 
     ≥3 38 23 40 
ACE: angiotensin-converting enzyme. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) are presented 
as mean ± standard deviation. 
1 
Below the target was defined as SBP <130 and DBP <80 mmHg and above the target 
as SBP ≥130 and/or DBP ≥80 mmHg. 
2
 Defined as the prescription of alpha blocker, vasodilator, and/or central 
working agent. 
Decline in renal function 
The median (IQR) number of available eGFR measurements during the first year of follow-up 
was 9 (6-13) and 98.6% of the patients had three or more eGFR measurements. In the total 
group of 436 patients, mean ± SD decline in renal function was 0.35 ± 0.75 ml/min/1.73 
m
2
/month. Mean ± SD decline in renal function was not dependent on the number of eGFR 
measurements and was 0.37 ± 0.89, 0.38 ± 0.62, 0.41 ± 0.72, and 0.26 ± 0.71 ml/min/1.73 
m
2
/month for patients with 2-6, 7-9, 10-13 and ≥14 eGFR measurements (quartiles) 
respectively. The analysis of SBP in steps of 10 mmHg showed a linear association, every 10 
mmHg increase in SBP resulted in an accelerated decline in renal function (crude additional 
decline 0.03 [95% confidence interval (CI) 0.01;0.06] ml/min/1.73 m
2
/month, Table 3). The 
analysis of SBP stratified in categories showed similar results, every consecutive category 
above the reference category of <130 mmHg (mean ± SD decline 0.22 ± 0.74 ml/min/1.73 
m
2
/month) resulted in an accelerated decline in renal function (Table 3). 
Every 10 mmHg increase in DBP also resulted in an accelerated decline in renal function 
(crude additional decline 0.07 [95% CI 0.02;0.12] ml/min/1.73 m
2
/month, Table 3). 
Furthermore, every consecutive category above the reference category of <80 mmHg (mean ± 
SD decline of 0.26 ± 0.90 ml/min/1.73 m
2
/month) resulted in an accelerated decline in renal 
function. However, the most pronounced decline in renal function was present in patients 
with DBP ≥100 mmHg. 
Using the blood pressure treatment target (SBP <130 mmHg and DBP <80 mmHg) showed 
that patients with SBP and/or DBP above the target had an accelerated decline in renal 
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function compared with patients with SBP and DBP below the target (mean ± SD decline 0.13 
± 0.85 ml/min/1.73 m
2
/month). Adjustment for confounders did not change these results 
essentially (Table 3). 


































Systolic blood pressure (mmHg): 
Per 10 436  0.03 [0.01;0.06] 0.04 [0.02;0.07] 0.04 [0.02;0.07] 
<130 79 14.0 0
4
 0 0 
130-149 116 12.8 0.13 [-0.09;0.34] 0.15 [-0.06;0.36] 0.14 [-0.07;0.35] 
150-169 125 12.7 0.14 [-0.08;0.35] 0.19 [-0.02;0.39] 0.17 [-0.04;0.38] 
170-189 72 14.2 0.19 [-0.05;0.43] 0.27 [0.04;0.51] 0.24 [0.00;0.48] 
≥190 44 13.3 0.34 [0.06;0.61] 0.44 [0.16;0.71] 0.43 [0.15;0.70] 
Diastolic blood pressure (mmHg): 
Per 10 436  0.07 [0.02;0.12] 0.05 [0.00;0.10] 0.05 [0.00;0.11] 
<80 122 13.4 0
5
 0 0 
80-89 151 13.7 0.08 [-0.10;0.26] 0.06 [-0.12;0.23] 0.07 [-0.11;0.25] 
90-99 98 13.3 0.12 [-0.07;0.32] 0.12 [-0.08;0.31] 0.12 [-0.08;0.32] 
≥100 65 11.9 0.29 [0.07;0.52] 0.23 [0.00;0.45] 0.22 [-0.01;0.44] 
Blood pressure treatment target (mmHg): 
<130/<80 47 14.2 0
6 
0 0 
≥130/<80 75 13.0 0.21 [-0.07;0.48] 0.31 [0.04;0.58] 0.31 [0.04;0.58] 
<130/≥80 32 13.8 0.22 [-0.12;0.55] 0.21 [-0.12;0.54] 0.26 [-0.08;0.59] 
≥130/≥80 282 13.1 0.27 [0.04;0.50] 0.30 [0.08;0.53] 0.31 [0.08;0.53] 
The decline [95% confidence interval (CI)] presented for each blood pressure category indicates the additional decline 
in renal function compared with the reference category (systolic blood pressure (SBP) <130 mmHg, diastolic blood 
pressure (DBP) <80 mmHg, and SBP/DBP <130/<80 mmHg). A negative decline is equivalent to a slower decline in 
renal function. 
1
 The mean estimated glomerular filtration rate (eGFR) in ml/min/1.73 m
2
 at baseline. 
2 
Adjusted for 
sex and age. 
3
 Adjusted for sex, age, race, smoking, primary kidney disease, and the co-morbidities cardiovascular 
disease and diabetes mellitus. 
4









 The mean ± 
SD decline in renal function is 0.13 ± 0.85 ml/min/1.73 m
2
/month. 
Start of renal replacement therapy 
During the first year of follow-up, of all patients 23% started hemodialysis and 22% peritoneal 
dialysis, 1% was transplanted, 5% died, 1% was lost to follow-up while 48% were still on pre-
dialysis care. Median (IQR) follow-up time was 351 (144-365) days, while follow-up time in 
patients starting RRT was 145 (87-234) days. In patients below and above the blood pressure 
treatment target at baseline, mean eGFR was 6.7 and 8.2 ml/min/1.73 m
2
 at the start of RRT 
respectively. The crude association of SBP and DBP categories with time until the start of RRT 
is shown in Figure 1A and 1B respectively. 
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Figure 1: Kaplan-Meier curve for time until the start of renal replacement therapy 
Systolic blood pressure and time until the start of RRT












events / nr at risk 
<130 9 / 91 8 / 81 5 / 71 7 / 66 
130-149  14 / 136 18 / 120 19 / 100 9 / 78 
150-169 18 / 147 27 / 128 20 / 98 9 / 78 
170-189 14 / 83 16 / 69 8 / 52 8 / 43 



























Diastolic blood pressure and time until the start of RRT











events / nr at risk 
<80 22 / 153 19 / 128 15 / 107 7 / 90 
80-89 15 / 174 27 / 158 22 / 125 12 / 102 
90-99 9 / 106 19 / 96 14 / 76 7 / 61 



























Systolic and diastolic blood pressure and time until the start of RRT











events / nr at risk 
<130/<80 6 / 58 6 / 51 2 / 44 3 / 42 
  130/<80 16 / 95 13 / 77 13 / 63 4 / 48 
<130/  80 3 / 33 2 / 30 3 / 27 4 / 24 






























Kaplan-Meier curve for the 
association of systolic blood 
pressure (SBP), diastolic blood 
pressure (DBP) and the 
combination of SBP and DBP with 
time until the start of renal 
replacement therapy (RRT) during 
the first year of follow-up in pre-
dialysis patients. Follow-up time in 
months (during the first year of 
follow-up) on the x-axis and the 
percentage of patients on pre-
dialysis care on the y-axis is plotted 
and stratified by SBP (A), DBP (B), 
and SBP/DBP (C) blood pressure 
categories. The numbers below the 
figures give the number of patients 
‘at risk’ (n) and the events in each 
blood pressure category for three-
month intervals. 
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Table 4 shows the crude and the adjusted hazard ratios (HRs) for every 10 mmHg increase in 
SBP and DBP, and for clinically relevant blood pressure categories compared with the 
reference category of SBP <130 mmHg or DBP <80 mmHg respectively. Patients with higher 
SBP had an earlier start of RRT. On a continuous scale, every 10 mmHg increase in SBP 
resulted in an earlier start of RRT (crude HR 1.08 [95% CI 1.03;1.13]). Furthermore, the 
adjusted rate of starting RRT was 1.60 fold higher [95% CI 1.02;2.50] in patients with SBP 130-
149 mmHg compared with patients with SBP <130 mmHg (Table 4). For DBP, every 10 mmHg 
increase resulted in an earlier start of RRT (crude HR 1.15 [95% CI 1.04;1.27]). The analysis 
with categories showed that only patients with DBP ≥100 mmHg had a pronounced earlier 
start of RRT (crude HR 1.84 [95% CI 1.26;2.69], Table 4 and Figure 1B). 
Table 4: Association of systolic and diastolic blood pressure with time until the start of renal replacement therapy 
during the first year of pre-dialysis care 
 Events/n Crude HR [95% CI] Adjusted HR
1
 [95% CI] Adjusted HR
2
 [95% CI] 
Systolic blood pressure (mmHg):  
Per 10 235/508 1.08 [1.03;1.13] 1.09 [1.04;1.14] 1.09 [1.04;1.14] 
<130 29/91 1 1 1 
130-149 60/136 1.52 [0.97;2.36] 1.54 [0.99;2.41] 1.60 [1.02;2.50] 
150-169 74/147 1.82 [1.19;2.80] 1.88 [1.22;2.90] 1.96 [1.27;3.02] 
170-189 46/83 2.09 [1.31;3.32] 2.20 [1.37;3.53] 2.25 [1.40;3.63] 
≥190 26/51 2.10 [1.24;3.57] 2.27 [1.33;3.90] 2.21 [1.28;3.80] 
Diastolic blood pressure (mmHg):  
Per 10 235/508 1.15 [1.04;1.27] 1.15 [1.04;1.27] 1.16 [1.05;1.28] 
<80 63/153 1 1 1 
80-89 76/174 1.02 [0.73;1.43] 1.03 [0.74;1.44] 1.05 [0.75;1.48] 
90-99 49/106 1.09 [0.75;1.58] 1.11 [0.76;1.62] 1.11 [0.76;1.62] 
≥100 47/75 1.84 [1.26;2.69] 1.85 [1.26;2.71] 1.88 [1.27;2.78] 
Blood pressure treatment target (mmHg): 
<130/<80 17/58 1 1 1 
≥130/<80 46/95 1.93 [1.11;3.37] 2.03 [1.15;3.57] 2.24 [1.26;3.97] 
<130/≥80 12/33 1.18 [0.56;2.47] 1.18 [0.56;2.47] 1.31 [0.62;2.78] 
≥130/≥80 160/322 1.91 [1.16;3.16] 1.96 [1.19;3.23] 2.08 [1.25;3.44] 
The hazard ratio (HR) [95% confidence interval (CI)] presented for each blood pressure category indicates the 
increased rate of starting renal replacement therapy compared with the reference category (systolic blood pressure 
(SBP) <130 mmHg, diastolic blood pressure (DBP) <80 mmHg, and SBP/DBP <130/<80 mmHg). 
1
 Adjusted for sex and 
age. 
2 
Adjusted for sex, age, race, smoking, primary kidney disease, and the co-morbidities cardiovascular disease and 
diabetes mellitus. 
Using the blood pressure treatment target (SBP <130 mmHg and DBP <80 mmHg) showed 
that patients with SBP above the target and DBP below the target started RRT earlier (crude 
HR 1.93 [95% CI 1.11;3.37]) compared with patients with both SBP and DBP below the target 
(Table 4 and Figure 1C). Patients with SBP <130 mmHg (below target) and DBP ≥80 mmHg 
(above target) had a similar rate of starting RRT as the reference group (patients with SBP 
<130 mmHg and DBP <80 mmHg). Having both SBP and DBP above the treatment target 
resulted in a higher rate of starting RRT (crude HR 1.91 [95% CI 1.16;3.16]) compared with 
having both SBP and DBP below the target. Adjustment for confounders did not change these 
results essentially (Table 4). 
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Sensitivity analyses 
To test the robustness of our findings, several sensitivity analyses were performed. First, in a 
sensitivity analysis with only six months of follow-up, results of the primary analyses were 
confirmed and point estimates were similar. Analyses with complete follow-up showed the 
same trend as in the primary analyses, however the associations were somewhat diluted. 
Every 10 mmHg increase in SBP or DBP resulted in an accelerated decline in renal function 
(adjusted additional decline 0.04 [95% CI 0.01;0.07] and 0.05 [95% CI 0.00;0.11] ml/min/1.73 
m
2
/month respectively) and an earlier start of RRT (HR 1.07 [95% CI 1.03;1.11] and 1.10 [95% 
CI 1.01;1.19] respectively). Second, other choices of blood pressure categories showed the 
same results as found in the primary analyses. Third, when including the covariates 
proteinuria, hemoglobin, and baseline eGFR in the model (sample size of 404 patients), the 
point estimates for decline in renal function and time until the start of RRT remained similar. 
With every 10 mmHg increase in SBP or DBP, decline in renal function accelerates (adjusted 
additional decline 0.04 [95% CI 0.02;0.07] and 0.07 [95% CI 0.02;0.12] ml/min/1.73 m
2
/month 
respectively) and the start of RRT is earlier (HR 1.07 [95% CI 1.01;1.13] and 1.17 [95% CI 
1.04;1.31] respectively). 
Discussion 
The results of this study show that 89% of the patients with CKD stages 4-5 starting pre-
dialysis care did not reach the blood pressure treatment target of SBP <130 mmHg and DBP 
<80 mmHg, even though the majority of these patients (92%) were treated with anti-
hypertensive drugs. Both higher SBP and DBP were associated with a faster progression of 
CKD. More specific, patients with SBP ≥130 mmHg or DBP ≥100 mmHg had an accelerated 
decline in renal function (eGFR) during pre-dialysis care which was accompanied by an earlier 
start of RRT, compared with patients with SBP <130 mmHg or DBP <100 mmHg. Further 
analysis showed that in patients with SBP above the target (≥130 mmHg), additionally having 
DBP above the target (≥80 mmHg) did not result in an accelerated decline in renal function or 
an earlier start of RRT. 
Our study is the first European study to report on the association of both SBP and DBP with 
the progression of CKD, as assessed by decline in renal function and time until the start of 
RRT, in a well-defined population of pre-dialysis patients with CKD stages 4-5. Every 10 mmHg 
increase in SBP or DBP resulted in an accelerated decline in renal function (adjusted 
additional decline 0.04 [95% CI 0.02;0.07] and 0.05 [95% CI 0.00;0.11] ml/min/1.73 m
2
/month 
respectively). Our data are in line with the findings of several observational studies such as 
the MDRD study,
24
 which showed that an increased mean arterial pressure is associated with 
an accelerated decline in renal function in patients with an eGFR between 13 and 24 
ml/min/1.73 m
2
. However, CKD patients with an eGFR below 13 ml/min/1.73 m
2
 were 
excluded from the MDRD study because they were likely to start dialysis before the effect of 
diet and blood pressure control could be evaluated.
25
 Furthermore, patients with severe co-
morbidities were excluded and the patient population in the MDRD study consisted mostly of 
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patients with polycystic kidney disease. Our patients may therefore be more representative of 
patient populations as seen by treating physicians in outpatient clinics, as our patient 
selection did not restrict on etiology of the primary kidney disease, level of eGFR or severity of 
co-morbidities. The results of our study also showed that every 10 mmHg increase in SBP or 
DBP respectively resulted in an adjusted 1.09 [95% CI 1.04;1.14] and 1.16 [95% CI 1.05;1.28] 
fold increased rate of starting RRT earlier. These results are in line with a study performed by 
Levin et al.
26
, who found that every 5 mmHg increase in SBP or DBP  resulted in an earlier 
start of RRT (HR 1.02 [95% CI 1.00;1.04] and 1.05 [95% CI 1.01;1.09] respectively) in a 
Canadian cohort of patients on pre-dialysis care (CKD stages 4-5, n=4,231).  
Our data are not in line with some previous published interventional trials on the effect of 
lowering blood pressure in CKD patients.
27-29
 These studies showed that in patients with CKD 
stages 3-5 intensive blood pressure lowering (<130/80 mmHg versus <140/90 mmHg) was not 
beneficial on the progression of CKD, defined as decline in renal function or time until the 
start of dialysis, transplantation, death and/or doubling of serum creatinine. There are several 
possible explanations for these contradictory findings. First, the study populations of the trials 
differ from our study population because the trials mainly consist of patients with CKD stage 3 
and our observational cohort consists of patients with advanced stages of CKD (4-5). 
Furthermore, the trials apply many patient exclusion criteria that will result in a relatively 
more healthy study population compared with our cohort. Second, the achieved blood 
pressure target in the intensively treated patients (<130/80 mmHg) had a large overlap with 
the normal treated patients (<140/90 mmHg). This finding suggests that blood pressure 
control is very difficult in patients with advanced stages of CKD and this can explain the high 
percentage (89%) of pre-dialysis patients in our cohort not reaching the treatment target, 
which is in line with another study.
30
 It can be reasoned that blood pressure control is easier 
to achieve in patients with early stages of CKD, as shown by Nakayama et al.
31
 Finally, the 
trials found that the effect of lowering blood pressure was beneficial in patients with more 
severe proteinuria and our cohort mainly consists of patients with proteinuria (89%).  
The PREPARE-1 study has potential strengths and limitations. First, in our cohort an equal 
number of patients started hemodialysis and peritoneal dialysis and therefore the results 
cannot be generalized to the United States pre-dialysis population. Furthermore, it has been 
estimated that in the general population 36-65% of the patients with an eGFR below 15 
ml/min/1.73 m
2
 are not treated by a nephrologist.
32
 Therefore, perhaps our results cannot be 
generalized to all patients with an eGFR below 15 ml/min/1.73 m
2
, but only to those receiving 
pre-dialysis care. However, for clinical practice our cohort is a very representative and 
relevant population. Second, for estimating the rate of decline in renal function, we assumed 
that the decline in renal function is linear in advanced CKD stages. It has been shown 
previously that linearity of the course in eGFR is a plausible assumption, although on 
theoretical grounds over a longer period of time an exponential decline could be present.
24
 
Third, SBP and DBP were collected only once at the start of pre-dialysis care. This may lead to 
less precision and more variability of the SBP and DBP measurement at baseline, possibly 
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resulting in underestimated effects. Furthermore, blood pressure may change during pre-
dialysis care. A time-dependent analysis with time varying blood pressure would be more 
accurate compared with an analysis with only one blood pressure measurement at baseline. 
However, such data were not available in our study. As an alternative, we showed that when 
using follow-up of six months the association of blood pressure with decline in renal function 
and time until the start of RRT remained similar, whereas the results were somewhat diluted 
when using complete follow-up. The latter may indeed suggest that blood pressure changes 
over time. We chose to use the first year of follow-up in our primary analyses in order to have 
a more precise estimation of the association of blood pressure with decline in renal function 
and time until the start of RRT. Fourth, it is possible that the association of blood pressure 
with progression of CKD is confounded by the prognosis of patients. However, baseline 
characteristics showed that referral of patients is mainly done by nephrologists and this 
percentage is comparable between patients below and above the blood pressure treatment 
target, which may give an indication that prognosis is similar. Furthermore, adjustment for 
sex, age, race, smoking, primary kidney disease, co-morbidities, hemoglobin, eGFR, and 
proteinuria eliminated a part of this confounding effect, but we cannot exclude some residual 
confounding of our effect measures. Adjustment for decline in renal function prior to starting 
pre-dialysis care was not possible because too few eGFR measurements were available. Fifth, 
the aim of this study was to investigate the association of baseline blood pressure with 
progression of CKD irrespective of blood pressure control by medication. Therefore, the 
definition of the blood pressure treatment target was solely based on blood pressure and 
results were not adjusted for the use of anti-hypertensive drugs. Finally, data regarding 
proteinuria, hemoglobin, and baseline eGFR were not available for all patients. Therefore, in 
order to maintain power and to avoid selection bias, we chose not to include these variables 
into our primary analyses. However, after adjustment for these covariates the point estimates 
for decline in renal function and time until the start of RRT remained similar. 
What could be an explanation for the found association of hypertension with an accelerated 
decline in renal function and an earlier start of RRT? Endothelial dysfunction is a pathological 
consequence of hypertension
33
 leading to vessel damage, causing atherosclerosis, and 
subsequently arterial stiffness. Arterial stiffness in turn can lead to an increased afterload, left 
ventricular hypertrophy, reduced coronary perfusion, congestive heart failure, and altered or 
reduced blood supply to tissues including the kidney.
34
 In pre-dialysis patients, arterial 
stiffness can lead to glomerular hypertension and thereby increased glomerular permeability 
and excessive filtration of proteins. Protein ultrafiltrates are toxic to the proximal tubules, 
resulting in tubular damage and scarring. Glomerular hypertension and increased 
ultrafiltration of proteins contribute to the progression of chronic renal damage and thereby 
renal function.
35
 It is also possible that blood pressure increases as the result of an 
accelerated decline in renal function, resulting in a vicious circle between blood pressure 
increase and decline in renal function. In our cohort, arterial stiffness seems a plausible 
explanation because with increasing pulse pressure, which is a marker for arterial stiffness, 
│Blood pressure and progression to end-stage renal disease  __________________________ 
│30 
decline in renal function accelerated and time until the start of RRT decreased (data not 
shown). 
The proposed blood pressure treatment target for patients with CKD is <130/80 mmHg, 
according to the K/DOQI, JNC 7, and AHA treatment guidelines for hypertension in CKD 
patients.
20-22
 The results of our study show that pre-dialysis patients with blood pressure 
below this target have the slowest decline in renal function and the latest start of RRT. Our 
results support the beneficial effect of keeping blood pressure levels, especially for SBP, 
below this treatment target at the start of pre-dialysis care. Randomized controlled trials are 
necessary to demonstrate whether active blood pressure lowering below this target is 
beneficial in pre-dialysis patients. 
___________________________________________________________________ Chapter 2│ 
31│ 
References 
1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 
2038-2047 
2. Gilbertson DT, Liu J, Xue JL et al. Projecting the number of patients with end-stage renal disease in the United 
States to the year 2015. J Am Soc Nephrol 2005; 16: 3736-3741 
3. Stengel B, Billon S, van Dijk PC et al. Trends in the incidence of renal replacement therapy for end-stage renal 
disease in Europe, 1990-1999. Nephrol Dial Transplant 2003; 18: 1824-1833 
4. Kronborg J, Solbu M, Njolstad I, Toft I, Eriksen BO, Jenssen T. Predictors of change in estimated GFR: a 
population-based 7-year follow-up from the Tromso study. Nephrol Dial Transplant 2008; 23: 2818-2826 
5. Krop JS, Coresh J, Chambless LE et al. A community-based study of explanatory factors for the excess risk for 
early renal function decline in blacks vs whites with diabetes: the Atherosclerosis Risk in Communities study. 
Arch Intern Med 1999; 159: 1777-1783 
6. Ribstein J, Du CG, Mimran A. Glucose tolerance and age-associated decline in renal function of hypertensive 
patients. J Hypertens 2001; 19: 2257-2264 
7. Sesso R, Prado F, Vicioso B, Ramos LR. Prospective study of progression of kidney dysfunction in community-
dwelling older adults. Nephrology (Carlton ) 2008; 13: 99-103 
8. Youssef AA, Srinivasan SR, Elkasabany A, Cruickshank JK, Berenson GS. Temporal relation between blood 
pressure and serum creatinine in young adults from a biracial community: the Bogalusa Heart Study. Am J 
Hypertens 2000; 13: 770-775 
9. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a 
community-based population. JAMA 2004; 291: 844-850 
10. Yamagata K, Ishida K, Sairenchi T et al. Risk factors for chronic kidney disease in a community-based population: 
a 10-year follow-up study. Kidney Int 2007; 71: 159-166 
11. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal 
disease in subjects without baseline kidney disease. Arch Intern Med 2005; 165: 923-928 
12. Iseki K, Kimura Y, Wakugami K et al. Comparison of the effect of blood pressure on the development of stroke, 
acute myocardial infarction, and end-stage renal disease. Hypertens Res 2000; 23: 143-149 
13. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 
334: 13-18 
14. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage 
renal disease in men and women. Hypertension 2003; 41: 1341-1345 
15. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J 
Kidney Dis 2002; 39: S1-266 
16. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int 1989; 
35: 670-674 
17. Jovanovic DB, Djukanovic L. Analysis of factors influencing chronic renal failure progression. Ren Fail 1999; 21: 
177-187 
18. Locatelli F, Marcelli D, Comelli M et al. Proteinuria and blood pressure as causal components of progression to 
end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant 1996; 11: 461-467 
19. Sarnak MJ, Greene T, Wang X et al. The effect of a lower target blood pressure on the progression of kidney 
disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142: 342-
351 
20. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J 
Kidney Dis 2004; 43: S1-290 
21. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572 
22. Rosendorff C. Hypertension and coronary artery disease: a summary of the American Heart Association scientific 
statement. J Clin Hypertens (Greenwich ) 2007; 9: 790-795 
23. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular 
filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study 
Group. Ann Intern Med 1999; 130: 461-470 
│Blood pressure and progression to end-stage renal disease  __________________________ 
│32 
24. Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the Modification of Diet 
in Renal Disease Study. Kidney Int 1997; 51: 1908-1919 
25. Beck GJ, Berg RL, Coggins CH et al. Design and statistical issues of the Modification of Diet in Renal Disease Trial. 
The Modification of Diet in Renal Disease Study Group. Control Clin Trials 1991; 12: 566-586 
26. Levin A, Djurdjev O, Beaulieu M, Er L. Variability and risk factors for kidney disease progression and death 
following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 2008; 52: 661-671 
27. Appel LJ, Wright JT, Jr., Greene T et al. Intensive blood-pressure control in hypertensive chronic kidney disease. 
N Engl J Med 2010; 363: 918-929 
28. Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the 
progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 
877-884 
29. Wright JT, Jr., Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on 
progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431 
30. van Zuilen AD, Wetzels JF, Bots ML, Van Blankestijn PJ. MASTERPLAN: study of the role of nurse practitioners in 
a multifactorial intervention to reduce cardiovascular risk in chronic kidney disease patients. J Nephrol 2008; 21: 
261-267 
31. Nakayama M, Sato T, Sato H et al. Different clinical outcomes for cardiovascular events and mortality in chronic 
kidney disease according to underlying renal disease: the Gonryo study. Clin Exp Nephrol 2010; 14: 333-339 
32. John R, Webb M, Young A, Stevens PE. Unreferred chronic kidney disease: a longitudinal study. Am J Kidney Dis 
2004; 43: 825-835 
33. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004; 15: 1983-1992 
34. Gusbeth-Tatomir P, Covic A. Causes and consequences of increased arterial stiffness in chronic kidney disease 
patients. Kidney Blood Press Res 2007; 30: 97-107 









Association of blood pressure with the start of 
renal replacement therapy in elderly compared with  
young patients receiving pre-dialysis care 
 
Moniek C.M. de Goeij
 
Dinanda J. de Jager 
Diana C. Grootendorst 
Nora Voormolen 
Yvo W.J. Sijpkens 
Sandra van Dijk 
Ellen K. Hoogeveen 
Jeroen P. Kooman 
Elisabeth W. Boeschoten 
Friedo W. Dekker 
Nynke Halbesma 
for the PREPARE-1 study group 
 
Am J Hypertens 2012;25(11):1175-81 
 
 
│Blood pressure in elderly compared with young   ___________________________________ 
│34 
Abstract 
Background:  In the growing elderly pre-dialysis population, little is known about the effect 
of identified risk factors on the progression to end-stage renal disease. Therefore, we 
investigated the association of systolic (SBP) and diastolic blood pressure (DBP) with the start 
of renal replacement therapy (RRT), in elderly (≥65 years) compared with young (<65 years) 
pre-dialysis patients. 
Methods:  In the PRE-dialysis PAtient REcord-1 (PREPARE-1) cohort, 547 incident pre-dialysis 
patients, referred as part of the usual care to eight Dutch outpatient clinics, were included 
(1999-2001) and followed until the start of dialysis, transplantation, death, or until January 1, 
2008. The outcome was the start of RRT. All analyses were stratified by age; <65 years (young) 
and ≥65 years (elderly). 
Results: In young pre-dialysis patients (n=268) higher SBP (every 20 mmHg increase) and 
high DBP (DBP ≥100 mmHg compared with 80-89 mmHg) were associated with a higher rate 
of starting RRT (adjusted hazard ratio (HR) 1.21 [95% confidence interval (CI) 1.09;1.34] and 
1.74 [95% CI 1.16;2.62] respectively). However, in elderly pre-dialysis patients (n=240) only 
patients with SBP ≥180 mmHg had an increased rate compared with patients with 140-159 
mmHg (adjusted HR 2.33 [95% CI 1.41;3.87]). Furthermore, patients with DBP <70 or ≥100 
mmHg had an increased rate of starting RRT, independent of SBP, compared with patients 
with 80-89 mmHg (fully-adjusted HR 1.72 [95% CI 1.01;2.94] and 2.05 [95% CI 1.13;3.73] 
respectively).  
Conclusion:  The association of SBP and DBP with the start of RRT is different between 
elderly and young pre-dialysis patients. 
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Introduction 
Worldwide, the elderly population (≥65 years) is growing because of increased longevity and 
better treatment of morbidities.
1;2
 With increasing age, renal function declines with ~0.4 
ml/min/1.73 m
2
/year from the age of eighteen years.
3
 Besides this, in general the prevalence 
of risk factors that accelerate renal function decline (RFD), such as hypertension
4
 and diabetes 
mellitus
5
 are rising. Therefore, the prevalence of elderly patients with chronic kidney disease 
(CKD) and end-stage renal disease has increased over the last decades and will continue to 
increase.
6
 The demand for pre-dialysis care in elderly CKD patients is growing due to this 
increasing number of elderly late-stage CKD patients. To formulate evidence-based treatment 
guidelines for elderly pre-dialysis patients, further studies should focus on the effect of known 
risk factors for an accelerated progression of CKD in this specific population. 
High blood pressure (BP) is a known and important risk factor, independent of other 
cardiovascular risk factors, for accelerated RFD in the general population
7
 and throughout all 
stages of CKD
8-13
. However, studies performed in the ‘healthy’ elderly population have shown 
that low rather than high BP is associated with both higher mortality and an accelerated RFD. 
Moreover, high BP even seems protective for mortality and RFD in elderly ‘healthy’ 
subjects.
14-17
 Such an inverse association of BP (systolic, SBP, and diastolic, DBP) with 
mortality is also present in patients on dialysis
18-24




Unfortunately, at the moment an evidence-based BP treatment guideline for the growing 
elderly pre-dialysis population is lacking. Moreover, there are some indications that low BP 
may result in an accelerated RFD in elderly pre-dialysis patients. Therefore, target BP levels 
may differ between the young and elderly. As a consequence, the aim of our study was to 
investigate the association of BP (SBP and DBP) with the start of renal replacement therapy 
(RRT; dialysis and transplantation) in patients with CKD stages 4-5 on pre-dialysis care, 
stratified in young (<65 years) and elderly (≥65 years) patients. Furthermore, we used the rate 
of RFD as secondary outcome. 
Methods 
Study design and participants 
The PRE-dialysis PAtient REcord-1 (PREPARE-1) study is a follow-up study in which incident 
adult patients with CKD stages 4-5 were included at referral to pre-dialysis care between 1999 
and 2001. Referral to these outpatient clinics of eight Dutch hospitals was indicated if patients 
were expected to need RRT within one year and if their estimated creatinine clearance was 
below 20 ml/min. Patients who spent less than one month on pre-dialysis care and patients 
with prior RRT were excluded. The clinical course of pre-dialysis patients was followed 
through the medical charts from the start of pre-dialysis care until the start of dialysis, 
transplantation, death, lost to follow-up or end of study (January 1, 2008), whichever was 
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earliest. Predefined data on demography, anthropometry, and clinical symptoms were 
extracted from medical charts at inclusion and at the end of follow-up. All available data 
concerning laboratory measurements during the whole pre-dialysis period were extracted 
from the hospital information systems until January 1, 2003. The study was approved by the 
Institutional Review Boards of the participating hospitals and conducted in concordance with 
Good Clinical Practice Guidelines. 
Measurements and definitions 
BP and the variables used for adjustment in the multivariable analyses were baseline values 
assessed at the first pre-dialysis visit and measured according to the standard care applied in 
each individual outpatient clinic. In The Netherlands, the most standard procedures for 
measuring BP are the use of cuff occlusion of the arm, auscultation method or occasionally 
the use of a device, with the patient in sitting position. Hypertension at baseline was defined 
as SBP ≥130 mmHg or DBP ≥80 mmHg, and further divided into modest controlled 
hypertension (SBP 130-149 mmHg or DBP 80-89 mmHg) and poor controlled hypertension 
(SBP ≥150 mmHg or DBP ≥90 mmHg).
26
 Estimated glomerular filtration rate (eGFR) was 
calculated using the four-variable Modification of Diet in Renal Disease formula, taking into 
account age, sex, race, and measured serum creatinine.
27
 Baseline serum creatinine, 
hemoglobin, and proteinuria measurements were defined as the measurement closest to the 
start of pre-dialysis care, within 90 days before and 14-30 days after the start. 
Outcome 
The outcome was the start of RRT during complete follow-up (until January 1, 2008). As a 
secondary outcome we used rate of RFD (ml/min/1.73 m
2
/month) during complete follow-up. 
Not for all included patients this decline was calculated during complete follow-up because 
eGFR measurements were only extracted until January 1, 2003, and 96 patients had not 
reached an endpoint on that date. However, it is reliable to assume that the RFD followed a 
linear pattern
28
 before and after this date. The method used for the estimation of the rate of 
RFD has been described in detail previously.
13
 In short, a linear regression line was fitted 
through the available eGFR measurements for each individual patient. The slope of this line 
expresses the monthly loss of eGFR.  
Statistical analyses 
Continuous data were expressed as mean ± standard deviation (SD) and skewed data as 
median (boundaries of interquartile range, IQR). All analyses were performed after 
stratification by age (<65 and ≥65 years), and SBP and DBP were analyzed in categories and 
continuously, only when the association was linear. The cutoff point of 65 years to define 
young and elderly patients was based both on literature and the median age (63 years) in our 
cohort. The following categories were used for SBP (<120, 120-139, 140-159 (reference), 160-
179, and ≥180 mmHg) and for DBP (<70, 70-79, 80-89 (reference), 90-99, and ≥100 mmHg). A 
Cox proportional hazard regression analysis was used to investigate the association of SBP 
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and DBP with the start of RRT. In all analyses, mortality and lost to follow-up were censored 
events. For the secondary outcome rate of RFD, the crude median (IQR) rate of RFD was 
calculated for all categories used in the Cox proportional hazard regression analyses. We 
reported median (IQR) because RFD was not normally distributed. With a non-parametric test 
(Kruskal-Wallis) we investigated whether the crude median RFD differed between the 
categories. For all Cox proportional hazard regression analyses, multivariable models were 
used to adjust for possible confounders such as age, sex, race, smoking, primary kidney 
disease, presence of cardiovascular co-morbidities (cardiovascular disease: i.e. angina 
pectoris, coronary disease, myocardial infarction, left ventricular hypertrophy, and congestive 
heart failure), diabetes mellitus, malignancy, pulmonary disease, baseline eGFR, proteinuria 
level, and hemoglobin level. In the fully-adjusted model investigating the association of DBP in 
categories with the start of RRT, we also included continuous SBP. This was done to check 
whether the effect of DBP was independent of SBP. For the two age-categories, the 
correlation between SBP and DBP was 0.628 in young and 0.500 in elderly patients. These 
values are both below the cutoff point of 0.700 used to check whether collinearity can be of 
great influence on the results of a regression model.
29
 For body mass index, baseline eGFR, 
proteinuria level, and hemoglobin level there were subjects with missing values (n=36, n=63, 
n=103, and n=64 respectively). These missing values were imputed with multiple imputation 
(using five repetitions),
30;31
 a recommended technique where missing data for a patient are 
imputed by a value that is predicted by other known characteristics of this patient (i.e. 
demographic, anthropometric, clinical characteristics, and outcome). Furthermore, two 
sensitivity analyses were performed. First, we repeated all analyses using as determinants the 
average of the BP measurement at the start and at the end of follow-up, both SBP and DBP, 
divided into the same categories as mentioned above. Second, we repeated all analyses with 
SBP and DBP as single and quadratic continuous variables to test whether a U-shaped 
association was present. Including SBP and DBP as a continuous instead of a categorical 
variable in the model will result in more statistical power. All p-values were two-tailed and 
p<0.05 was considered statistically significant. Data were analyzed with PASW/SPSS version 
17 (SPSS, Chicago, IL). 
Results 
Baseline characteristics 
From the 547 incident pre-dialysis patients included, 525 patients had no prior RRT and spent 
more than one month on pre-dialysis care. SBP and DBP measurements at baseline were 
available for 508 patients who were included in our statistical analyses. Of these patients, 
53% were younger than 65 years (young) and 47% were 65 years or older (elderly). Elderly 
compared with young patients had a higher SBP, lower DBP, higher eGFR, lower levels of 
proteinuria, and higher prevalence of co-morbidities (Tables 1 and 2). 
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Of all patients, 92% were treated with anti-hypertensive drugs. Of the elderly patients, 45% 
received three or more different types of anti-hypertensive drugs, while among the young 
patients this was only 32% (Table 2). According to the type of medication, an angiotensin-
converting enzyme inhibitor (ACEi) was prescribed less often, an angiotensin-II receptor 
blocker (ARB) just as often, and other types of anti-hypertensive medication more frequently 
in elderly compared with young patients. 
The median (IQR) follow-up time was 53 (23-99) weeks in young and 43 (20-99) weeks in 
elderly patients. For the time until the start of RRT these numbers were 50 (21-81) and 34 
(18-89) weeks, respectively. During complete follow-up, 40% of the young patients started 
hemodialysis and 43% peritoneal dialysis, 7% were transplanted, 4% died, and 6% were lost to 
follow-up. In elderly patients, 46% started hemodialysis and 27% peritoneal dialysis, 0% was 
transplanted, 20% died, and 7% were lost to follow-up. 
Table 1: Demographic, anthropometric, and clinical characteristics at baseline for the total study population and 
stratified in young and elderly patients 









Age (years) 63 (50-73) 50 (40-57) 73 (69-77) 
Sex (% men) 57 53 60 
Race (not Black, %) 97 94 99 




 25.8 ± 4.7 25.3 ± 4.8 26.3 ± 4.5 
Smokers / quitters (%) 56 52 60 
Primary kidney disease (%)
2
    
     Diabetes mellitus 17 14 20 
     Glomerulonephritis 10 14 5 
     Interstitial nephropathy 16 17 14 
     Renal vascular disease/nephrosclerosis 23 15 31 




13.2 ± 5.8 12.7 ± 5.4 13.8 ± 6.2 
Proteinuria (g/24h)
1
 2.0 (0.7-3.9) 2.4 (0.8-4.2) 1.8 (0.7-3.4) 
Hemoglobin (g/dl)
1
 11.3 ± 1.6 11.4 ± 1.7 11.3 ± 1.6 
Co-morbidities (%)    
     Cardiovascular disease
4
 48 35 64 
     Diabetes mellitus
5
 27 17 38 
     Malignancy 11 6 17 
     Pulmonary disease 15 10 21 
Median (boundaries of interquartile range) is given for age and proteinuria and for the other continuous variables 
mean ± standard deviation is given. 
1
 Body mass index was available for 472, proteinuria for 405, and hemoglobin 
level for 444 patients. 
2
 Classified into seven categories according to the European Renal Association / European 
Dialysis and Transplantation Association. 
3
 Estimated glomerular filtration rate (eGFR) is calculated with the four-
variable Modification of Diet in Renal Disease formula and available for 445 patients. 
4
 Defined as presence of angina 
pectoris, coronary disease, congestive heart failure, left ventricular hypertrophy, and myocardial infarction.  
5
 Defined as the presence of diabetes mellitus as primary kidney disease or co-morbidity. 
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Table 2: Blood pressure characteristics at baseline for the total study population and stratified in young and elderly 
patients 









Systolic blood pressure (mmHg)
 
152 ± 27 148 ± 28 157 ± 26 
Diastolic blood pressure (mmHg)
 
83 ± 14 86 ± 14 80 ± 13 
Pulse pressure (mmHg) 69 ± 23 62 ± 22 77 ± 23 
Hypertension (%)
1 
   
     Moderate controlled 26 28 24 
     Poor controlled 63 59 67 
Isolated hypertension (%)
2
 39 28 51 
Anti-hypertensive drug types (%)    
     ACE-inhibitor 43 47 38 
     Angiotensin-II receptor blocker 20 19 20 
     Beta-blocker 39 36 41 
     Calcium antagonist 45 42 49 
     Diuretic 48 43 54 
     Other
3
 14 12 17 
Number of anti-hypertensive drug types (%)    
     0 8 8 8 
     1 26 29 22 
     2 28 31 25 
     ≥3 38 32 45 
ACE: angiotensin-converting enzyme. Systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse 
pressure are given as mean ± standard deviation. 
1
 Defined as moderate controlled (SBP 130-149 mmHg or DBP 80-89 
mmHg) and poor controlled hypertension (SBP ≥150 mmHg or DBP ≥90 mmHg). 
2 
Defined as SBP ≥140 mmHg and 
DBP <90 mmHg. 
3 
Defined as prescription of an alpha blocker, vasodilator, or central working agent. 
Association of BP with the start of RRT 
Young patients with SBP <120 mmHg had a lower rate of starting RRT compared with young 
patients with SBP 140-159 mmHg (adjusted hazard ratio (HR) 0.81 [95% confidence interval 
(CI) 0.47;1.42], Table 3). Young patients with a SBP ≥180 mmHg had a higher rate of starting 
RRT compared with young patients with SBP 140-159 mmHg. Analyzing SBP in categories of 
20 mmHg resulted in the same pattern, every 20 mmHg increase in SBP was associated with a 
higher rate of starting RRT (adjusted HR 1.21 [95% CI 1.09;1.34]). Young patients with DBP 
≥100 mmHg had an adjusted 1.74 [95% CI 1.16;2.62] fold increased rate of starting RRT than 
young patients with DBP 80-89 mmHg (Table 4). This effect was diluted after including SBP in 
the model (Figure 1). 
Elderly patients with SBP <120 mmHg had an increased rate of starting RRT compared with 
elderly patients with SBP 140-159 mmHg (adjusted HR 2.82 [95% CI 1.21;6.59], Table 3). 
However, the number of patients (n=12) and events (n=9) in the category SBP <120 mmHg 
were too small to draw firm conclusions. In line with the results found for young patients with 
a high SBP, elderly patients with SBP ≥180 mmHg had a higher rate of starting RRT, compared 
with the reference category (elderly patients with SBP 140-159 mmHg). The association of 
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DBP with the start of RRT in elderly patients showed a U-shaped pattern because elderly 
patients with DBP <70 mmHg (adjusted HR 1.60 [95% CI 0.95;2.70]) or ≥100 mmHg (adjusted 
HR 2.32 [95% CI 1.33;4.04]) had an increased rate compared with elderly patients with DBP 
80-89 mmHg (Table 4). Including SBP in the model resulted in an even stronger U-shaped 
pattern (fully-adjusted HR 1.72 [95% CI 1.01;2.94] and 2.05 [95% CI 1.13;3.73] respectively, 
Figure 1). 
Figure 1: Association of diastolic blood pressure with the rate of starting renal replacement therapy 













































Table 3: Association of systolic blood pressure with the start of renal replacement therapy, stratified in young and 
elderly patients 

















<65 years (young patients)   
<120    20/24 0.69 [0.42;1.14] 0.73 [0.44;1.20] 0.81 [0.47;1.42] -0.27 (-0.37;-0.03)
4 
120-139 62/73 0.92 [0.65;1.30] 0.93 [0.66;1.32] 0.96 [0.66;1.41] -0.32 (-0.48;-0.18) 
140-159 68/76 1 1 1 -0.35 (-0.58;-0.17) 
160-179 55/56 1.56 [1.09;2.24] 1.53 [1.07;2.20] 1.54 [1.03;2.29] -0.42 (-0.68;-0.26) 
≥180 36/39 1.71 [1.14;2.56] 1.89 [1.25;2.87] 1.88 [1.18;3.00] -0.51 (-0.99;-0.19) 
≥65 years (elderly patients)   
<120    9/12 1.31 [0.64;2.69] 1.42 [0.69;2.93] 2.82 [1.21;6.59] -0.11 (-0.28;0.47) 
120-139 22/36 0.74 [0.44;1.24] 0.72 [0.43;1.22] 1.04 [0.59;1.84] -0.26 (-0.43;0.13) 
140-159 43/61 1 1 1 -0.15 (-0.35;0.02) 
160-179 65/85 0.97 [0.66;1.43] 0.96 [0.65;1.42] 1.23 [0.80;1.89] -0.21 (-0.44;-0.04) 
≥180 36/46 1.14 [0.73;1.77] 1.12 [0.72;1.75] 2.33 [1.41;3.87] -0.34 (-0.65;-0.06) 
The hazard ratio (HR) [95% confidence interval (CI)] gives the increased rate of starting renal replacement therapy for 
each systolic blood pressure (SBP) category compared with the reference category (140-159 mmHg). 
1
 Adjusted for 
sex and age. 
2
 Adjusted for sex, age, race, smoking, primary kidney disease, cardiovascular disease, diabetes mellitus, 
malignancy, pulmonary disease, baseline estimated glomerular filtration rate, proteinuria, and hemoglobin. 
3
 Median 
(boundaries of interquartile range (IQR)) renal function decline (RFD). 
4
 The p-value from the non-parametric 
(Kruskal-Wallis) test, investigating whether RFD differs between the SBP categories, is ≥0.05-<0.10. 
Association of diastolic blood pressure (DBP) with the 
rate of starting renal replacement therapy (RRT), fully-
adjusted; including systolic blood pressure (SBP), in 
young (<65 years, left part of graph, closed dots) and 
elderly (≥65 years, right part of graph, open dots) pre-
dialysis patients. The hazard ratio (HR, closed or open 
black dot) and its 95% confidence interval (95% CI, 
black lines) gives the increased rate of starting RRT for 
each category compared to the reference category 
(80-89 mmHg) stratified by age. The HRs are adjusted 
for sex, race, smoking, primary kidney disease, 
cardiovascular disease, diabetes mellitus, malignancy, 
pulmonary disease, baseline estimated glomerular 
filtration rate, proteinuria level, hemoglobin level, and 
SBP. 
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Table 4: Association of diastolic blood pressure with the start of renal replacement therapy, stratified in young and 
elderly patients 

















<65 years (young patients)   
<70 7/9 1.07 [0.50;2.32] 1.10 [0.51;2.39] 0.74 [0.29;1.87] -0.27 (-0.48;0.10)
4
 
70-79 49/55 0.99 [0.70;1.42] 0.97 [0.68;1.39] 0.83 [0.56;1.23] -0.28 (-0.44;-0.11) 
80-89 84/96 1 1 1 -0.35 (-0.62;-0.18) 
90-99 53/57 1.27 [0.90;1.80] 1.27 [0.90;1.80] 0.99 [0.66;1. 49] -0.35 (-0.69;-0.21) 
≥100 48/51 1.97 [1.38;2.83] 1.94 [1.35;2.78] 1.74 [1.16;2.62] -0.51 (-1.04;-0.20) 
≥65 years (elderly patients)   
<70 27/35 1.39 [0.87;2.22] 1.38 [0.86;2.23] 1.60 [0.95;2.70] -0.14 (-0.38;0.12) 
70-79 39/54 1.15 [0.76;1.75] 1.14 [0.75;1.74] 1.50 [0.96;2.35] -0.16 (-0.38;0.04) 
80-89 52/78 1 1 1 -0.19 (-0.44;-0.03) 
90-99 36/49 1.03 [0.67;1.58] 1.03 [0.67;1.58] 1.32 [0.83;2.08] -0.28 (-0.43;-0.04) 
≥100 21/24 1.61 [0.96;2.67] 1.51 [0.90;2.54] 2.32 [1.33;4.04] -0.27 (-0.70;0.03) 
The hazard ratio (HR) [95% confidence interval (CI)] gives the increased rate of starting renal replacement therapy for 
each diastolic blood pressure (DBP) category compared with the reference category (80-89 mmHg). 
1
 Adjusted for sex 
and age. 
2
 Adjusted for sex, age, race, smoking, primary kidney disease, cardiovascular disease, diabetes mellitus, 
malignancy, pulmonary disease, baseline estimated glomerular filtration rate, proteinuria, and hemoglobin. 
3
 Median 
(boundaries of interquartile range (IQR)) renal function decline (RFD). 
4
 The p-value from the non-parametric 
(Kruskal-Wallis) test, investigating whether RFD differs between the DBP categories, is ≥0.05-<0.10. 
Sensitivity analyses 
The results remained comparable when taking the average of the SBP and DBP measurements 
at the start and at the end of follow-up as determinants (ten and twelve young and nine and 
twelve elderly patients had missing SBP and DBP measurements, respectively, at the end of 
follow-up and were therefore not included in this analysis). In young patients the HRs for the 
SBP categories were; 0.68 [95% CI 0.38;1.21] for <120 mmHg, 1.09 [95% CI 0.77;1.54] for 120-
139 mmHg, 1.53 [95% CI 1.03;2.28] for 160-179 mmHg, and 2.08 [95% CI 1.15;3.77] for ≥180 
mmHg compared with the reference group (140-159 mmHg). In elderly patients these HRs 
were 2.38 [95% CI 1.02;5.53], 0.79 [95% CI 0.48;1.29], 1.29 [95% CI 0.84;1.97], and 1.91 [95% 
CI 1.12;3.23] respectively. In young patients the HRs for the DBP categories were; 0.46 [95% CI 
0.17;1.26] for <70 mmHg, 0.71 [95% CI 0.49;1.01] for 70-79 mmHg, 1.09 [95% CI 0.75;1.58] for 
90-99 mmHg, and 1.54 [95% CI 0.92;2.56] for ≥100 mmHg compared with the reference group 
(80-89 mmHg). In elderly patients these HRs were 2.27 [95% CI 1.34;3.83], 1.15 [95% CI 
0.75;1.76], 1.87 [95% CI 1.07;3.25], and 2.22 [95% CI 0.89;5.50] respectively. Second, the 
quadratic term for DBP in elderly patients was significant (p=0.003) indicating a U-shaped 
association. 
Discussion 
The association of BP with the start of RRT was different in elderly (≥65 years) compared with 
young (<65 years) pre-dialysis patients. In young pre-dialysis patients, the rate of starting RRT 
increases with increasing SBP and with high DBP (≥100 mmHg). Only elderly patients in the 
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highest SBP category (≥180 mmHg) had an increased rate of starting RRT. DBP showed a U-
shaped association with the start of RRT in elderly pre-dialysis patients because elderly 
patients with DBP <70 mmHg or ≥100 mmHg had a higher rate than patients with DBP 80-89 
mmHg. In conclusion, our analyses may indicate that in young pre-dialysis patients a SBP 
and/or DBP as low as possible is beneficial. In elderly pre-dialysis patients, a moderate 
increased SBP and DBP does not seem harmful. In this specific patient group only very high 
SBP and DBP, and low DBP, were associated with a higher rate of starting RRT.  
 Our study shows that in young pre-dialysis patients high BP (SBP and DBP) accelerates the 
need to start with RRT, which is in line with several other studies performed in patients with 
CKD stages 3-5.
13;28;32
 As far as we know, no other study focused on this association in young 
compared with elderly well defined pre-dialysis patients. We found a smaller effect size, 
crude and sex- and age-adjusted, of BP with the start of RRT in elderly compared with young 
pre-dialysis patients. A possible explanation for this smaller effect size could be differences in 
the composition of factors that influence the decision to start with RRT between elderly and 
young patients, such as levels of eGFR, the presence of co-morbidities, prognosis, anticipated 
quality of life, treatment burden, and preference of the patients.
6;33;34
 This explanation seems 
plausible, as in the elderly pre-dialysis patients the effect sizes became higher and more 
similar to the young pre-dialysis patients after adjustment for factors influencing prognosis. 
Furthermore, we found that in elderly pre-dialysis patients both low and high DBP accelerates 
the need to start with RRT. An association of low DBP with a faster RFD has also been found in 
the general ‘healthy’ elderly population.
15
 Besides the elderly population, patients with 
cardiovascular disease also have a higher risk of a second cardiovascular event when they 
have a low DBP.
35;36
 This harmful effect of DBP is probably due to the fact that a low DBP 
often coincides with the presence of cardiovascular co-morbidities, such as congestive heart 
failure, myocardial infarction, and/or valvular heart disease. 
The PREPARE-1 study has some limitations. First, our results cannot be generalized to all 
patients with CKD stages 4-5, only to those patients receiving pre-dialysis care in an 
outpatient clinic. However, for clinical practice our cohort is a very representative and 
relevant population. Second, SBP and DBP were collected only once at the start of pre-dialysis 
care. This type of collection may lead to less precision and more variability of the BP 
measurements at baseline, and thereby may result in underestimated effects. Furthermore, 
during pre-dialysis care BP could change due to treatment with anti-hypertensive drugs. 
Therefore, an analysis with time-varying BP would be interesting, but not possible with the 
data available (only BP measurement at the start and end of follow-up). Third, we used the 
complete follow-up in our cohort providing us with enough events in each of the five 
categories used in our analyses. However, previous analyses
13
 showed that the association of 
BP with the start of RRT is somewhat diluted when complete instead of six or twelve months 
of follow-up is being used. Therefore, our results may be an underestimation of the real 
effect. Fourth, PREPARE-1 is an observational study including pre-dialysis patients when 
referred to an outpatient clinic. The clinical moment of referral differs between pre-dialysis 
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patients. Therefore, differences in prognosis at baseline could be present between patients 
with low and patients with high BP. A part of this problem was eliminated through adjustment 
for many potential confounders, but residual confounding could still be present. 
Unfortunately, we could not adjust for RFD before the start of pre-dialysis care. 
In elderly pre-dialysis patients, both low and high DBP (U-shape) were associated, 
independent of SBP, with the start of RRT. Possible biological explanations for this U-shape 
are an accelerated RFD, the use of ACEi/ARBs, the presence of co-morbidities, arterial 
stiffness and thereby congestive heart failure, and/or chronic hypoperfusion. First, RFD 
cannot be the complete explanation because our results in elderly patients showed that RFD 
was not always consistent with the rate of starting RRT. This is supported by our findings that 
the residual renal function at the start of RRT was highest in the elderly patients in the lowest 
DBP and SBP category. Second, a consensus has been reached that ACEi/ARBs can slow down 
RFD independent of BP lowering. In addition, ACEi/ARBs can also cause a temporary loss of 
renal function. However, after adjusting our analyses for ACEi and ARB prescriptions the 
results did not change (data not shown). Possibly, frail elderly patients received a relatively 
higher dosage of ACEi and ARB prescriptions compared with young patients. Unfortunately, in 
our cohort no data on dosages were available. Third, although the U-shaped association 
remained present after adjustment for the most important co-morbidities, we could not 
control for severity and duration of co-morbidities because these data were not available in 
the PREPARE-1 study. Therefore, differences in severity and duration of co-morbidities still 
can be a part of the explanation for the U-shaped association of BP with the start of RRT. 
Fourth, arterial stiffness of the vessel wall, often accompanied with low DBP, is one of the 
pathophysiological changes becoming more pronounced with age.
37;38
 These changes can 
result in isolated systolic hypertension (which is defined as SBP ≥140 mmHg and DBP <90 
mmHg
26
) and thereby an increased pulse pressure (marker for arterial stiffness), an increased 
afterload, left ventricular hypertrophy, reduced coronary perfusion, congestive heart failure, 
and altered or reduced blood supply to the tissues.
39
 These clinical processes are often 
accompanied with renal damage. In our pre-dialysis population, isolated systolic hypertension 
was present in 28% of the young and in 51% of the elderly patients. Also angina pectoris and 
myocardial infarction, consequences of reduced coronary perfusion, and left ventricular 
hypertrophy were more present in the elderly population. These numbers indicate that the 
presence of arterial stiffness was higher in elderly compared with young patients. However, 
both low and high DBP (U-shape) were associated with a higher rate of starting RRT, 
independent of SBP. Therefore, an increased pulse pressure could not be the entire 
explanation for the association of low DBP with the start of RRT. Furthermore, after 
adjustment for or stratification by the presence of left ventricular hypertrophy, angina 
pectoris, myocardial infarction, coronary disease, or congestive heart failure, the U-shaped 
association remained present in our cohort. However, congestive heart failure and a low BP 
often coincide, and therefore we cannot exclude the possibility that symptoms associated 
with congestive heart failure influence the clinical decision to start with RRT. Fifth, chronic 
hypoperfusion could be the cause of a higher rate of starting RRT in patients with low DBP. It 
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is possible that in elderly pre-dialysis patients low DBP, leading to hypoperfusion, may 
introduce overhydration and thereby lead to an earlier start of RRT. However, adjustment for 
overhydration did not change the results. 
Our data showed that SBP and DBP at the start of pre-dialysis care are differently associated 
with the start of RRT in elderly compared with young pre-dialysis patients and this could have 
clinical implications. In young pre-dialysis patients, it seems important to keep SBP and DBP as 
low as possible. Therefore, the current BP treatment target of <130/80 mmHg
26;40
 in CKD 
patients, irrespective of age, seems correct for young pre-dialysis patients. However, the very 
low percentage of patients on pre-dialysis care achieving this treatment target level may 
suggest that it is very difficult to bring SBP and DBP into the range proposed in the guidelines. 
In elderly patients, only very high SBP and DBP were associated with the start of RRT. 
Therefore, targeting a blood pressure level of 130/80 mmHg may not be necessary in elderly 
pre-dialysis patients. This is of interest because anti-hypertensive drugs can cause a lot of side 
effects in elderly patients. Furthermore, elderly patients with extreme low DBP should be 
monitored carefully because they started RRT earlier than patients with moderate DBP levels. 
Our data are consistent with these clinical implications, but do not provide enough evidence 
to change clinical practice due to the observational character of our study. Therefore, further 
studies are necessary to investigate whether a less stringent BP treatment target for elderly 
pre-dialysis patients is just as beneficial or better as the current target, to postpone the start 
of RRT. 
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Abstract 
Background:  Proteinuria is a risk marker for progression of chronic kidney disease (CKD) 
and treatment with an angiotensin-converting enzyme inhibitor and/or angiotensin-II 
receptor blocker (ACEi/ARB) is beneficial in these patients. However, little is known about 
proteinuria and ACEi/ARB treatment in patients on specialized pre-dialysis care. Therefore, we 
investigated the association of urinary protein excretion (UPE) and ACEi/ARB treatment with 
renal function decline (RFD) and/or the start of renal replacement therapy (RRT) in patients 
on pre-dialysis care. 
Methods:  In the PRE-dialysis PAtient REcord-1 (PREPARE-1) cohort, 547 incident pre-dialysis 
patients (CKD stages 4-5), referred as part of the usual care to outpatient clinics of eight 
Dutch hospitals, were included (1999-2001) and followed until the start of RRT, mortality, or 
January 1, 2008. The main outcomes were rate of RFD, estimated as the slope of available 
estimated glomerular filtration rate (eGFR) measurements, and the start of RRT.  
Results:  Patients with mild proteinuria (>0.3 to ≤1.0 g/24h) had an adjusted additional RFD 
of 0.35 [95% confidence interval (CI) 0.01;0.68] ml/min/1.73 m
2
/month and a higher rate of 
starting RRT (adjusted hazard ratio (HR) 1.70 [95% CI 1.05;2.77]) compared with patients 
without proteinuria (≤0.3 g/24h). With every consecutive UPE category (>1.0 to ≤3.0, >3.0 to 
≤6.0, and >6.0 g/24h), RFD accelerated and the start of RRT was earlier. Furthermore, patients 
starting (n=16) or continuing (n=133) treatment with ACEi/ARBs during pre-dialysis care had a 
lower rate of starting RRT compared with patients not using treatment (n=152, adjusted HR 
0.56 [95% CI 0.29;1.08] and 0.90 [95% CI 0.68;1.20], respectively). 
Conclusion:  In patients on pre-dialysis care, we confirmed that proteinuria is a risk marker 
for the progression of CKD. Furthermore, no evidence was present that the use of ACEi/ARBs 
is deleterious. 
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Introduction 
Proteinuria is an important risk marker for renal function decline (RFD)
1-3
 and progression to 
chronic kidney disease (CKD)
4-7
 in the general ‘healthy’ population. In patients with CKD 
(mainly stages 1-4) proteinuria, defined by a specific cutoff value, remains a risk marker for 
CKD progression.
4;8-14
 Proteinuria deserves much attention because it is a ‘modifiable’ risk 
marker that can be treated with anti-hypertensive medication such as an angiotensin-
converting enzyme inhibitor (ACEi) or angiotensin-II receptor blocker (ARB). 
Several trials have shown that treatment with ACEi/ARBs can delay the progression to end-
stage renal disease and lower the risk of mortality in patients with CKD.
15-20
 Brenner et al.
15
 
showed that treatment with an ARB results in a 28% risk reduction of progression to end-
stage renal disease and 25% risk reduction of doubling of serum creatinine. For an ACEi the 
results vary from risk reductions of approximately 22 to 56%.
16-20
 Based on this evidence, the 
current guidelines recommend to start treatment with ACEi/ARBs, independent of the exact 
stage of CKD, when the protein-to-creatinine ratio is ≥500-1,000 mg/g (equivalent to ≥0.5-1.0 
g/24h).
21
 However, for the specific population of patients with CKD stages 4-5 on specialized 
pre-dialysis care, little evidence is available about whether proteinuria is still a risk marker for 
disease progression and whether a higher proteinuria level strengthens this effect (dose-
response relation). Furthermore, it is unknown whether treatment with ACEi/ARBs might 
delay the need for renal replacement therapy (RRT) in this specific patient group on pre-
dialysis care. 
Indeed, the evidence for the effect of ACEi/ARBs on CKD progression is contradictory in 
patients on pre-dialysis care who are in the transition phase between advanced CKD and 
dialysis. In clinical practice, not prescribing ACEi/ARBs or discontinuing ACEi/ARBs during pre-
dialysis care is common practice, especially in the elderly and patients with acute renal 
failure. This practice was recently supported by a study that showed a delayed onset of RRT 
after the discontinuation of ACEi/ARBs in advanced CKD patients (stages 4-5).
22
 Furthermore, 
a debate is ongoing concerning the general applicability of the many trials showing a delayed 




Taking all these considerations into account, the first aim of this study was to investigate 
whether and from what level urinary protein excretion (UPE) is an independent risk marker 
for the progression of CKD, assessed as RFD and the start of RRT, in the specific population of 
patients on pre-dialysis care (advanced CKD stages 4-5). Our second aim was to investigate 
what the frequency is of different prescription choices of ACEi/ARB treatment at the start of 
pre-dialysis care (yes or no treatment) and during pre-dialysis care (no use, start, stop, or 
continue treatment) within the population of patients on pre-dialysis care and whether 
treatment with ACEi/ARBs at the start and during pre-dialysis care were associated with the 
progression to RRT. 
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Methods 
Study design and participants 
The PRE-dialysis PAtient REcord-1 (PREPARE-1) study is a follow-up study in which consecutive 
incident adult patients with advanced CKD were included from outpatient clinics of eight 
Dutch hospitals when referred for pre-dialysis care between 1999 and 2001. Referral to these 
outpatient clinics was indicated if patients were expected to need RRT within one year and if 
their estimated creatinine clearance was below 20 ml/min. Patients who spent less than one 
month on pre-dialysis care or patients with prior RRT were excluded. The clinical course of 
pre-dialysis patients was followed through the medical charts until the start of dialysis, 
transplantation, death, lost to follow-up, or January 1, 2008, whichever was earliest. 
Predefined data on demography, anthropometry, and clinical symptoms were extracted from 
medical charts at the start and end of follow-up. All available data concerning laboratory 
measurements during pre-dialysis care were extracted from the hospital information systems. 
The use of medication and laboratory measurements during pre-dialysis care were extracted 
until January 1, 2003. The study was approved by the Institutional Review Boards of the 
participating hospitals. 
Measurements and definitions 
A 24 hour urine sample was collected routinely at the first pre-dialysis visit, and the amount 
of excreted protein (g) in this sample was measured according to the standard procedure 
applied in each outpatient clinic. Data on treatment with ACEi/ARBs was collected at the first 
pre-dialysis visit and at the end of follow-up. All other variables used for the adjustment in 
multivariable analyses were routinely assessed at the first pre-dialysis visit and measured 
according to the standard procedure applied in each outpatient clinic. The presence of 
proteinuria was defined as excreting more than 0.3 g/24h protein in the urine, according to 
the guidelines.
24
 Glomerular filtration rate (GFR) was estimated using the four-variable 
Modification of Diet in Renal Disease formula, taking into account age, sex, race, and serum 
creatinine.
25
 Baseline serum creatinine, hemoglobin, and proteinuria measurements were 
defined as the measurement closest to the start of pre-dialysis care, within 90 days before 
and 14-30 days after the start of pre-dialysis care. 
Outcome 
The study outcomes were RFD and the start of RRT during complete follow-up (until January 
1, 2008). For the patients who were still in the study after January 1, 2003 (n=75) no complete 
follow-up data on eGFR and medication use was available. To prevent loss of power, we also 
included these patients and made the assumption that RFD followed a linear pattern
26
 and 
medication use remained stable after this date. It is plausible to assume that these 75 
patients are ‘stable’ patients because none of them started dialysis within the first two years 
of pre-dialysis care. In each individual patient, the rate of RFD was estimated as the slope of a 
linear regression model including all available eGFR measurements. eGFR measurements 
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between one month prior to inclusion and two weeks before reaching an endpoint were used 
and at least two measurements had to be available to estimate the rate of RFD. Furthermore, 
the start of RRT was defined as starting dialysis or being transplanted during pre-dialysis care. 
Statistical analyses 
Continuous data were expressed as mean ± standard deviation (SD) and skewed data as 
median (boundaries of interquartile range, IQR). UPE was divided into five categories; ≤0.3 
(no proteinuria, reference group), >0.3 to ≤1.0, >1.0 to ≤3.0, >3.0 to ≤6.0, and >6.0 g/24h. This 
classification is based on the definition of proteinuria (>0.3 g/24h) and the upper limit of the 
treatment target of proteinuria (≤1.0 g/24h) below which UPE at least should be reduced. 
Furthermore, to investigate the frequency of different ACEi/ARB prescription choices and the 
association of ACEi/ARB treatment  with the start of RRT, we performed an analysis with 
ACEi/ARB treatment at the start of pre-dialysis care (yes or no treatment) and the change of 
ACEi/ARB treatment during pre-dialysis care (no use, start, stop, or continue treatment) as 
determinants. We also chose to investigate the change of ACEi/ARB treatment during pre-
dialysis care because it is known from clinical practice that in certain patients on pre-dialysis 
care, often with the worst prognosis, treatment is not started or discontinued to preserve 
renal function. For the change of treatment during pre-dialysis care, four categories were 
defined based on the prescription of ACEi/ARBs at the start of pre-dialysis care and at the end 
of follow-up. The categories were coded as follows: (1) no use of treatment (reference group); 
‘no’ at the start and ‘no’ at the end of follow-up; (2) start treatment; ‘no’ at the start and ‘yes’ 
at the end of follow-up; (3) stop treatment; ‘yes’ at the start and ‘no’ at the end of follow-up, 
and (4) continue treatment; ‘yes’ at the start and ‘yes’ at the end of follow-up. The baseline 
and treatment characteristics were presented for the total study population and for the 
population stratified by the five UPE categories. 
A linear regression analysis was used to investigate the association of UPE, both continuously 
and in the defined five categories, with RFD. Multivariable analyses were used to adjust for 
the possible confounders age, sex, primary kidney disease, baseline eGFR, systolic blood 
pressure, hemoglobin level, presence of cardiovascular disease (angina pectoris, coronary 
disease, and/or myocardial infarction), and presence of diabetes mellitus. Systolic blood 
pressure and/or hemoglobin level were missing for nine patients.  
Cox proportional hazard regression analysis was used to assess the association of: (1) UPE, 
continuously and in the five defined categories, and (2) ACEi/ARB treatment, at the start (yes, 
no), and changes during pre-dialysis care (no use, start, stop, continue), with the start of RRT. 
The hazard ratio of starting RRT was adjusted for the same confounders as used in the 
multivariable linear regression analysis described earlier. The time from the first pre-dialysis 
visit until the start of RRT was used as follow-up time in the Cox proportional hazard 
regression model. Both ‘mortality’ and ‘lost to follow-up’ were censored events. Finally, we 
also investigated whether the association of ACEi/ARB treatment at the start or during pre-
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dialysis care with the start of RRT is dependent on the level of proteinuria, by performing 
analyses stratified by the five UPE categories. 
Multiple sensitivity analyses were performed. First, we investigated whether the association 
of UPE with the progression of CKD is different after stratifying by treatment with ACEi/ARBs 
at the start of pre-dialysis care. Second, all analyses with the start of RRT as outcome were 
repeated with follow-up time until January 1, 2003 instead of January 1, 2008. Third, a linear 
mixed model was used to validate our chosen method for estimating the rate of RFD. Fourth, 
systolic blood pressure, hemoglobin, UPE and RFD were imputed (using five repetitions) in 
patients who had no prior RRT and received at least one month of pre-dialysis care (n=525) 
with a missing value at baseline (n=17, n=68, n=112, and n=53 respectively). Multiple 
imputation is a recommended technique where missing data for a patient are imputed by a 
value that is predicted by other known characteristics of this patient (i.e. demographic, 
anthropometric, and clinical characteristics, as well as the outcome).
27;28
 Multiple imputation 
may increase statistical power because all patients are included in the analysis. At the same 
time, it may reduce selection bias as patients with missing values often have poor prognosis 




In our pre-dialysis cohort, 547 patients were included, of whom 525 patients had no prior RRT 
and received at least one month of pre-dialysis care. At baseline, UPE was available for 413 
patients and these patients were included in our statistical analyses. These 413 patients were 
slightly younger, had a higher systolic blood pressure, lower eGFR, and higher prevalence of 
cardiovascular disease and diabetes mellitus compared with patients without an available 
UPE at baseline (n=112). At the start of pre-dialysis care, 368 of the 413 patients (89%) had 
proteinuria (>0.3 g/24h, Table 1). Patients with proteinuria were younger, more often male, 
had a higher prevalence of diabetes mellitus, a lower eGFR, and higher systolic blood 
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Treatment characteristics 
At the start of pre-dialysis care, 41% (n=168) of the 413 patients were not treated and 59% 
(n=245) were treated with ACEi/ARBs (Figure 1). Furthermore, of all patients, 4% (n=16) 
started treatment and 27% (n=112) stopped treatment with ACEi/ARBs during pre-dialysis 
care. This means that 10% (16 of the 168) of the patients not treated at the start of pre-
dialysis care started treatment, and 46% (112 of the 245) of the patients treated at the start 
of pre-dialysis care stopped ACEi/ARB treatment. The treatment characteristics did not differ 
much between the UPE categories (Figure 1). The frequency of patients starting ACEi/ARB 
treatment was somewhat lower in patients with proteinuria (>0.3 to ≤6.0 g/24h) compared 
with patients without proteinuria. Furthermore, the frequency of patients continuing 
treatment was somewhat higher in patients with proteinuria. 
Figure 1: Treatment with ACEi/ARBs during pre-dialysis care 

















































Association of UPE with the progression of CKD 
Two or more eGFR measurements to estimate the rate of RFD, were available for 408 
patients. In these patients, the median (IQR) number of available eGFR measurements was 13 
(7-19) and the mean ± SD RFD was 0.43 ± 0.87 ml/min/1.73 m
2
/month. RFD accelerated with 
increasing UPE (adjusted additional decline 0.04 [95% confidence interval (CI) 0.01;0.08] 
ml/min/1.73 m
2
/month per g/24h increase, Table 2). The same trend was present when UPE 
was analyzed in categories. Even patients with mild proteinuria (>0.3 to ≤1.0 g/24h) already 
had an accelerated RFD (adjusted additional decline 0.35 [95% CI 0.01;0.68] ml/min/1.73 
m
2
/month) compared with patients without proteinuria (≤0.3 g/24h, mean ± SD decline 0.07 ± 
0.84 ml/min/1.73 m
2
/month). Every consecutive higher UPE category showed an increasing 
additional decline compared with the reference category (patients without proteinuria, ≤0.3 
g/24h). 
Treatment characteristics of the total 
population and stratified by urinary protein 
excretion (UPE) categories. On the y-axis the 
percentage (%) of patients in each of the four 
ACEi/ARB treatment categories during pre-
dialysis care (legend) is presented. The four 
treatment categories with ACEi/ARBs were 
based on the use or no use of ACEi/ARBs at the 
start of pre-dialysis care and at the end of 
follow-up (no use, start, stop, and continue). 
The results are given for the total population 
(all, x-axis) and stratified by UPE categories 
(≤0.3, >0.3 to ≤1.0, >1.0 to ≤3.0, >3.0 to ≤6.0, 
and >6.0 g/24 h, x-axis). 
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At the end of follow-up (January 1, 2008), 43% started hemodialysis and 37% peritoneal 
dialysis, 4% were transplanted, 11% died, and 5% were lost to follow-up. The median (IQR) 
follow-up time was 11.6 (4.7-22.4) months. For the consecutive UPE categories the follow-up 
time was 23.0 (10.9-42.5), 16.4 (6.0-29.2), 14.1 (4.8-24.1), 7.0 (4.2-15.0), and 6.9 months (3.2-
17.7). The association of increasing UPE with the start of RRT showed a similar pattern as 
increasing UPE with RFD (adjusted hazard ratio (HR) 1.06 [95% CI 1.02;1.10] per g/24h 
increase, Table 3). Patients with mild proteinuria (>0.3 to ≤1.0 g/24h) had a higher rate of 
starting RRT compared with patients without proteinuria (adjusted HR 1.70 [95% CI 
1.05;2.77]). Every consecutive higher UPE category showed an even higher rate compared 
with the reference category. 





























Amount of urinary protein excretion (g/24h): 
Steps of 1 408 13.1 ± 5.6 0.05 [0.02;0.09] 0.05 [0.02;0.08] 0.04 [0.01;0.08] 
≤0.3 45 17.1 ± 9.2 0
4
 0 0 
>0.3 - ≤1.0 86 13.6 ± 4.5 0.26 [-0.05;0.57] 0.24 [-0.07;0.55] 0.35 [0.01;0.68] 
>1.0 - ≤3.0 132 13.1 ± 5.6 0.31 [0.02;0.60] 0.28 [-0.02;0.57] 0.34 [0.01;0.66] 
>3.0 - ≤6.0 98 11.6 ± 4.2 0.56 [0.25;0.86] 0.50 [0.19;0.81] 0.53 [0.18;0.89] 
>6.0 47 11.2 ± 3.6 0.62 [0.27;0.97] 0.59 [0.23;0.94] 0.64 [0.22;1.06] 
The decline [95% confidence interval (CI)] for steps of 1 indicates the additional renal function decline (RFD) with 
every 1 g/24h increase in urinary protein excretion (UPE). The decline [95% CI] presented for each UPE category 
indicates the additional RFD compared with the reference category (no proteinuria, ≤0.3 g/24h). A positive decline is 
equivalent to a faster RFD. 
1
 Mean estimated glomerular filtration rate (eGFR) in ml/min/1.73 m
2
 at baseline.  
2
 Adjusted for sex and age. 
3
 Adjusted for sex, age, primary kidney disease, systolic blood pressure, hemoglobin level, 
baseline eGFR, and the co-morbidities cardiovascular disease and diabetes mellitus and complete data available for 
399 patients. 
4
 The mean ± standard deviation crude RFD is 0.07 ± 0.84 ml/min/1.73 m
2
/month for the reference 
group. 
Table 3: Association of urinary protein excretion with the start of renal replacement therapy 
 Events/n Crude HR [95% CI] Adjusted HR
1
 [95% CI] Adjusted HR
2
 [95% CI] 
Amount of urinary protein excretion (g/24h): 
Steps of 1 344/413 1.09 [1.06;1.13] 1.09 [1.06;1.12] 1.06 [1.02;1.10] 
≤0.3 27/45 1 1 1 
>0.3 - ≤1.0 72/88 1.95 [1.24;3.06] 1.86 [1.18;2.94] 1.70 [1.05;2.77] 
>1.0 - ≤3.0 109/132 2.19 [1.43;3.37] 1.98 [1.28;3.08] 1.87 [1.17;3.00] 
>3.0 - ≤6.0 92/101 4.03 [2.58;6.29] 3.68 [2.34;5.81] 2.62 [1.59;4.33] 
>6.0 44/47 3.67 [2.25;5.99] 3.44 [2.10;5.63] 2.52 [1.45;4.39] 
The hazard ratio (HR) [95% confidence interval (CI)] for steps of 1 indicates the increased rate of starting renal 
replacement therapy (RRT) with every 1 g/24h increase in urinary protein excretion (UPE). The HR [95% CI] presented 
for each UPE category indicates the increased rate of starting RRT compared with the reference category (no 
proteinuria, ≤0.3 g/24h). 
1
 Adjusted for sex and age. 
2
 Adjusted for sex, age, primary kidney disease, systolic blood 
pressure, hemoglobin level, baseline eGFR, and the co-morbidities cardiovascular disease and diabetes mellitus and 
complete data available for 404 patients. 
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Association of treatment with ACEi/ARBs with the start of RRT 
The median (IQR) follow-up time was 11.4 months (4.8-22.1) for patients treated and 12.5 
months (4.2-23.2) for patients not treated with ACEi/ARBs at the start of pre-dialysis care. The 
Cox proportional hazard regression model also showed that patients treated with ACEi/ARBs 
at the start of pre-dialysis care had a somewhat higher rate of starting RRT compared with 
patients not treated with ACEi/ARBs (adjusted HR 1.13 [95% CI 0.89;1.44], Table 4). For 
patients not using, starting, stopping, or continuing treatment during pre-dialysis care, the 
median (IQR) follow-up time was 11.7 (4.1-21.7), 16.0 (4.6-34.7), 8.2 (4.5-20.6), and 11.8 (6.7-
24.9) months, respectively. Patients starting treatment with ACEi/ARBs during pre-dialysis 
care had a lower rate of starting RRT compared with patients not using treatment with 
ACEi/ARBs, which was not significant (adjusted HR 0.56 [95% CI 0.29;1.08], Table 4). Patients 
continuing treatment with ACEi/ARBs during pre-dialysis care also had a slightly lower rate of 
starting RRT compared with the patients not using treatment (adjusted HR 0.90 [95% CI 
0.68;1.20]). Compared with the reference group, patients discontinuing the use of ACEi/ARBs 
during pre-dialysis care had a higher rate of starting RRT. However, this difference was not 
significant (adjusted HR 1.27 [95% CI 0.95;1.70]). Furthermore, the association of ACEi/ARB 
treatment at the start or during pre-dialysis care with the start of RRT varied through the UPE 
categories; however, no clear pattern was detected. 













ACEi/ARB       
Not treated No - 133/168 1 1 1 
Treated Yes - 211/245 1.08 [0.87;1.35] 1.05 [0.84;1.31] 1.13 [0.89;1.44] 
ACEi/ARB       
No use No No 122/152 1 1 1 
Start No Yes 11/16 0.67 [0.36;1.24] 0.63 [0.34;1.17] 0.56 [0.29;1.08] 
Stop Yes No 95/112 1.18 [0.90;1.55] 1.17 [0.89;1.53] 1.27 [0.95;1.70] 
Continue Yes Yes 116/133 0.95 [0.73;1.22] 0.89 [0.69;1.15] 0.90 [0.68;1.20] 
The hazard ratio (HR) [95% confidence interval (CI)] presented for each treatment category (the use of ACEi/ARBs at 
the start of pre-dialysis care, or the use of ACEi/ARBs during pre-dialysis care) indicates the increased rate of starting 
renal replacement therapy (RRT) compared with the reference category (no use at the start or during pre-dialysis 
care). 
1
 Defined as the use of ACEi/ARBs at the start of pre-dialysis care and at the end of follow-up (RRT, mortality, 
lost to follow-up, or January 1, 2003). 
2
 Adjusted for sex and age. 
3
 Adjusted for sex, age, primary kidney disease, 
systolic blood pressure, hemoglobin level, baseline eGFR, and the co-morbidities cardiovascular disease and diabetes 
mellitus and complete data available for 404 patients. 
Sensitivity analyses 
The point estimates for the association of UPE with RFD and the start of RRT were higher in 
patients treated than in patients not treated with ACEi/ARBs at the start of pre-dialysis care. 
The point estimates for the association of UPE and the use of ACEi/ARBs with the start of RRT 
remained similar when using follow-up until January 1, 2003 for all patients. Only the 
confidence intervals for the hazard ratios became somewhat larger, probably because 75 
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patients have not reached an endpoint on this date yet. Using linear mixed models resulted in 
similar significant results for the association of UPE with RFD, with lower point estimates and 
smaller confidence intervals. Finally, multiple imputation resulted in similar results for the 
continuous and categorical association of UPE with RFD and the start of RRT. 
Discussion 
In our cohort of patients on specialized pre-dialysis care, 89% of the patients had proteinuria 
(>0.3 g/24h) and almost half of the patients, irrespective of proteinuria, were not treated with 
ACEi/ARBs. Of all 413 patients, only 10% of the patients not treated with ACEi/ARBs at the 
start of pre-dialysis care started the treatment, and 46% of the patients treated with 
ACEi/ARBs at the start of pre-dialysis care discontinued the treatment during pre-dialysis care. 
Increased UPE was associated with a faster progression of CKD, assessed as an accelerated 
RFD and an earlier start of RRT. Even patients with mild proteinuria (>0.3 to ≤1.0 g/24h) 
already experienced a faster progression of CKD compared with patients without proteinuria 
(≤0.3 g/24h) and every consecutive higher UPE category resulted in an even faster 
progression of CKD. Patients treated with ACEi/ARBs at the start of pre-dialysis care started 
RRT somewhat earlier. In contrast, according to ACEi/ARB treatment during pre-dialysis care, 
patients continuing or starting treatment with ACEi/ARBs during pre-dialysis care, had a 
somewhat later start of RRT compared with patients not using ACEi/ARB treatment. 
Furthermore, patients discontinuing treatment had a considerable faster rate of starting RRT 
compared with patients not using ACEi/ARB treatment during pre-dialysis care. Therefore, the 
small increased rate in all patients on ACEi/ARB treatment at the start of pre-dialysis care can 
be explained by the increased rate of starting RRT and shorter median follow-up time in 
patients discontinuing treatment with ACEi/ARBs during pre-dialysis care as seen in our 
analyses. These results may indicate that in the clinic, treatment with ACEi/ARBs is especially 
discontinued in patients with a bad prognosis. 
 Our findings of a dose-response relation between increasing UPE and a faster progression of 
CKD, assessed as RFD and the start of RRT, has not been shown previously in patients with 
advanced CKD (stages 4-5). A faster progression was already present in patients with mild 
proteinuria (>0.3 to ≤1.0 g/24h). Other observational studies have investigated proteinuria as 
a risk marker for CKD progression.
4;8;10-14
 However, these studies included patients in all 
stages of CKD and/or proteinuria was defined only as a dichotomous variable. The study of 
Obi et al.
10
 resembles our study the most, as this study was performed in a cohort of patients 
with CKD stages 3-5 referred to nephrologists. They showed that patients with overt 
proteinuria, defined as a urinary protein/creatinine ratio ≥1 g protein/g creatinine or a urine 
dipstick ≥2+ (both equivalent to ≥1.0 g/24h), started RRT earlier compared with patients 
without overt proteinuria (adjusted HR 4.97 [95% CI 2.23;11.1]). Besides these observational 
studies, a meta-analysis by Jafar et al.
17
 showed that the beneficial effect of ACEi/ARBs on the 
progression of CKD, defined as the doubling of serum creatinine or progression to end-stage 
renal disease, acts in part via the lowering of proteinuria. This finding may indicate that 
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lowering proteinuria slows down the progression of CKD which is consistent with the dose-
response relation we found between increasing UPE and a faster progression of CKD. 
In our cohort, 59% of the patients (245 of the 413 patients) were treated with ACEi/ARBs 
(most of them used an ACEi) and this finding is in line with other studies.
29;30
 Furthermore, we 
found that 112 of the 245 patients (46%) who were treated with ACEi/ARBs at the start of 
pre-dialysis care discontinued the use of ACEi/ARBs during pre-dialysis care. For the 168 
patients not treated with ACEi/ARBs at the start of pre-dialysis care, only 16 patients (10%) 
started treatment. These findings are in line with the clinical practice because in many pre-
dialysis patients treatment with ACEi/ARBs is not started or discontinued to preserve the 
patients’ renal function or because of hyperkalemia. Recently, this practice became more 
evidence-based, as Ahmed et al.
22
 showed that discontinuing the use of ACEi/ARBs delayed 
the onset of RRT in patients with CKD stages 4-5. However, their patient population was very 
specific, consisting of elderly patients (mean ± SD age of 73.3 ± 1.8 years) with relatively high 
eGFR (16.38 ± SD 1 ml/min/1.73 m
2
). Unfortunately, in our cohort we could not investigate 
whether kidney function improves after discontinuation of ACEi/ARB treatment because we 
do not know the exact date of discontinuation. Therefore, future studies should focus on this 
possible beneficial effect of not prescribing ACEi/ARB treatment in patients on pre-dialysis 
care. 
Our study furthermore showed that ACEi/ARB treatment at the start of pre-dialysis care was 
associated with a somewhat faster progression to RRT (adjusted HR 1.13 [95% CI 0.89;1.44]). 
This finding is in line with the study of Ahmed et al.
22
, who showed that treatment with 
ACEi/ARBs in pre-dialysis patients is detrimental. However, this possible detrimental effect of 
ACEi/ARBs disappeared when we performed an analysis taking into account the treatment of 
ACEi/ARBs during pre-dialysis care (no use, start, stop, or continue treatment). Patients who 
discontinue ACEi/ARB treatment during pre-dialysis care started RRT earlier than patients not 
using treatment, which explained the detrimental effect found at baseline. However, patients 
continuing or starting treatment with ACEi/ARBs during pre-dialysis care have a somewhat 
slower progression to RRT compared with patients not using treatment with ACEi/ARBs. This 
finding is in line with several trials performed in CKD patients
15-20
, but in contrast to the study 
of Ahmed et al.
22
. An explanation for this contradictory finding could be that in the study of 
Ahmed et al., all included patients discontinued ACEi/ARB treatment and in our study, 
ACEi/ARB treatment was only discontinued in patients with clinical indications to stop, such as 
hyperkalemia, renal dysfunction, and/or angioedema.
31
 
Our results representing the association of ACEi/ARB treatment with the start of RRT are 
therefore contradictory. We found a very small detrimental effect of ACEi/ARB treatment, but 
this effect became somewhat beneficial when we excluded patients that discontinue the 
treatment. Because of this current clinical practice to stop or not start ACEi/ARB treatment in 
some pre-dialysis patients to preserve renal function, we could get problems with 
confounding by indication. Therefore, it is difficult to prove whether our findings of a 
somewhat beneficial effect of treatment with ACEi/ARBs during pre-dialysis care is due to the 
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absence of clinical indications to stop the treatment, often related to a better prognosis, or 
due to a real beneficial effect of ACEi/ARBs. The combination of our observational results 
showing that the clinical practice is to discontinue ACEi/ARB treatment in specific pre-dialysis 
patients and the fact that the patients in the study of Ahmed et al.
22
 were mainly elderly 
patients with a relatively high eGFR may support the thought that ACEi/ARB treatment is not 
beneficial for a specific subgroup of pre-dialysis patients. However, future studies in pre-
dialysis patients should elaborate whether discontinuation of ACEi/ARBs is indeed beneficial, 
and if so, for which specific subgroups.  
Our study has some potential limitations. First, in the general population, 36-65% of the 
patients with an eGFR below 15 ml/min/1.73 m
2
 are not treated by a nephrologist.
32
 
Therefore, our results may not be generalizable to all patients with an eGFR below 15 
ml/min/1.73 m
2
, but only to those who receive specialized pre-dialysis care. However, for 
clinical practice our cohort is a highly representative and relevant population because this is 
the patient population seen and treated by nephrologists. Second, for estimating the rate of 
RFD with available eGFR measurements, we assumed that RFD follows a linear pattern in the 
advanced stages of CKD. It has been shown previously that linearity of the course in eGFR is a 
reliable assumption, although on theoretical grounds an exponential decline could be present 
over a longer period of time.
26
 Third, our finding that treatment with ACEi/ARBs during pre-
dialysis care resulted in a slower progression of CKD should be interpreted with caution due 
to the observational character of our study and thereby possible confounding by indication. 
To draw confirmative conclusions about the effect of a treatment, a randomized controlled 
trial is the most optimal study design to ensure an equal prognosis between the two 
treatment groups. However, the results in our study did not change essentially after the 
adjustment for clinical indications (high blood pressure and proteinuria) and contraindications 
(hyperkalemia and edema; data not shown) considered in the decision to prescribe anti-
hypertensive medication. Unfortunately, we cannot adjust for RFD before the start of pre-
dialysis care, the third main indication. No RFD could be estimated because the number of 
available creatinine levels prior to one month before the start of pre-dialysis care was too 
scarce in our cohort. However, if patients treated with ACEi/ARBs indeed had a faster RFD 
before the start of pre-dialysis care, our observed associations might even be stronger. 
Fourth, the prescription of ACEi/ARBs was only assessed at the start of pre-dialysis care and at 
the end of follow-up. The treatment regimen in the intervening time and the actual 
compliance to the medication is unknown and could not be accounted for. However, it is 
unlikely that patients stop and restart treatment with ACEi/ARBs during pre-dialysis care. 
Besides this, we do not know the exact date of discontinuation of ACEi/ARBs, which could be 
just before the start of dialysis. Furthermore, we were not able to perform an analysis in 
which the single treatment with ACEis or ARBs and the combined treatment with ACEis and 
ARBs was investigated due to the low frequency of patients using an ARB. 
Our results indicate that during specialized pre-dialysis care, proteinuria can be used as a risk 
marker, independent of other risk factors, for the progression of CKD. High-risk pre-dialysis 
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patients can be identified, treated more strictly, and timely preparation for dialysis can be 
assured. Furthermore, in our pre-dialysis cohort, a large part of the patients were not treated 
with ACEi/ARBs to lower proteinuria and slow down the progression of CKD. More studies are 
necessary to elaborate on the clinical indications for discontinuation of ACEi/ARB treatment 
and the clinical course after discontinuation. Moreover, patients starting or continuing 
treatment with ACEi/ARBs during pre-dialysis care started RRT somewhat later, indicating no 
deleterious effect of ACEi/ARB treatment. In conclusion, the results from this study provide 
evidence for using the proteinuria level as a strong and independent risk marker for the 
progression of CKD in patients on specialized pre-dialysis care. 
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Abstract 
Background: Little is known about the effect of low-density lipoprotein (LDL) cholesterol, 
triglyceride (TG), and high-density lipoprotein (HDL) cholesterol levels on renal function 
decline in patients receiving specialized pre-dialysis care. 
Methods: In the prospective PRE-dialysis PAtient REcord-2 (PREPARE-2) study, incident 
patients starting pre-dialysis care were included when referred to one of 25 Dutch specialized 
pre-dialysis outpatient clinics (2004-2011). Clinical and laboratory data were collected every 
six-month interval. A linear mixed model was used to compare renal function decline 
between patients with LDL cholesterol, TG, or HDL cholesterol levels above and below the 
treatment target (LDL cholesterol: <2.50 mmol/l, TG: <2.25 mmol/l, and HDL cholesterol: 
≥1.00 mmol/l). Additionally the HDL/LDL cholesterol ratio was investigated (≥0.4). 
Results:  In our study population (n=306), the median age was 69 years, and 70% were male. 
Patients with LDL cholesterol levels above the target of 2.50 mmol/l experienced an 
accelerated renal function decline compared with patients with levels below the target (crude 
additional decline 0.10 [95% confidence interval (CI) 0.00;0.20] ml/min/1.73 m
2
/month, 
p<0.05). A similar trend was found for TG levels above the target of 2.25 mmol/l (0.05 [95% CI 
-0.06;0.16] ml/min/1.73 m
2
/month) and for a HDL/LDL cholesterol ratio below 0.4 (0.06 [95% 
CI -0.05;0.18] ml/min/1.73 m
2
/month). Adjustment for potential confounders resulted in 
similar results and exclusion of patients whom were prescribed lipid-lowering medication 
(statin, fibrate, or cholesterol absorption inhibitor) resulted in a larger estimated effect. 
Conclusion:  Especially high levels of LDL cholesterol were associated with an accelerated 
renal function decline, independent of the prescription of lipid-lowering medication. 
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Introduction 
In the general population it is known that abnormal lipid levels (i.e. high low-density 
lipoprotein (LDL) cholesterol, high triglycerides (TG), and low high-density lipoprotein (HDL) 
cholesterol) are associated with higher cardiovascular mortality.
1-3
 For patients on dialysis 
treatment, the association of abnormal lipid levels with all-cause and cardiovascular mortality 
is different compared with the general population. In this phase, having abnormal lipid levels 
(especially high total cholesterol) seems to have a beneficial effect, associated with lower 
risks of mortality.
4-6
 Studies investigating the association of abnormal lipid levels with all-
cause and cardiovascular mortality in chronic kidney disease (CKD) patients not on dialysis
7-9
, 
showed no or a slightly reversed association. However, this reversed association was again 
mainly observed for total cholesterol levels, which is a combination of ‘good’ and ‘bad’ lipids. 
Furthermore, low cholesterol levels may be a consequence of inflammatory processes.
10;11
 
Besides this, a subgroup analysis of a recently published large trial showed that a lipid-
lowering combination therapy of a statin plus cholesterol absorption inhibitor, both LDL 
cholesterol-lowering drugs, decreased the risk of major cardiovascular events, including 
cardiovascular mortality, in pre-dialysis patients.
12
 Primarily based on the results from this 
trial, lipid-lowering medication is recommended to pre-dialysis patients for preventing 
cardiovascular complications. Is there also enough evidence available for renal function 
decline, another important clinical outcome? 
In the general population, several studies found a possible association of abnormal lipid levels 
with an accelerated renal function decline.
13-16
 This association seems comparable in patients 
with CKD, in whom abnormal lipid levels are associated with a faster progression.
17-21
 
However, these studies mainly focused on total cholesterol levels in early-stage CKD patients 
(stages 1-3). Data are lacking on the association of high LDL cholesterol, high TG, and low HDL 
cholesterol levels with progression of CKD in pre-dialysis patients (stages 4-5). Furthermore, 
trials investigating the effect of statins on disease progression, either defined by increasing 
proteinuria levels or renal function decline, are scarce and show contradictory results in pre-
dialysis patients.
12;22
 Therefore, we investigated the association of abnormal lipid levels (high 
LDL cholesterol, high TG, and low HDL cholesterol) with renal function decline in incident 
patients receiving specialized pre-dialysis care (CKD stages 4-5). 
Methods 
Study design 
The PRE-dialysis PAtient REcord-2 (PREPARE-2) study is an ongoing, prospective follow-up 
study of incident pre-dialysis patients treated in one of the 25 participating nephrology 
outpatient clinics in The Netherlands. Patients were included between July 2004 and June 
2011, at the start of specialized pre-dialysis care. They were treated by their nephrologists in 
their regular scheme according to the treatment guidelines of the Dutch Federation of 
Nephrology
23
, a guideline partly based on the K/DOQI and KDIGO guidelines
24;25
. At the start 
│Lipid levels and renal function decline   ___________________________________________ 
│66 
of specialized pre-dialysis care and in subsequent six-month intervals clinical data were 
collected. Patients were followed until the start of dialysis, receiving a kidney transplant, 
death, or censoring. Censoring was defined as: moving to an outpatient clinic not participating 
in the PREPARE-2 study, recovery of kidney function, refusal of further study participation, 
lost to follow-up, or August 1, 2012 (end of follow-up), whichever came first. The study was 
approved by the Medical Ethics Committee or Institutional Review Board (as appropriate) of 
all participating centers. 
Patients 
To be eligible for inclusion in the PREPARE-2 study, patients had to be at least eighteen years 
of age and the inclusion should take place at the moment of referral to a specialized pre-
dialysis outpatient clinic. In practice, this refers to incident pre-dialysis patients with an 
estimated glomerular filtration rate (eGFR) of less than 20-30 ml/min/1.73 m
2
, in whom renal 
function loss is progressive. Patients with a failing kidney transplant were also included in the 
study if the transplantation was at least one year ago. All participants gave their written 
informed consent prior to study inclusion. 
Data collection 
Data on demography, biometry, primary kidney disease, co-morbidities, medication use, and 
health-related quality of life were collected at the start of specialized pre-dialysis care and in 
subsequent six-month intervals. Corresponding laboratory data were extracted from the 
electronic hospital information systems or medical records. Primary kidney disease was 




Measurements and definitions 
GFR was estimated using the four-variable Modification of Diet in Renal Disease (MDRD) 
formula.
27
 TG and HDL cholesterol levels (given in mmol/l) were directly measured according 
to the standard procedure in each participating outpatient clinic. LDL cholesterol (given in 
mmol/l) was either directly measured or estimated with the Friedewald equation; total 




The primary outcome of our study was renal function decline. To assess this decline, all 
individual eGFR measurements during the first two years of pre-dialysis care were used. 
Complete follow-up was not used because the healthy and stable patients, whom are still on 
pre-dialysis care after two years, will then have a relatively large contribution to the overall 
renal function decline, possibly leading to a dilution of the estimated decline. 
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Statistical analyses 
For our statistical analyses we only included the patients with at least one LDL cholesterol, TG, 
HDL cholesterol, and eGFR measurement during the first two years of pre-dialysis care 
(n=306). Baseline characteristics were presented as mean ± standard deviation (SD) for 
normally distributed variables and as median (boundaries of interquartile range, IQR) for 
skewed variables. LDL cholesterol, TG, and HDL cholesterol levels were used as determinants. 





 pre-dialysis guidelines. The targets were  <2.50 mmol/l 
for LDL cholesterol, <2.25 mmol/l for TG, and ≥1.00 mmol/l for HDL cholesterol. Two 
additional analyses were performed: HDL cholesterol relative to LDL cholesterol (ratio: 1 
mmol/l / 2.50 mmol/l = 0.4; target: ≥0.4) because HDL cholesterol levels can be influenced by 
LDL cholesterol levels, and the number of targets that are not reached (ranging from 1, not 
reaching one of the three targets, to 3, reaching none of the targets), to estimate the 
combined effect of lipid levels. 
To associate these lipid levels with renal function decline we used a linear mixed model. This 
model takes into account a correlation between individual repeated eGFR measurements and 
the deviation of the individual slopes from the mean slope.
30
 All lipid levels and eGFR 
measurements during the first two years of pre-dialysis care were included in the model. The 
covariates included in the model were time (random), lipid levels, and time*lipid levels 
(interaction term; to assess the difference in renal function decline between the lipid level 
categories). All analyses were adjusted for the potential baseline confounders age, sex, 
primary kidney disease, smoking status, cardiovascular disease, diabetes mellitus, body mass 
index, systolic blood pressure, and proteinuria. In an additional model we further adjusted for 
available malnutrition-inflammation complex system related factors (albumin, c-reactive 
protein, and subjective global assessment). To maintain power and avoid bias, missing 
baseline confounder values were imputed (using ten repetitions) with the method of multiple 
imputation in PASW/SPSS version 20.0. This is a recommended technique where missing data 
for a patient are imputed by a value that is predicted by other known characteristics of this 
patient.
31;32
 All characteristics in Table 1 and 2, follow-up time, and the outcome (dialysis, 
transplantation, death, or censoring) were included in the imputation model because missing 
baseline characteristics are often related to the outcome.
33
 For each baseline characteristic, 
the number of patients with an available value is given in Table 1 and 2. Skewed distributed 
continuous variables, including follow-up time, were logarithmically transformed. 
We performed several additional analyses. First, we excluded patients who were prescribed 
lipid-lowering medication, defined as either a statin, a fibrate, or a cholesterol absorption 
inhibitor. Second, we analyzed the abnormal lipid levels continuously to investigate whether 
there was a similar association throughout the entire range of lipid levels. Third, we compared 
the effect of LDL cholesterol levels on renal function decline between the centers who 
estimated LDL cholesterol levels with the Friedewald equation and the centers who directly 
measured LDL cholesterol. Fourth, we excluded eGFR values measured in the two weeks 
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before starting dialysis, receiving a kidney transplant, death, or censoring because there can 
be a large variation between eGFR measurements during this period. Finally, we repeated all 
analyses after excluding the patients with only one eGFR measurement, to check whether the 
results from our linear mixed model were robust. P-values <0.05 were considered statistically 
significant and data were analyzed with PASW/SPSS version 20.0. 
Results 
Baseline characteristics 
Of the 502 patients, 306 patients had at least one LDL cholesterol, TG, HDL cholesterol, and 
eGFR measurement during the first two years of follow-up. These 306 patients were included 
in our statistical analyses and the known baseline characteristics of these patients (Table 1) 
were very similar to the baseline characteristics of the 196 patients excluded. The median age 
of the population was 69 (IQR 56-76) years of whom 70% were male. Mean eGFR was 16.7 ± 
SD 6.1 ml/min/1.73 m
2
 and median proteinuria was 1.1 (IQR 0.3-2.2) g/24h. Stratification by 
the LDL cholesterol treatment target (<2.50 mmol/l) revealed that patients above the target 
were slightly younger, less often male, had a slightly higher eGFR, higher systolic blood 
pressure, and had less often diabetes mellitus and cardiovascular disease (as primary kidney 
disease or co-morbidity) than patients below the target. 


















Age (years) 69 (56-76) 70 (60-78) 67 (55-75) 
Sex (male, %) 70 73 62 
Smokers / quitters <1 year before inclusion (%) 26 26 27 
Primary kidney disease (%)    
     Diabetes mellitus 15 18 10 
     Glomerulonephritis 12 11 10 
     Renal vascular disease 32 36 27 





 16.7 ± 6.1 15.9 ± 6.1 16.5 ± 5.8 
Proteinuria (g/24h)
3
 1.1 (0.3-2.2) 1.2 (0.4-2.3) 1.0 (0.3-2.2) 
Systolic blood pressure (mmHg)
4
 143 ± 22 142 ± 20 146 ± 23 
Hemoglobin (g/dl)
5 
12.3 ± 1.4 12.3 ± 1.4 12.3 ± 1.4 
Cardiovascular disease (%)
6
 43 46 37 
Diabetes mellitus (%)
7
 27 37 17 
Median (boundaries of interquartile range) is given for age and proteinuria and mean ± standard deviation is given 
for all other normally distributed continuous variables. 
1
 Before multiple imputation, low density lipoprotein (LDL) 
cholesterol levels were available for 197 patients. 
2
 Estimated glomerular filtration rate (eGFR) is calculated with the 
four-variable Modification of Diet in Renal Disease formula and available for 286 patients. 
3
 Available for 178 patients.  
4 
Available for 304 patients. 
5 
Available for 288 patients. 
6
 Defined as the presence of a cerebrovascular accident, 
vascular problems, angina pectoris, myocardial infarction, or decompensatio cordis. 
7
 Present as primary kidney 
disease or co-morbidity. 
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At the start of pre-dialysis care 17% of all 306 patients were treated with lipid-lowering 
medication (including statins, fibrates, and cholesterol absorption inhibitors, Table 2). Of the 
patients with LDL cholesterol levels above the treatment target (≥2.50 mmol/l) only 19% were 
prescribed lipid-lowering medication. For patients with TG levels above the treatment target 
(≥2.25 mmol/l) this percentage was 23%. After six months of follow-up, these percentages 
slightly increased to 21% and 26% respectively. After stratification by the LDL cholesterol 
treatment target (<2.50 mmol/l), malnutrition/inflammation markers – such as serum 
albumin and c-reactive protein – were similar between patients below and above the target. 
Table 2: Baseline lipid, treatment, and malnutrition-inflammation characteristics for the total population and 




















 2.5 ± 0.9 1.8 ± 0.5 3.2 ± 0.7 
TG (mmol/l)
2
 1.8 ± 1.1 1.7 ± 0.9 1.9 ± 0.8 
HDL cholesterol (mmol/l)
2
 1.3 ± 0.4 1.2 ± 0.4 1.4 ± 0.5 
Lipid-lowering medication (%)
3
 17 17 19 




 26.4 ± 4.8 26.9 ± 5.1 25.9 ± 4.7 
Albumin (mmol/l)
5
 41.0 ± 4.5 40.6 ± 4.7 42.0 ± 4.0 
C-reactive protein (mg/l)
6
 4.2 (3.0-10.0) 4.5 (1.9-13.3) 4.0 (3.0-8.0) 
Subjective global assessment (%)
7
    
     Well nourished 88 89 90 
     Moderately malnourished 12 11 10 
     Severely malnourished 0 0 0 
Median (boundaries of interquartile range) is given for C-reactive protein and mean ± standard deviation is given for 
all other normally distributed continuous variables. 
1
 Before multiple imputation, low density lipoprotein (LDL) 
cholesterol levels were available for 197 patients. 
2
 Triglyceride (TG) and high density lipoprotein (HDL) cholesterol 
levels were available for 206 and 203 patients.
 3
 Defined as the prescription of statins, fibrates, and cholesterol 
absorption inhibitors and available for 270 patients. 
4
 Available for 303 patients. 
5 
Available for 270 patients.  
6 
Available for 178 patients. 
7
 Defined as well nourished (subjective global assessment (SGA) 6-7), moderately 
malnourished (SGA 3-5), and severely malnourished (SGA 1-2) and available for 232 patients. 
Renal function decline 
The overall renal function decline for all 306 patients was 0.19 [95% confidence interval (CI) 
0.14;0.23] ml/min/1.73 m
2
/month. The median number of eGFR measurements during the 
first two years of follow-up was 3 (IQR 2-4) and 8%, 33%, and 59% of these patients had one, 
two, and three or more measurements respectively. Patients with LDL cholesterol levels 
above the treatment target of 2.50 mmol/l experienced an additional renal function decline 
(crude 0.10 [95% CI 0.00;0.20] ml/min/1.73 m
2
/month, p<0.05) compared with patients with 
levels below the target (mean decline of 0.11 ml/min/1.73 m
2
/month, Table 3 and Figure 1A). 
A similar trend (crude 0.05 [95% CI -0.06;0.16] ml/min/1.73 m
2
/month) was found for patients 
with TG levels above the treatment target of 2.25 mmol/l (mean decline of 0.15 ml/min/1.73 
m
2
/month in patients with levels below the target, Table 3 and Figure 1B). For HDL 
cholesterol the association was reversed, meaning that patients with HDL cholesterol levels 
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below the treatment target of 1.00 mmol/l experienced a slower renal function decline (crude 
-0.06 [95% CI -0.17;0.04] ml/min/1.73 m
2
/month) compared with patients with levels above 
the target (mean decline of 0.17 ml/min/1.73 m
2
/month, Table 3 and Figure 1C). However, 
when we analyzed HDL cholesterol levels as a ratio of LDL cholesterol levels (1.00 mmol/l / 
2.50 mmol/l = 0.4), we again found a trend towards a faster renal function decline in patients 
with a ratio below 0.4 (crude 0.06 [95% CI -0.05;0.18] ml/min/1.73 m
2
/month) compared with 
patients above this ratio (mean decline of 0.14 ml/min/1.73 m
2
/month, Table 3 and Figure 
1D). Adjustment for potential confounders did not change the results substantially (Table 3). 
Analyzing the number of targets not reached (including LDL cholesterol, TG, and HDL/LDL 
cholesterol ratio (range 1-3)) showed no additional decline when two or more targets, instead 
of only one target, were not reached. 
Additional analyses 
LDL cholesterol levels above the treatment target of 2.50 mmol/l remained associated with an 
accelerated renal function decline after excluding patients whom were prescribed lipid-
lowering medication, at any moment during follow-up (n=224 included in analysis, additional 
decline of 0.14 [95% CI 0.03;0.24] ml/min/1.73 m
2
/month, model 3 adjusted). The association 
of LDL cholesterol levels with renal function decline was comparable between centers that 
estimated (n=91) and directly measured (n=215) LDL cholesterol (additional decline of 0.12 
[95% CI -0.04;0.27] ml/min/1.73 m
2
/month, model 3 adjusted, and 0.07 [95% CI -0.05;0.19] 
ml/min/1.73 m
2
/month, model 3 adjusted, respectively). Analyzing LDL cholesterol levels 
continuously resulted in an adjusted additional renal function decline of 0.06 ml/min/1.73 
m
2
/month ([95% CI 0.01;0.11], model 3 adjusted) per each 1 mmol/l increase. For TG levels 
and the HDL/LDL ratio the trend remained present but did not reach statistical significance. 
Excluding eGFR values measured in the two weeks before reaching an endpoint (starting 
dialysis, receiving a kidney transplant, death, censoring) or excluding patients with only one 
eGFR measurement (n=281 included in analysis) resulted in very similar results. 
Figure 1: Association of lipid levels with renal function decline 
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The lines represent the crude renal function decline for patients below and above the recommended treatment 
target for low density lipoprotein (LDL) cholesterol levels (A), triglyceride (TG) levels (B), high density lipoprotein 
(HDL) cholesterol levels (C), and the HDL/LDL cholesterol ratio (D). These intercepts and slopes were estimated  
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Discussion 
In our cohort of incident patients receiving pre-dialysis care, an accelerated renal function 
decline was present in patients with LDL cholesterol levels above compared with below the 
treatment target (<2.50 mmol/l), independent of the prescription of lipid-lowering 
medication. For TG levels above the treatment target (≥2.25 mmol/l) and a HDL/LDL 
cholesterol ratio below 0.4 a trend was present, which did not reach statistical significance. 
Furthermore, at the start of pre-dialysis care lipid-lowering medication was only prescribed to 
19% of the patients with LDL cholesterol levels above the treatment target and 23% of the 
patients with TG levels above the treatment target. 
Our observation that abnormal lipid levels were associated with an accelerated renal function 
decline is in line with studies performed in patients with early to moderate stages of CKD 
(stages 1-4).
17-21
 Our findings are not in line with studies performed in patients receiving 
dialysis, in whom abnormal lipid levels seem to be beneficial.
4-6
 In terms of risk profiles, pre-
dialysis patients resemble early-stage CKD patients more than patients receiving dialysis. This 
could explain why we did not find a similar reversed association as seen in dialysis patients. 
Moreover, we found that especially high LDL cholesterol levels were associated with an 
accelerated renal function decline. Our results may therefore suggest that statins (possibly 
combined with cholesterol absorption inhibitors), which mainly lowers LDL cholesterol, can 
slow down renal function decline. However, statin trials showed contradictory effects on 
renal function decline in pre-dialysis patients
22;34;35
, but we have to keep in mind that these 
trials rarely included patients with advanced stages of CKD (4-5). Only in the recently 
published SHARP trial
12
 more than half of the included pre-dialysis patients had CKD stages  
4-5 (3,786 out of 6,247). This trial showed no effect on the combined endpoint of reaching 
end-stage renal disease, defined as starting dialysis or receiving a kidney transplant, or the 
doubling of serum creatinine. This is in line with our findings, revealing that the effect of 
abnormal lipid levels on renal function decline was independent of the prescription of lipid-
lowering medication. Unfortunately, our study was underpowered to investigate the course 
of renal function decline in patients who were prescribed these medications (n=52). 
Furthermore, we found a low percentage of patients whom were prescribed lipid-lowering 
medication (17%), which is in line with other studies performed in pre-dialysis patients
36
 and 
in patients receiving hemodialysis
37
. In addition, a striking finding in our cohort is that only 
19% of the patients with LDL cholesterol levels above the treatment target (≥2.50 mmol/l) 
and 23% of the patients with TG levels above the treatment target (≥2.25 mmol/l) were 
actually prescribed lipid-lowering medication at baseline. These percentages increased to 21% 
and 26% respectively after six months of pre-dialysis care, but were still quite low. These 
findings are in line with the study of Mason et al.
37
, showing that only 20.8% of the patients 
on hemodialysis with a total cholesterol level ≥5.17 mmol/l, resembling patients with LDL 
cholesterol and/or TG levels above the treatment target, were actually treated with statins. 
An explanation for this low percentage in patients receiving pre-dialysis care and dialysis 
treatment could be that physicians are not convinced that the prescription of lipid-lowering 
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medication is beneficial in these patients. For example, it may have been unclear for 
physicians whether patients with abnormal lipid levels, but without an additional 
cardiovascular risk factor (e.g. history of diabetes mellitus or cardiovascular disease), should 
be treated with lipid-lowering medication. Our findings indeed showed a low prevalence of 
these co-morbidities in patients with LDL cholesterol levels above the treatment target of 
2.50 mmol/l. Furthermore, a subgroup analysis in the SHARP trial suggests that lipid-lowering 
medication is beneficial for patients without diabetes mellitus or cardiovascular disease, 
leading to less major cardiovascular events. This evidence may have convinced physicians to 
only prescribe lipid-lowering medication to these patients. However, the effect of lipid-
lowering medication on renal function decline has not been elucidated yet. More trials in pre-
dialysis patients that investigate this effect are needed but may not be justified to perform. 
The effect of lipid-lowering medication on the reduction of major cardiovascular events is 
substantial and this evidence may be sufficient to prescribe these medications to pre-dialysis 
patients. Therefore, post-hoc subgroup analyses of published trials, meta-analyses, and new 
prospective follow-up data should gain more information about the possible renoprotective 
effect of lipid-lowering medication. 
The great strength of our study is the longitudinal character in incident patients. In this way 
we could take into account lipid level variability and changes during pre-dialysis care. 
Furthermore, we could assess renal function decline, which is a more detailed outcome 
measure as compared with the robust measures used in for example the SHARP trial (starting 
end-stage renal disease or doubling of serum creatinine). A disadvantage of our study is the 
presence of missing data. Lipid levels were not routinely measured at each pre-dialysis care 
visit. These missing data resulted in exclusion of 39% (196 out of 502) of the patients. 
Fortunately, baseline characteristics were very similar between the 306 patients included and 
196 patients excluded from our statistical analyses. Therefore, we could reasonably assume 
that the exclusion of patients with missing lipid levels did not bias our results. The last thing 
we have to keep in mind is that our study only includes patients with an eGFR <20-30 
ml/min/1.73 m
2
 who are referred to an outpatient clinic for pre-dialysis care. Therefore, these 
results are not generalizable to all patients with CKD stages 4-5. 
In conclusion, high levels of LDL cholesterol are associated with an accelerated renal function 
decline. These findings make the recommendation to prescribe lipid-lowering medication to 
pre-dialysis patients even stronger. However, further research in the specific population of 
pre-dialysis patients is necessary to investigate whether lipid-lowering medication can indeed 
slow down renal function decline. 
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Abstract 
Background:  Concerns are present on the limited value of renal function alone in defining 
the optimal moment to start with dialysis. Uremic symptoms and health-related quality of life 
(HRQOL) may have additional clinical value in defining this moment, but no prospective data 
are available. The aims of our study were to describe the course of uremic symptoms and 
HRQOL during pre-dialysis care and to investigate their association with the start of dialysis. 
Methods:  In the prospective PRE-dialysis PAtient REcord-2 (PREPARE-2) cohort study, 
incident patients starting specialized pre-dialysis care were included when referred to one of 
the 25 Dutch participating outpatient clinics (2004-2011). In the present analysis, 436 patients 
were included because of available information on uremic symptoms and HRQOL. Clinical 
data, uremic symptoms (revised illness perception questionnaire), and HRQOL (short form-36 
questionnaire; physical and mental summary score) were collected every six-month interval. 
A time-dependent Cox proportional hazards model was used to associate uremic symptoms 
and physical/mental HRQOL with the start of dialysis. 
Results:  All symptoms increased, especially fatigue and loss of strength, and both the 
physical and mental summary score decreased over time, with the most pronounced change 
during the last 6-12 months. Furthermore, each additional symptom (adjusted hazard ratio 
(HR) 1.05 [95% confidence interval (CI) 1.00;1.10]) and each 3-point lower physical and 
mental summary score (adjusted HR 1.04 [95% CI 1.02;1.06] and 1.04 [95% CI 1.02;1.07] 
respectively) were associated with a higher risk of starting dialysis within the subsequent six 
months. 
Conclusion:  The number of uremic symptoms increased and both the physical and mental 
HRQOL score decreased during pre-dialysis care and these changes were associated with the 
start of dialysis. These results may indicate that symptoms and HRQOL are good markers for 
the medical condition and disease stage of pre-dialysis patients, and are therefore good 
candidates to be used in defining the optimal moment to start with dialysis. 
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Introduction 
A large debate is ongoing about the optimal moment to start with dialysis.
1-5
 The last decades 





 and the first randomized controlled trial, the Initiating Dialysis 
Early and Late (IDEAL) study
19
, showed no difference in patient survival between early and 
late initiation of dialysis. In addition, consensus has been reached within the European Renal 
Best Practice guidelines on the limited value of renal function alone in the decision to start 
with dialysis.
4
 Uremic signs and symptoms (throughout text indicated as symptoms) and a low 
health-related quality of life (HRQOL), are highly present in pre-dialysis patients and therefore 
may have an added clinical value on top of renal function in this difficult decision. 
Symptoms can start appearing when renal function decreases to half of the normal function 
and continue to rise when renal function further decreases.
20
 Furthermore, several cross-
sectional studies showed that a low renal function is associated with a low HRQOL
21-23
 and 
that HRQOL is a good predictor for mortality and progression to end-stage renal disease in 
chronic kidney disease (CKD) patients
24
. However, knowledge is lacking on the specific 
development of symptoms and HRQOL during pre-dialysis care. Several guidelines indicating 
when to start dialysis already take into account the presence of symptoms.
25;26
 However, the 
incorporation of these symptoms into the guidelines are not consistent and specific. 
Furthermore, both the IDEAL study and some observational studies showed that for the 
decision to start with dialysis, symptoms were at least as important as renal function.
3;4;19;27
 In 
the late-start group of the IDEAL study, many patients (75.9%) started dialysis earlier than 
intentioned because of these symptoms. However, no prospective data is present about 
which symptoms and what level of HRQOL are important for nephrologists and patients in this 
decision.  
To get a better understanding of whether, when, and how the presence of symptoms and the 
level of HRQOL could be used in clinical practice in defining the optimal moment to start with 
dialysis, knowledge on the precise course of multiple symptoms and HRQOL, both physical 
and mental, in pre-dialysis patients is necessary. Therefore, our aims were to describe the 
course of symptoms and HRQOL during pre-dialysis care (CKD stages 4-5) and their 
associations with the risk of starting dialysis. 
Methods 
Study design 
The PRE-dialysis PAtient REcord-2 (PREPARE-2) study is a follow-up study of incident pre-
dialysis patients treated in 25 Dutch nephrology outpatient clinics in The Netherlands. Of 
these participating outpatient clinics 4 were academic and 21 were peripheral, and all were 
publicly funded. Patients were included between July 2004 and June 2011, at the start of 
specialized pre-dialysis care. Patients were treated by their nephrologists in a regular scheme 
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according to the treatment guidelines of the Dutch Federation of Nephrology
28
, a Dutch 
guideline partly based on the K/DOQI
26
 and KDIGO guidelines
29
. Patients were followed until 
the start of dialysis, receiving a kidney transplant, death, or censoring. Censoring was defined 
as: moving to an outpatient clinic not participating in the PREPARE-2 study, recovery of kidney 
function, refusal of further study participation, lost to follow-up or August 1, 2012, whichever 
came first. The study was approved by the Medical Ethics Committee or Institutional Review 
Board (as appropriate) of all participating centers. 
Patients 
To be eligible for inclusion, patients had to be at least eighteen years of age and the inclusion 
should take place at the moment of referral to a specialized pre-dialysis outpatient clinic. In 
practice, this refers to incident pre-dialysis patients with an estimated glomerular filtration 
rate (eGFR) of less than 20-30 ml/min/1.73 m
2
, and most of them have a progressive renal 
function loss. Patients with a failing kidney transplant were also included in the study if the 
transplantation was at least one year ago. All participants gave their written informed consent 
prior to study inclusion. 
Data collection 
Data on demography, biometry, primary kidney disease, co-morbidities, medication use, and 
HRQOL were collected at the start of specialized pre-dialysis care, at the moment of reaching 
one of the study endpoints (throughout text indicated as endpoint) as described above, and in 
intermediate six-month intervals. Laboratory data were extracted from the electronic hospital 
information systems or medical records. Primary kidney disease was classified according to 




Measurements and definitions 
The revised illness perception questionnaire (IPQ-R)
31
 was used to assess the onset of 
symptoms. This questionnaire has been validated
32;33
 and is widely used in the field of 
nephrology
34-36
. The following symptoms from the IPQ-R (12 out of 14 symptoms) can be 
considered as uremia- or disease-related and were included in our analyses; pain, nausea, 
breathlessness, weight loss, fatigue, stiff joints, wheeziness, headaches, upset stomach, sleep 
difficulties, dizziness, and loss of strength. The onset of these symptoms during pre-dialysis 
care was defined as answering ‘yes’ for the first time on the question ‘I have experienced this 
complaint since the beginning of my kidney disease’. HRQOL was assessed with the short 
form-36 (SF-36) questionnaire
37
, a generic validated questionnaire consisting of 36 items that 
can be divided into eight subscales. The scores on the individual items within a subscale were 
summed and transformed to a 0-100 scale, with higher scores indicating a better HRQOL. The 
eight subscales can further be divided into two summary measures; physical summary score 
(consisting of the four subscales physical functioning, role-physical, bodily pain, and general 
health) and mental summary score (consisting of the four subscales vitality, social functioning, 
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role-emotional, and mental health). Only the two summary measures (unstandardized) were 
used in our analyses. Estimated GFR and creatinine clearance (CrCl) were used as indicators 
for renal function. GFR was estimated using the four-variable Modification of Diet in Renal 
Disease (MDRD) formula.
38
 CrCl was estimated with the following formula: creatinine in urine 
(mmol/24h) * 700 / serum creatinine (µmol/l), and normalized per 1.73 m
2
 of body surface 
area using the formula of Du Bois and Du Bois
39
. The measurement at the moment of reaching 
an endpoint was defined as follows; the measurement closest to the moment of reaching an 
endpoint and not measured more than six months before this moment. 
Outcome 
The outcomes for our first aim were the frequencies of all symptoms and the mean physical 
and mental summary score over time before reaching one of the endpoints. The outcome for 
our second aim was the start of dialysis during follow-up. 
Statistical analyses 
The patients who filled in at least one HRQOL questionnaire, including the IPQ-R and the SF-
36, during pre-dialysis care (n=436) were included. Baseline characteristics were presented as 
mean ± standard deviation (SD) for normally distributed variables and as median (boundaries 
of interquartile range, IQR) for skewed variables. Missing values at baseline and at the 
moment of reaching an endpoint were imputed (using twenty repetitions) with the method of 
multiple imputation in PASW/SPSS version 20.0. This is a recommended technique when data 
is missing at random, in which missing data for a patient are imputed by a value that is 
predicted by other known characteristics of this patient.
40;41
 All characteristics in Table 1, all 
symptoms, and the physical and mental summary score (at baseline and at the moment of 
reaching an endpoint), follow-up time, and the type of endpoint reached (starting dialysis, 
receiving a kidney transplant, death, end of follow-up (August 1, 2012), or other endpoint; 
moving to an outpatient clinic not participating in the PREPARE-2 study, recovery of kidney 
function, refusal of further study participation, or lost to follow-up) were included in the 
model. Skewed distributed continuous variables and the follow-up time were logarithmically 
transformed. At baseline, 100% of the patients filled in a questionnaire completely or partly 
and this was 66% at the moment of reaching an endpoint. 
To describe the course of symptoms and HRQOL during pre-dialysis care, the frequency of all 
twelve separate symptoms, the mean (standard error of the mean [SEM]) total number of 
symptoms, the mean [SEM] physical summary score, and the mean [SEM] mental summary 
score at the start of pre-dialysis care and at the moment of reaching an endpoint were 
calculated. A linear mixed model was used to investigate the statistical difference between 
these two time points, adjusted for eGFR. This model takes into account correlations between 
repeated measurements within the same individual. Second, the mean [SEM] total number of 
symptoms, physical summary score, mental summary score, eGFR, and CrCl at the moment of 
reaching an endpoint and the preceding three time points were estimated with a linear mixed 
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model. Moreover, on each time point a Pearson’s correlation was calculated between eGFR or 
CrCl and the total number of symptoms, the physical summary score, and the mental 
summary score. Furthermore, we repeated all analyses in the subgroup of patients that 
started dialysis and in the subgroup of patients that did not start with dialysis but reached 
one of the other type of endpoints. 
A time-dependent Cox proportional hazards model was used to investigate the risk of starting 
dialysis within six months. Symptoms were analyzed separate and as a total number. The 
physical and mental summary score were analyzed in steps of 3 score points (is considered to 
be clinically relevant
42
). The analyses were adjusted for the potential confounders age, sex, 
diabetes mellitus, cardiovascular disease, and time-dependent eGFR. 
To test the robustness of our analyses, four sensitivity analyses were performed. First, we 
repeated our analyses subdividing the group of patients who did not start with dialysis into 
more categories: receiving a kidney transplant, death, end of follow-up, and other endpoint. 
Second, we repeated our imputation procedure and analyses after defining our measurement 
at the moment of reaching an endpoint as really measured at that moment, and not in the 
preceding six months. Third, we performed a time-dependent Cox proportional hazards 
model with starting dialysis, receiving a kidney transplant, and death as a combined outcome. 
Fourth, we used other available measurements to define weight loss and fatigue at the 
moment of reaching an endpoint. Weight loss was redefined as >5% of weight lost. Fatigue 
was redefined as scoring below the Dutch mean normal score on the vitality subscale of the 





In total, 502 incident pre-dialysis patients were included in the PREPARE-2 study of whom 436 
patients were available for our analysis. Table 1 shows that the median (IQR) age of these 
patients was 69 (56-76) years, 66% were male and the mean ± SD eGFR was 16.9 ± 6.1 
ml/min/1.73 m
2
. The 66 patients excluded from our analyses were younger, had a lower eGFR 
and CrCl, experienced more proteinuria, and had a higher prevalence of diabetes mellitus. 
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Age (years) 69 (56-76) 68 (56-75) 71 (56-78) 
Sex (male, %) 66 68 64 
Caucasian (%) 92 92 93 




 26.7 ± 5.1 27.1 ± 5.0 26.2 ± 5.2 
Smokers / quitters <1 year before inclusion (%) 25 24 25 
Primary kidney disease (%)    
     Diabetes mellitus 13 12 15 
     Glomerulonephritis 14 14 13 
     Renal vascular disease 31 31 30 





 16.9 ± 6.1 14.5 ± 5.3 19.4 ± 5.8 
Proteinuria (g/24h)
3
 1.0 (0.3-2.2) 1.4 (0.4-2.6) 0.7 (0.2-1.4) 
Urea (mmol/l)
4
 22.2 ± 7.0 23.7 ± 7.1 20.5 ± 6.6 




 19.2 ± 7.9 16.6 ± 7.0 22.6 ± 7.7 
Systolic blood pressure (mmHg)
6
 142 ± 22 143 ± 22 140 ± 23 
Hemoglobin (g/dl)
7
 12.3 ± 1.5 12.2 ± 1.4 12.4 ± 1.6 
Potassium (mmol/l)
8
 4.7 ± 0.6 4.7 ± 0.7 4.7 ± 0.6 
Bicarbonate (mmol/l)
9
 23.0 ± 4.0 22.1 ± 3.7 24.0 ± 4.0 
Co-morbidities (%)    
     Cardiovascular disease
10
 42 42 43 
     Diabetes Mellitus
11
 26 25 27 
Median (boundaries of interquartile range) is given for age and proteinuria and mean ± standard deviation is given 
for all other normally distributed continuous variables. 
1
 Available for 428 patients. 
2
 Estimated glomerular filtration 
rate (eGFR) is calculated with the four-variable Modification of Diet in Renal Disease formula and available for 379 
patients. 
3
 Available for 225 patients. 
4 
Available for 365 patients. 
5
 Creatinine clearance is estimated with the formula 
creatinine in urine (mmol/24h) * 700 / serum creatinine (µmol/l) and available for 242 patients. 
6 
Available for 432 
patients. 
7 
Available for 378 patients. 
8 
Available for 377 patients. 
9 
Available for 223 patients. 
10
 Defined as presence 
of a cerebrovascular accident, vascular problems, angina pectoris, myocardial infarction, or decompensatio cordis.  
11 
Present as primary kidney disease or co-morbidity. 
Description of the course of symptoms, HRQOL, and renal function 
In total, 225 of the 436 patients (52%) started dialysis (median follow-up 12.2 (IQR 5.3-21.4) 
months). Of the 211 patients that reached another endpoint (median follow-up 22.5 (IQR 
11.9-40.8) months), 15% were transplanted, 13% died, 24% refused further participation, 8% 
had a recovered kidney function, 4% moved to another center, and 36% were still in the 
study. The overall eGFR and CrCl decline (n=436) were 0.16 [95% CI 0.11;0.21] and 0.21 [95% 
CI 0.10;0.32] ml/min/1.73 m
2
/month respectively. The median number of filled in HRQOL 
questionnaires was 3 (IQR 2-4) and respectively 19%, 26%, and 55% filled in one, two, and 
three or more questionnaires during pre-dialysis care. Only the minority were filled in with 
the help of medical staff (1%). Furthermore, 21% were filled in with the help of a friend or 
family member and 78% were filled in with no help. After imputation all patients had at least 
two complete questionnaires. 
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The course of the total number of 
symptoms is presented for the total 
population (A) and stratified by the 
type of endpoint reached (dialysis or 
other endpoint, B). The black and grey 
dots indicate the mean and the error 
bars indicate the standard error of the 
mean [SEM]. The time in months 
before reaching an endpoint is 
presented on the x-axis (-12 means 
that the measurement was 7-12 
months before reaching an endpoint, 
 -18 means 13-18 months etc). On the 
y-axis, the mean [SEM] total number 
of symptoms is presented, which can 
range from 0 to 12. 
At the start of pre-dialysis care, most of the symptoms were already experienced by 20 to 
50% of the patients (Table 2). Only the symptoms fatigue, stiff joints, and loss of strength 
were experienced by more than 50% of the patients. The onset of fatigue and loss of strength 
were the strongest during pre-dialysis care and of wheeziness, headaches, and upset stomach 
the lowest. The onset of all symptoms was comparable between patients who started dialysis 
and patients reaching another endpoint. The mean [SEM] total number of symptoms was 4.8 
[0.1] at the start of pre-dialysis care and 6.7 [0.2] at the moment of reaching an endpoint. 
Figure 1A depicts the course of the total number of symptoms during the last two years of 
pre-dialysis care. The onset of symptoms was most frequent during the last six to twelve 
months before reaching an endpoint, which was comparable between patients who started 
dialysis and patients reaching another endpoint (Figure 1B). On all four time points, 
symptoms were not correlated with eGFR or CrCl. 
The physical summary score decreased from 54.4 [SEM 1.1] at the start of pre-dialysis care to 
47.0 [SEM 1.3] at the moment of reaching an endpoint (Table 2). The mental summary score 
decreased from 67.8 [SEM 1.0] to 58.9 [SEM 1.4]. The sharpest decrease was observed in the 
six to twelve months before reaching an endpoint (Figure 2A). After stratification by the type 
of endpoint reached, patients who started dialysis showed a slightly stronger decrease of 
both the physical and mental summary score (Figure 2B). On all four time points, no 
correlation was present with eGFR or CrCl. Figure 3A confirms the gradual decrease of eGFR 
and CrCl during pre-dialysis care, which was stronger in patients who started dialysis (Figure 
3B). 




























































___________________________________________________________________ Chapter 6│ 
85│ 

























































The course of the physical and 
mental summary score are presented 
for the total population (A) and 
stratified by the type of endpoint 
reached (dialysis or other endpoint, 
B). The black and grey dots indicate 
the mean and the error bars indicate 
the standard error of the mean 
[SEM]. The time in months before 
reaching an endpoint is presented on 
the x-axis (-12 means that the 
measurement was 7-12 months 
before the moment of reaching an 
endpoint, -18 means 13-18 months 
etc). On the y-axis, the mean [SEM] 
score from the short form-36 
questionnaire is presented 
(separately for the physical and 
mental summary measure), which 































































































































The course of estimated glomerular 
filtration rate (eGFR) and creatinine 
clearance (CrCl) are presented for the 
total population (A) and stratified by 
the type of endpoint reached (dialysis 
or other endpoint, B). The black and 
grey dots indicate the mean and the 
error bars indicate the standard error 
of the mean [SEM]. The time in 
months before reaching an endpoint 
is presented on the x-axis (-12 means 
that the measurement was 7-12 
months before the moment of 
reaching an endpoint, -18 means 13-
18 months etc). On the left y-axis, the 
mean [SEM] eGFR (ml/min/1.73 m
2
) 
is presented, and on the right y-axis 
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Association of symptoms and HRQOL with the start of dialysis 
The symptoms breathlessness, weight loss, fatigue, and wheeziness showed the strongest 
association with the start of dialysis within the subsequent six months (Table 3, adjusted 
column). Each additional symptom resulted in a crude 1.02 fold [95% confidence interval (CI) 
0.97;1.07] increased risk. Adjustment for potential confounders increased this hazard ratio 
(HR) to 1.05 [95% CI 1.00;1.10]. For HRQOL, every 3-point lower physical and mental summary 
score were associated with a higher risk of starting dialysis within the subsequent six months 
(crude HR 1.03 [95% CI 1.01;1.05] and HR 1.04 [95% CI 1.02;1.06], respectively). The results 
slightly increased after adjustment for potential confounders (Table 3). 
Sensitivity analyses 
All sensitivity analyses - 1.) extensive stratification of the subgroup of patients that did not 
start with dialysis but reached one of the other type of endpoints, 2.) defining the 
measurement at the moment of reaching an endpoint as really measured at that moment 
(not in the preceding six months), 3.) using a combined outcome including the start of dialysis, 
receiving a kidney transplant, and death, and 4.) redefining fatigue and weight loss - resulted 
in comparable courses of symptoms and HRQOL over time and similar risk estimates, implying 
robust results. 
Table 3: Association of symptoms and a low health-related quality of life with the risk of starting dialysis within the 
subsequent six months based on separate time-dependent Cox proportional hazards model 
 Crude HR [95% CI] 
(events/n = 225/436) 
Adjusted HR
1
 [95% CI] 
(events/n = 225/436) 
Symptoms   
     Pain 1.02 [0.77;1.35] 1.04 [0.78;1.39] 
     Nausea 1.13 [0.85;1.49] 1.10 [0.81;1.49] 
     Breathlessness 1.29 [0.98;1.69] 1.28 [0.96;1.71] 
     Weight loss 1.00 [0.75;1.32] 1.33 [0.99;1.77] 
     Fatigue 1.25 [0.81;1.94] 1.48 [0.94;2.31] 
     Stiff joints 0.95 [0.72;1.26] 1.07 [0.80;1.44] 
     Wheeziness 1.06 [0.79;1.42] 1.29 [0.94;1.78] 
     Headaches 0.86 [0.63;1.18] 1.08 [0.76;1.53] 
     Upset stomach 1.08 [0.82;1.43] 0.90 [0.67;1.22] 
     Sleep difficulties 1.22 [0.92;1.60] 1.17 [0.89;1.55] 
     Dizziness 0.95 [0.72;1.26] 1.13 [0.86;1.49] 
     Loss of strength 1.00 [0.74;1.34] 1.20 [0.89;1.64] 
     Number (per 1 complaint) 1.02 [0.97;1.07] 1.05 [1.00;1.10] 
HRQOL   










HRQOL; health-related quality of life. The hazard ratio (HR) [95% confidence interval (CI)] represents the increased 
risk of starting dialysis within the subsequent six months in patients with the symptom compared with patients 
without the symptom present, the increased risk with each additional symptom, and the increased risk with every  
3-point lower physical and mental summary score. 
1
 Adjusted for age, sex, diabetes mellitus, cardiovascular disease, 
and time dependent eGFR. 
2
 p <0.05; 
3 
p <0.005. 
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Discussion 
In our cohort of incident patients on pre-dialysis care, many patients had already experienced 
symptoms at the start of pre-dialysis care. In addition, the presence of all reported symptoms 
increased during pre-dialysis care, especially fatigue and loss of strength. HRQOL, defined as 
physical and mental summary score, decreased during pre-dialysis care. The sharpest increase 
of symptoms and decrease of HRQOL was observed during the last six to twelve months of 
pre-dialysis care. These results were supported by the observation that patients who reported 
a high number of symptoms or a low HRQOL started dialysis earlier than patients who 
reported a low number of symptoms or a high HRQOL. 
To our knowledge, this is the first study to report the onset of symptoms over time in patients 
on specialized pre-dialysis care. Our finding that HRQOL, both physical and mental, decreased 
during pre-dialysis care is in line with other studies.
21-23
 These cross-sectional studies 
demonstrated that HRQOL was highest in the ‘healthy’ general population, lowest in patients 
on dialysis, and in between in patients with CKD not on dialysis. However, the results of these 
studies were not CKD-stage specific and because of the cross-sectional character, the change 
of HRQOL over time could not be described or associated with the start of dialysis. 
Therefore, the major strength of our study is the follow-up character, instead of a cross-
sectional design. This gave us the opportunity to report the course of symptoms and HRQOL 
over the last years of pre-dialysis care. However, an issue that deserves further attention is 
that not all consecutive patients starting pre-dialysis care were included in the PREPARE-2 
study, only those who were asked and willing to participate, which could have led to selection 
bias. Unfortunately, it is very difficult to ascertain the direction of this bias. Besides this 
important issue, some patients reached another endpoint than dialysis, leading to a large 
diversity of patients at the moment of reaching an endpoint. However, results were 
comparable between all type of endpoints reached. Another issue that deserves attention is 
that symptoms were obtained from the IPQ-R. This questionnaire is not primarily designed to 
assess the longitudinal presence of symptoms and does not include questions about severity. 
This means that the ‘yes’ category of the IPQ-R consists of patients having experienced the 
onset of that symptom a few years ago or just recently. This mixture of onset times in our 
study could have led to an underestimation of the real risks of starting dialysis. Besides this, 
symptom burden is a reliable measure because it shows similar correlations with HRQOL and 
illness perceptions as symptom severity.
44;45
 Moreover, in answering symptom questions in 
the IPQ-R, patients’ perceptions of illness play a major role.
46
 The formulation of the question 
may also influence the response of patients. However, more objective measures of weight 
loss and fatigue resulted in similar frequencies. Finally, a completely filled in IPQ-R and SF-36 
questionnaire were not available for 66 patients. Therefore, our choice to only analyze 
patients with at least one filled in questionnaire could have led to selection bias.
41
 However, 
the 66 excluded patients had a slightly worse prognosis than the 436 included patients, so our 
results may be an underestimation. 
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Uremia is defined as all the signs and symptoms accompanying advanced kidney failure that 
cannot be attributed to co-morbid disease. The onset of uremia-related signs and symptoms 
can become present when renal function decreases to half of the normal function (normal 
eGFR is 100-120 ml/min/1.73 m
2
 on the age of 30) and continue to rise when renal function 
further decreases.
20
 This means that uremia-related symptoms mainly become present in 
patients with CKD stages 4-5. Therefore, the results from our pre-dialysis cohort, showing an 
increase in symptoms over time and as a consequence a decrease in perceived physical and 
mental HRQOL, are biologically plausible. Breathlessness, weight loss, fatigue, and wheeziness 
were the symptoms most strongly associated with the start of dialysis. This finding could 
indicate that these symptoms were considered the most by nephrologists and patients in the 
decision to start with dialysis. However, in our cohort data is lacking on whether the decision 
to start was indeed based on these symptoms. The possible role of breathlessness and 
wheeziness in the decision to start with dialysis could be explained by the presence of fluid 
overload. Fluid overload is a main indication to start with dialysis, as is stated in several 
guidelines
25;26
, and breathlessness and wheeziness can be consequences of pulmonary 
edema. 
In conclusion, the presence of all symptoms increases and both physical and mental HRQOL 
decreases during pre-dialysis care with the sharpest change in the last six to twelve months 
before reaching an endpoint. This may indicate that symptoms and both physical and mental 
HRQOL are good markers for the medical condition and disease stage of pre-dialysis patients, 
and are therefore good candidates to be used in defining the optimal moment to start with 
dialysis. Indeed, we found that several symptoms and a lower level of HRQOL were already 
associated with the start of dialysis, which may indicate that these symptoms were already 
considered by nephrologists and patients in this decision. However, for each individual we 
need to know the exact reason for starting dialysis and the survival time on dialysis, to 
investigate on which specific symptoms and what level of HRQOL this decision should be 
based. Therefore, in the future, more research should focus on finding clinical signs and 
symptoms that can help to plan when to start dialysis to increase survival and HRQOL on 
dialysis. The European EQUAL study
47
 will focus on this specific question. Eventually, a clinical 
decision rule based on all known factors may be a good and helpful tool for nephrologists and 
patients to make a more evidence-based choice when a patient needs to start with dialysis. 
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Abstract 
Background:  In pre-dialysis patients, the optimal treatment choices for controlling 
hemoglobin (Hb) are unknown because targeting high Hb levels has negative effects – poorer 
survival – but possible positive effects as well – better health-related quality of life (HRQOL). 
Moreover, these negative and positive effects may be different in specific subgroups, for 
example young versus elderly patients. 
Methods:  In the prospective PRE-dialysis PAtient REcord-2 (PREPARE-2) follow-up study, 
incident patients starting pre-dialysis care were included between 2004 and 2011 when 
referred to one of the 25 participating Dutch outpatient clinics. HRQOL was assessed each six-
month interval with the short form-36 questionnaire (physical/mental summary measure and 
eight subscales (range 0-100)). A linear mixed model was used to associate Hb (<11, 11-12 
(reference), 12-13, ≥13 g/dl) with HRQOL, stratified by anemia-medication (erythropoiesis 
stimulating agent and/or iron supplement, ESA/iron) and age (young: <65 years, elderly: ≥65 
years). 
Results:  In elderly patients (n=214) only, a natural high Hb (≥13 g/dl versus 11-12 g/dl) was 
associated with a statistically significant (p<0.05) and/or clinically relevant (>3-5 points) 
higher physical (11.9 [95% confidence interval (CI) 1.7;22.2]) and mental (6.4 [95% CI  
-1.7;14.6]) summary score. An ESA/iron induced high Hb did not result in a higher HRQOL in 
elderly patients. However, in young patients (n=157), only an ESA/iron induced high Hb (≥13 
versus 11-12 g/dl) showed an association with a higher physical (8.9 [95% CI 2.1;15.8]) and 
mental (6.2 [95% CI -0.4;12.8]) summary score. This effect was present on all physical and 
mental subscales, with the exception of mental health. 
Conclusion:  The association of Hb levels with HRQOL is different between young and elderly 
patients with or without prescribed ESA/iron on specialized pre-dialysis care. Therefore, 
medical care should aim for shared-decision making regarding the appropriate Hb target for 
each patient leading to a more individualized care. 
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Introduction 
Anemia is a common complication in patients with chronic kidney disease (CKD)
1
, and 
associated with increased mortality and morbidity, lower health-related quality of life 
(HRQOL), and faster progression to end-stage renal disease
2-9
. Therefore, treatment of 
anemia with erythropoiesis stimulating agents (ESA), iron supplements, or a combination of 
the two is important, and several studies have shown that treatment with ESA has a beneficial 
effect on various health outcomes.
10-14
 
However, the optimal hemoglobin (Hb) treatment target level for anemic patients with CKD is 
still unknown. A meta-analysis
15
 showed that targeting high Hb levels (≥12 g/dl) with ESA in 
anemic CKD patients increases their HRQOL. Positive effects were predominantly found on 
the physical summary measure of the short form-36 (SF-36) questionnaire.
16
 These effects are 
biologically plausible because common symptoms like low energy, fatigue, and weakness can 
be ameliorated by treating anemic patients with ESA.
11
 Moreover, increasing HRQOL may 
have additional positive effects independently of other factors because it has been shown 
that starting dialysis with a high HRQOL increases survival.
17;18
 
Besides the positive effects on HRQOL, high Hb targets (≥12 g/dl) in CKD patients can also 
have negative effects, such as an increased risk of mortality and cardiovascular events, and an 
accelerated progression to end-stage renal disease.
19
 These contradictory results on different 
health outcomes indicate that it is important to make a well-considered treatment decision, 
taking personal preferences of CKD patients into account. Good clinical practice would be that 
each patient discusses the possible positive effects on HRQOL and possible negative effects 
on other clinical outcomes together with their physician to make an informed decision about 
the appropriate Hb treatment target. 
Unfortunately, there is still insufficient evidence regarding the effect of targeting high Hb 
levels with anemia-medication on HRQOL to make such a well-considered decision. The 
studies that are available do not report all HRQOL subscales, do not show clinically relevant 
effects, and only report results about a heterogeneous population, instead of different 
subgroups of CKD patients. For example, positive effects on HRQOL may vary with age and 
CKD stage. Elderly patients and late-stage CKD patients experience more morbidities and have 




 CKD patients. A lower HRQOL can 
lead to a larger possible improvement. Or the opposite may take place, in which treatment 
ameliorates anemia-related symptoms whereas other morbidity-related symptoms among 
older patients in late CKD stages remain present, and consequently lead to a less increased 
HRQOL. 
The aim of the current study was to gain more knowledge about the combined association of 
Hb levels and the prescription of anemia-medication on all HRQOL subscales, in elderly 
compared with young CKD patients starting specialized pre-dialysis care. 




The PRE-dialysis PAtient REcord-2 (PREPARE-2) study is an ongoing, prospective follow-up 
study of incident pre-dialysis patients treated in 25 nephrology outpatient clinics in The 
Netherlands. Patients were included between July 2004 and June 2011, at the start of 
specialized pre-dialysis care. They were treated by their nephrologist in their regular scheme 
according to the treatment guideline of the Dutch Federation of Nephrology
22
, a guideline 




 guidelines. Patients were followed until the start of 
dialysis, receiving a kidney transplant, death, or censoring. Censoring was defined as: moving 
to an outpatient clinic not participating in the PREPARE-2 study, recovery of kidney function, 
refusal of further study participation, lost to follow-up, or August 1, 2012 (end of follow-up), 
whichever came first. The study was approved by the Medical Ethics Committee or the 
Institutional Review Board (as appropriate) of all participating centers. 
Patients 
To be eligible for inclusion, patients had to be at least eighteen years of age and the inclusion 
should take place at the moment of referral to a specialized pre-dialysis outpatient clinic. In 
practice, this refers to incident pre-dialysis patients with an estimated glomerular filtration 
rate (eGFR) of less than 20-30 ml/min/1.73 m
2
, in whom renal function loss is progressive. 
Patients with a failing kidney transplant were also included in the study, if the transplantation 
was at least one year ago. All participants gave their written informed consent prior to study 
inclusion. 
Data collection 
Data on demography, biometry, primary kidney disease, co-morbidities, medication 
prescriptions, and HRQOL were collected at the start of specialized pre-dialysis care and in 
subsequent six-month intervals. Corresponding laboratory data were extracted from the 
electronic hospital information systems or medical records. Primary kidney disease was 




Measurements and definitions 
HRQOL was assessed with the generic validated SF-36 questionnaire
16
, which consists of 36 
items that can be divided into eight subscales. The scores on the items within each subscale 
are summed and transformed to a 0-100 scale, with higher scores indicating a better HRQOL. 
Two summary measures can be composed of the eight subscales: physical summary score 
(consisting of the four subscales physical functioning, role-physical, bodily pain, and general 
health) and mental summary score (consisting of the four subscales vitality, social functioning, 
role-emotional, and mental health). GFR was estimated using the four-variable Modification 
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of Diet in Renal Disease (MDRD) formula
26
. The Hb levels (mmol/l) were measured according 
to the standard procedure in each participating outpatient clinic. We converted the Hb level 
in mmol/l to g/dl with the conversion factor 1.6113 and categorized it into four groups (<11, 
≥11-<12, ≥12-<13, and ≥13 g/dl). The chosen categories were based on the current treatment 





Continuous baseline characteristics were presented as mean ± standard deviation (SD) or 
median (boundaries of interquartile range, IQR) and dichotomous baseline characteristics 
were presented as percentages. A linear mixed model was used to associate the Hb 
categories (11-12 g/dl as reference) with HRQOL during the first two years of pre-dialysis care. 
We chose to restrict the time of follow-up until two years to prevent selection bias, as the 
healthy and stable patients, whom are still on pre-dialysis care after two years, would have a 
relatively large contribution to the overall association. In the model we included the four Hb 
categories as a fixed independent variable and the continuous HRQOL as a dependent 
variable, both updated each six months, and the variable time as a random variable. The 
results from this model indicate the difference in HRQOL score between the different Hb 
categories (compared with the reference category ≥11-<12 g/dl) on each time point during 
the first two years of pre-dialysis care. In other words, the results indicate the ‘average’ 
HRQOL difference between Hb categories. This linear mixed model was also performed after 
stratification by (1) the prescription of anemia-medication (erythropoiesis stimulating agent 
and/or iron supplement, ESA/iron) at the start of pre-dialysis care (yes/no) and (2) age 
(young: <65 years, and elderly: ≥65 years). To avoid power problems we also performed a 
continuous (per 1 g/dl increase) analysis in patients with Hb levels ≥11 g/dl (i.e. patients with 
optimal and high Hb levels). Patients with Hb levels <11 g/dl were excluded because 
categorical analyses before stratification showed a different effect size on HRQOL in these 
patients. We adjusted for the potential baseline confounders age, sex, primary kidney 
disease, cardiovascular disease, diabetes mellitus, eGFR, proteinuria, albumin, and systolic 
blood pressure. Associations of Hb with HRQOL were interpreted both statistically (p<0.05) 
and clinically (categorical analyses: >3-5 points
28
, and for the continuous analyses: >1.5-2.5 
points per each 1 g/dl increase). When information on stratification variables – age and 
ESA/iron prescription - or confounders were missing at the start of pre-dialysis care, data 
were imputed with the method of multiple imputation in PASW/SPSS (using ten repetitions). 
Multiple imputation is a technique where missing data for a patient are imputed by a value 
that is predicted by other known characteristics of this patient.
29;30
 The imputation model 
included all characteristics described in Table 1, plus the outcome reached and follow-up time 
because missing baseline characteristics are often related to the outcome.
31
 Skewed 
distributed continuous variables, including follow-up time, were logarithmically transformed 
before entering into the model. All statistical analyses were performed with PASW/SPSS 
version 20.0. 
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Sensitivity analyses 
We performed five sensitivity analyses to test the robustness of our results. First, we 
repeated all analyses after imputation of the missing baseline characteristics of all 502 
included patients. Second, after defining young patients as <70 years and elderly patients as 
≥70 years, analyses were repeated. Third, we repeated all linear mixed model analyses with 
an additional interaction term in the model: Hb categories*time. By including this term we 
investigated whether the association between Hb and HRQOL is different over time. In other 
words, whether the pattern of HRQOL over time differs between the Hb categories. Fourth, 
during pre-dialysis care some patients discontinue and others start using ESA/iron and 
patients can switch from the category <65 to ≥65 years. Therefore, we included the time-
dependent variables ESA/iron prescription and age (young: <65 years, elderly: ≥65 years), 
updated each six months, in the linear mixed model instead of stratifying the analyses by 
ESA/iron prescription and age at the start of pre-dialysis care. Thereafter, we performed an 
additional analysis with the potential confounders systolic blood pressure, eGFR, proteinuria, 
and albumin also included as time-dependent variables. 
Results 
Baseline characteristics 
Of the 502 patients included in the PREPARE-2 study, 371 patients were included in our 
primary statistical analyses. Patients were excluded if a Hb measurement and physical or 
mental summary score in the same six-month interval during the first two years of pre-dialysis 
care were not available. Table 1 shows the baseline clinical characteristics of these patients. 
Respectively 19%, 30%, and 51% had Hb levels below, on, or above the current treatment 
target (11-12 g/dl, Table 1). The majority had renal vascular disease as primary kidney disease 
and often diabetes mellitus as co-morbidity. Patients with Hb levels ≥13 g/dl had a higher 
eGFR, lower body mass index, less often diabetes mellitus, and more often cardiovascular 
disease compared with patients on target (≥11-<12 g/dl). Moreover, the higher prevalence of 
cardiovascular disease was present in elderly patients (≥65 years; 62% for ≥13 g/dl and 45% 
for 11-12 g/dl) and not in young patients (<65 years; 32% and 28%, respectively). Information 
regarding prescription of medication at the start of pre-dialysis care was only available for 323 
(87%) patients. Of these, 54% were prescribed ESA/iron therapy, which was similar across all 
Hb levels. Darbepoetin and iron supplements were prescribed more often than epoetin, 
especially in patients with high Hb levels (≥12 g/dl). 
Association of Hb levels with HRQOL 
Patients with high Hb levels (≥13 g/dl) had a statistically (p<0.05) and clinically (>3-5 points) 
higher physical summary score (56.7 versus 51.8, Table 2) compared with patients on target 
(11-12 g/dl). Adjustment for confounders did not essentially change the results. On all 
physical subscales, with the exception of bodily pain, this difference was clinically relevant. 
Furthermore, patients with low Hb levels (<11 g/dl) had a lower mental summary score 
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compared with patients on target (60.4 versus 66.1, p<0.05). On all subscales of the mental 
summary measure, with the exception of mental health, this difference was clinically 
relevant. 

















Age (years) 69 (55-76) 70 (51-78) 69 (57-75) 69 (57-76) 65 (53-76) 
Sex (%, male) 67 60 67 65 73 




 26.4 ± 4.9 27.0 ± 5.4 26.3 ± 5.0 26.4 ± 4.6 26.1 ± 4.8 
Smokers / quitters <1 year before 
inclusion (%) 
24 18 24 24 27 
Primary kidney disease (%)      
     Diabetes mellitus 13 18 11 12 13 
     Glomerulonephritis 14 10 14 17 12 
     Renal vascular disease 30 41 28 29 29 





 16.9 ± 6.0 15.5 ± 4.9 15.9 ± 5.9 17.6 ± 5.2 18.4 ± 6.8 
Urinary protein excretion (g/24h)
4
 1.0 (0.3-2.1) 1.1 (0.3-2.0) 1.0 (0.4-2.4) 0.7 (0.2-2.0) 1.1 (0.4-2.2) 
Urea (mmol/l)
5
 22.1 ± 7.0 23.7 ± 7.1 22.6 ± 6.9 21.1 ± 6.4 21.4 ± 7.5 
Albumin (g/l)
6
 40.7 ± 4.6 39.1 ± 5.0 40.5 ± 4.4 41.3 ± 4.7 41.5 ± 4.5 
Systolic blood pressure (mmHg)
7
 142 ± 22 142 ± 23 144 ± 24 139 ± 19 141 ± 23 
Hemoglobin (g/dl)
1
 12.3 ± 1.5 10.3 ± 0.5 11.6 ± 0.3 12.5 ± 0.3 14.0 ± 0.9 
Diabetes mellitus (%)
8
 26 38 25 21 22 
Cardiovascular disease (%)
9
 43 40 39 41 47 
Continuous variables are presented as mean ± standard deviation for normally distributed variables and as median 
(boundaries of interquartile range) for skewed variables. 
1
 Hemoglobin level is given in g/dl and available for 353 












 Estimated glomerular filtration rate (eGFR) is 
calculated with the four-variable Modification of Diet in Renal Disease formula and available for 351 patients.  
8
 Defined as the presence of a cerebrovascular accident, vascular problems, angina pectoris, myocardial infarction, or 
decompensatio cordis. 
9
 Present as primary kidney disease or co-morbidity. 
Table 2: Association of hemoglobin levels with health-related quality of life during pre-dialysis care 
 <11 
Mean [95% CI] 
≥11-<12 
Mean [95% CI] 
≥12-<13 
Mean [95% CI] 
≥13 
Mean [95% CI] 





Role-physical 39.7 [32.9;46.6] 43.0 [37.1;48.9] 43.1 [37.2;49.1] 50.3 [44.2;56.4] 
Bodily pain 65.1 [61.1;69.2]
1,2 
70.8 [67.3;74.3] 71.6 [68.1;75.1] 73.6 [70.0;77.1] 
General health 38.5 [35.8;41.1] 38.7 [36.4;41.0] 40.0 [37.7;42.3] 41.8 [39.4;44.1]
1,2 





 52.8 [50.2;55.5] 52.6 [49.9;55.2] 52.9 [50.2;55.7] 
Social functioning 65.3 [61.5;69.1]
1,2
 73.0 [69.7;76.3] 71.7 [68.3;75.0] 75.3 [71.9;78.7] 
Role-emotional 62.1 [55.4;68.7] 68.6 [63.1;74.1] 69.1 [63.4;74.7] 71.9 [66.6;77.2] 
Mental health 70.1 [67.3;72.8] 72.8 [70.4;75.2] 73.4 [71.0;75.8] 73.5 [71.0;75.9] 
Mental summary 60.4 [57.2;63.7]
1,2
 66.1 [63.3;68.9] 66.4 [63.6;69.3] 67.7 [64.8;70.6] 
For each hemoglobin (Hb, g/dl) category the mean [95% confidence interval (CI)] score on the two summary 
measures and eight subscales is given. The p-values are from a linear mixed model investigating whether the scores 
were significantly different compared with the reference category (Hb level of ≥11-<12 g/dl). 
1
 Crude p<0.05.  
2 
Adjusted p<0.05: sex, age, primary kidney disease, estimated glomerular filtration rate, proteinuria, albumin, systolic 
blood pressure, cardiovascular disease, and diabetes mellitus. 
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Association of Hb levels with HRQOL, stratified by ESA/iron prescription and 
age 
In young patients (<65 years) not prescribed ESA/iron at the start of pre-dialysis care, the 
physical and mental summary scores were similar across all Hb levels (Tables 3 and 4). When 
young patients were prescribed ESA/iron, high Hb levels (≥13 g/dl) resulted in a statistically 
significant and clinically relevant higher physical (8.9 [95% confidence interval (CI) 2.1;15.8]) 
and clinically relevant mental summary score (6.2 [95% CI -0.4;12.8]) compared with young 
patients on target (≥11-<12 g/dl, Table 3). Comparable results were found when analyzing Hb 
levels continuously; per 1 g/dl increase of Hb, the physical summary score increased with 4.0 
[95% CI 1.2;6.7] and the mental summary score with 2.4 [95% CI -0.1;4.9] points in patients 
with Hb levels ≥11 g/dl (Table 4). On all physical and mental subscales, with the exception of 
mental health, this difference was clinically relevant (>1.5-2.5 points increase with each 1 g/dl 
Hb increase, Figures 1A and 1B). 
In elderly patients (≥65 years) not prescribed ESA/iron at the start of pre-dialysis care, natural 
high Hb levels were associated with a statistically significant and clinically relevant higher 
physical and clinically relevant mental summary score compared with elderly patients with 
natural Hb levels ≥11 and <12 g/dl (11.9 [95% CI 1.7;22.2] and 6.4 [95% CI -1.7;14.6], 
respectively, Table 3). Continuous analyses showed similar results; per 1 g/dl increase of Hb, 
the physical summary score increases with 3.6 [95% CI -0.1;7.2] and the mental summary 
score with 2.5 [95% CI -0.6;5.6] points in patients with a Hb level ≥11 g/dl (Table 4). On all 
physical subscales and the mental subscales role emotional and mental health, this difference 
was clinically relevant (Figures 1C and 1D). 
In contrast, in elderly patients who were prescribed ESA/iron higher Hb levels were not 
associated with HRQOL. However, low Hb levels (<11 g/dl) were associated with a lower 
physical (-7.4 [95% CI -13.7;-1.0]) and mental summary score (-14.2 [95% CI -20.7;-7.6]) 
compared with target Hb levels (Table 3). Adjustment for confounders did not essentially 
change the results (Table 3). 
Sensitivity analyses 
Our first sensitivity analysis showed that results were essentially the same when repeating 
analyses after imputation or after defining young patients as <70 instead of <65 years. None 
of the linear mixed models showed a significant interaction term between Hb categories and 
time, indicating that the association of Hb with HRQOL did not change during pre-dialysis 
care. Using time-dependent variables of ESA/iron prescription, age, and the potential 
confounders during pre-dialysis care also did not change the results. 
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Table 3: Association of categorical hemoglobin levels with the physical and mental summary score on each time point 










Crude ∆ score 
[95% CI] 
≥13 
Crude ∆ score 
[95% CI] 
Physical summary      
Young – No ESA/iron 79 -1.1 [-9.4;7.1] 0 -3.1 [-9.5;3.2] -0.9 [-8.2;6.4] 
Elderly – No ESA/iron 88 1.5 [-7.0;10.1] 0 4.1 [-4.4;12.6] 11.9 [1.7;22.2]
1,2
 
Young – ESA/iron 78 1.7 [-6.1;9.4] 0 2.2 [-4.5;8.9] 8.9 [2.1;15.8]
1,2
 
Elderly – ESA/iron 126 -7.4 [-13.7;-1.0]
1
 0 3.7 [-1.7;9.0] 1.1 [-5.0;7.2] 
Mental summary      
Young – No ESA/iron 79 1.8 [-6.5;10.1] 0 0.4 [-6.1;6.9] 0.0 [-7.4;7.3] 
Elderly – No ESA/iron 88 -3.0 [-10.0;3.9] 0 1.1 [-5.7;7.9] 6.4 [-1.7;14.6]
2 
Young – ESA/iron 78 -1.5 [-8.5;5.6] 0 2.7 [-3.7;9.2] 6.2 [-0.4;12.8] 
Elderly – ESA/iron 126 -14.2 [-20.7;-7.6]
1,2
 0 -1.2 [-6.7;4.3] -2.6 [-8.8;3.6] 
For each hemoglobin (Hb, g/dl) category the difference (∆ score) [95% confidence interval (CI)] in the physical and 
mental summary score is given, compared with the reference category (Hb level of ≥11-<12 g/dl). All analyses were 
stratified by ESA/iron prescription at the start of pre-dialysis care and age (<65 years, young, and ≥65 years, elderly). 
The p-values are from a linear mixed model investigating whether the scores were significantly different between the 
Hb categories. 
1
 Crude p<0.05. 
2 
Adjusted p<0.05: adjusted for sex, age, primary kidney disease, estimated glomerular 
filtration rate, proteinuria, albumin, systolic blood pressure, cardiovascular disease, and diabetes mellitus. 
Table 4: Association of continuous hemoglobin levels with the physical and mental summary score on each time point 





Hb ≥11: optimal and high 
Per 1 g/dl increase 
Crude ∆ score 
[95% CI] 
Physical summary   
Young – No ESA/iron 79 1.0 [-1.5;3.6] 
Elderly – No ESA/iron 88 3.6 [-0.1;7.2]
2 
Young – ESA/iron 78 4.0 [1.2;6.7]
1,2
 
Elderly – ESA/iron 126 1.0 [-1.6;3.6] 
Mental summary   
Young – No ESA/iron 79 0.9 [-1.7;3.4] 
Elderly – No ESA/iron 88 2.5 [-0.6;5.6]
2
 
Young – ESA/iron 78 2.4 [-0.1;4.9] 







For each 1 g/dl increase in hemoglobin (Hb) level the difference (∆ score) 
[95% confidence interval (CI)] in the physical and mental summary score is 
given. All analyses were stratified by ESA/iron prescription at the start of pre-
dialysis care and age (<65 years, young, and ≥65 years, elderly). The p-values 
are from a linear mixed model investigating whether the scores significantly 
changed with each g/dl Hb increase. 
1
 Crude p<0.05. 
2
 Adjusted p<0.05: 
adjusted for sex, age, primary kidney disease, estimated glomerular filtration 
rate, proteinuria, albumin, systolic blood pressure, cardiovascular disease, and 
diabetes mellitus. 
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Figure 1: Association of hemoglobin levels with all physical and mental subscales during pre-dialysis care in patients 
with a hemoglobin level ≥11 g/dl, stratified by ESA/iron prescription and age 































































































































The bars indicate the change and the error bars the 95% confidence interval of the subscale scores (y-axis), with each 
1 g/dl increase in hemoglobin (Hb) level. Analyses were stratified by ESA/iron prescription at the start of pre-dialysis 
care and for age (young: <65 years, and elderly: ≥65 years). A linear mixed model was used to investigate whether the 
subscale scores changed significantly. The dashed horizontal lines represent an increase in the subscale score of 1.5-
2.5 points with each 1 g/dl increase in Hb, which is considered clinically relevant. * Crude p<0.05. 
∆ 
Adjusted p<0.05: 
adjusted for sex, age, primary kidney disease, estimated glomerular filtration rate, proteinuria, albumin, systolic 
blood pressure, cardiovascular disease, and diabetes mellitus. 
Discussion 
This study in patients on specialized pre-dialysis care found several significant improvements 
in HRQOL throughout different ranges of Hb levels. The most pronounced difference in 
HRQOL was present in patients with Hb levels below compared with on target (11-12 g/dl) 
and this difference was clinically relevant for the mental summary measure and five 
subscales; role-physical, bodily pain, vitality, social functioning, and role-emotional. In 
patients with high Hb levels (≥13 g/dl), additional increases of HRQOL were present, which 
were clinically relevant for the physical summary measure and four subscales; physical 
functioning, role-physical, general health and role-emotional. These findings are in line with 
the literature
3
, although the study of Finkelstein et al. found a stronger effect on the vitality 
subscale in the upper Hb ranges. 
Although these results in the overall heterogeneous pre-dialysis population are interesting, 
we should focus on specific subgroups because after stratifying by the prescription of 
ESA/iron and age (young, <65 years, and elderly, ≥65 years), various associations of Hb levels 
___________________________________________________________________ Chapter 7│ 
103│ 
with HRQOL were found. In elderly patients without ESA/iron prescription, high Hb levels (≥13 
g/dl) were associated with a clinically relevant higher physical and mental summary score, 
except on the subscales vitality and social functioning. No association was found in young 
patients without ESA/iron prescription. Possibly, elderly patients with high ‘natural’ Hb levels 
(≥13 g/dl) are very vital (score on the subscale vitality in our data; 51.6) and have less severe 
co-morbidities, and thereby experience a high HRQOL. Furthermore, the absent association of 
low Hb levels (<11 g/dl) with HRQOL in both young and elderly patients without ESA/iron 
prescription may be explained by the presence of clinical indications to not prescribe ESA/iron 
despite low Hb levels, for instance the absence of anemia-related symptoms. 
Besides this, young patients with high Hb levels (≥13 g/dl) compared with patients on target 
(11-12 g/dl) who are prescribed ESA/iron experienced a clinically relevant higher physical and 
mental summary score, except for the subscale mental health, and this difference was most 
pronounced for the physical summary measure. In contrast, in elderly patients who are 
prescribed ESA/iron no association was found between high Hb levels and better HRQOL. 
Only elderly patients with low Hb levels (<11 g/dl) had a lower physical and mental summary 
score, and this difference was most pronounced on the mental summary measure. 
Our finding that in young anemic patients high Hb levels were independently associated with 
a higher physical summary score is in line with the pre-dialysis trials included in the meta-
analysis of Clement et al.
32-36
 However, the effects found in these trials were on average 
smaller than in our study. This discrepancy can be explained by age (our cohort is younger) 
and a different classification of Hb categories.
32;34;36
 Our finding that high Hb levels in young 
patients who are prescribed ESA/iron were also independently associated with a higher 
mental summary score is in line with two trials included in the meta-analysis.
32;33
 An 
explanation for finding an increased HRQOL with higher Hb levels in young and not in elderly 
patients who are prescribed ESA/iron could be the following. Besides anemia, elderly patients 
often experience many co-morbidities. By prescribing ESA/iron, elderly patients are only 
relieved of their anemia-related symptoms and this may lead to a smaller improvement of 
HRQOL than in young patients. Another explanation could be that, compared with young 
patients, elderly patients experience less demanding daily activities, such as occupational 
activities.
37
 The effects in young patients were mainly found on the physical subscale role-
physical and on the mental subscale social functioning. This finding could be explained by the 
fact that, generally speaking, daily activities are restored when Hb is targeted to 11-12 g/dl, 
but that in young patients a higher Hb level may be necessary to perform all daily activities. 
Our study furthermore showed that for 68 patients who were prescribed ESA/iron Hb levels 
were still below target (<11 g/dl). Possible explanations for this low Hb level are ESA 
resistance (non-responders)
38
 and ESA/iron non-compliance. Non-compliance to medication is 
extremely high (30-60%) in patients with chronic illnesses
39
, including CKD patients
40
. In this 
study, we found that solely in elderly patients low Hb levels, despite ESA/iron prescription, 
were associated with a lower HRQOL, especially regarding the mental summary measure. A 
possible explanation for this discrepancy could be that elderly patients often are prescribed 
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more medications and lifestyle restrictions than young patients. Being non-compliant can 
thereby affect various aspects of their health and can consequently lead to a lower HRQOL. 
The stronger effect on the mental summary measure could be explained by the fact that 
normalization of Hb levels with ESA/iron has the strongest effect on the mental subscale 
vitality
28




In contrast to the beneficial effect on HRQOL, targeting high Hb levels may have serious 
disadvantages as well. Consistent with the studies showing a higher risk of cardiovascular 
events when targeting high Hb levels
19
, we found a higher prevalence of cardiovascular 
disease in patients with Hb levels ≥13 g/dl compared with 11-12 g/dl (47% versus 39%). 
Moreover, this higher prevalence of cardiovascular disease was more pronounced in elderly 
compared with young patients. This finding may implicate that in elderly patients prescribed 
with ESA/iron, high Hb levels do lead to negative effects but not give rise to positive effects. 
This may even more advocate the development of age-specific anemia treatment guidelines 
for patients on pre-dialysis care. Unfortunately, we could not investigate whether the 
mortality risk increases with increasing Hb levels due to the low event rate before the start of 
dialysis. 
A great strength of the PREPARE-2 study is the longitudinal instead of cross-sectional 
character, resulting in Hb levels and HRQOL measurements for every six-month interval 
during pre-dialysis care. Because of these repeated measurements, changes over time, for 
example HRQOL, can be investigated. Furthermore, our results can be generalized to the 
complete period of pre-dialysis care in patients with an eGFR below 30 ml/min/1.73 m
2
 who 
are starting specialized pre-dialysis care. A disadvantage of our study is that we have missing 
data because not all patients visited a pre-dialysis outpatient clinic each six months and most 
data was routinely collected. Due to the missing data, we could only include 371 of the 502 
patients in our statistical analyses, which may lead to selection bias. However, baseline 
characteristics were similar between the 371 included and 131 excluded patients. 
Furthermore, results remained similar after imputing missing values at the start of pre-dialysis 
care for all 502 patients included in the study, which makes it less likely that our analyses 
suffered from selection bias. In addition, we stratified by ESA/iron therapy solely based on the 
prescription of these medications at the start of pre-dialysis care. In practice, the prescription 
of ESA/iron can change over time. However, results did not change when the prescription of 
these medications was updated over time. Furthermore, we only know whether ESA/iron was 
prescribed and we do not know what the medication compliance rates are. 
Although trials are needed to confirm our findings, our results indicate that targeting high Hb 
levels in young, and not in elderly, patients on specialized pre-dialysis care increases their 
HRQOL. Furthermore, more studies are needed to investigate whether the negative effects of 
targeting high Hb levels on clinical outcomes are more present in elderly compared with 
young patients. We believe that future research should investigate negative (mortality and 
morbidity) and positive (better HRQOL and survival on dialysis) effects in subgroups of specific 
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patients. This scientific evidence is needed to better inform physicians and patients for 
making an individualized treatment decision regarding the appropriate Hb target, also based 
on patients’ preferences. 
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Abstract 
Background:  Studies performed in the United States showed that blacks progress from 
chronic kidney disease (CKD) to end-stage renal disease faster than do whites. Possible 
explanations are differences in healthcare system factors. This study investigated whether 
progression is also faster in a universal healthcare system, where all patients receive 
comparable care. 
Methods:  Data from the PRE-dialysis PAtient REcord (PREPARE) study, a multicenter follow-
up study of patients with CKD who started pre-dialysis care in The Netherlands between 1999 
and 2011 were analyzed. Time-dependent Cox proportional hazards models were used to 
estimate the hazard ratio (HR) for starting renal replacement therapy (RRT) and linear mixed 
models were used to compare renal function decline (RFD) between blacks and whites. To 
explore possible mechanisms, analyses were adjusted for patient characteristics. 
Results:  At initiation of pre-dialysis care, blacks (n=49) were younger, had more diabetes 
mellitus, higher proteinuria levels, and a higher estimated glomerular filtration rate than 
whites (n=946). Median follow-up time in months was similar (blacks: 13.9 (boundaries of 
interquartile range (IQR) 5.3-19.5); whites 13.1 (IQR 5.1-24.0)). For blacks compared with 
whites, the crude HR for starting RRT within the first 15 months was 0.86 [95% confidence 
interval (CI) 0.55;1.34] and from 15 months onward 2.26 [95% CI 1.03;4.95], which increased 
after adjustment. RFD was faster by 0.18 [95% CI 0.05;0.32] ml/min/1.73 m
2
/month in blacks 
compared with whites. 
Conclusion:  Blacks receiving pre-dialysis care in a universal healthcare system have faster 
disease progression than whites, suggesting that healthcare system factors have a less 
influential role than had been thought in explaining black-white differences. 
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Introduction 
Black Americans have a threefold higher incidence of end-stage renal disease (ESRD) 
compared with white Americans.
1
 This has been largely attributed to faster rates of 
progression from chronic kidney disease (CKD) to ESRD in blacks.
2-4
 Explanations are likely to 
involve a complex interaction of biologic, societal, and healthcare system factors.
5;6
 Biologic 
factors may relate to genetic differences.
7-9
 Societal factors may relate to a lower 
socioeconomic status among blacks and possible cultural conflicts for blacks that lead to 
reduced adherence of health recommendations.
5
 Healthcare system factors may relate to 
differences in access to healthcare and decreased quality of care for blacks.
5
 
Most studies regarding black-white differences in progression to ESRD derive from the United 
States.
10
 In the United States, blacks have less access to healthcare and studies suggest that 
blacks receive lower quality of care.
11;12
 To investigate the role of healthcare differences in 
the faster progression to ESRD in blacks, several studies have tried to control for it by studying 
cohorts of patients who are insured in the healthcare system of the United States, for 
example by Medicare
13;14
 or the department of Veterans Affairs
2;15
. However, these studies 
included only subsets of patients and therefore have limited generalizability.
10
 
To get further insight into the role of healthcare system factors, studies are needed in a 
setting where all patients have equal access to healthcare and receive similar highly 
standardized care, irrespective of age or socioeconomic status. The pre-dialysis care setting in 
The Netherlands is such a setting.
16
 Patients with CKD stages 4-5 are referred to specialized 
pre-dialysis care to adequately prepare for renal replacement therapy (RRT) and to improve 
therapeutic options. During this care, patients are monitored closely by nephrologists, 
dietitians, and social workers and are treated according to strict guidelines.
17;18
 
We sought to determine whether black and white patients with CKD starting specialized pre-
dialysis care in the universal healthcare system of The Netherlands have differences in time 
until the start of RRT and rate of renal function decline. 
Methods 
Study design  
Data from the PRE-dialysis PAtient REcord (PREPARE) study were used. PREPARE is a 
multicenter follow-up study of incident patients starting specialized pre-dialysis care 
(eighteen years or older) in The Netherlands. In practice, patients are referred to a pre-
dialysis nephrology outpatient clinic if they have an estimated glomerular filtration rate 
(eGFR) below 20-30 ml/min/1.73 m² (CKD stages 4-5) and a progressive loss of renal function. 
The PREPARE study consists of a retrospective and a prospective cohort. In the retrospective 
cohort (PREPARE-I), incident patients who had their first pre-dialysis visit between 1999 and 
2001 were included from eight outpatient clinics. In the prospective cohort (PREPARE-II), 
incident patients who started pre-dialysis care in one of 25 participating outpatient clinics 
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between 2004 and 2011, were willing to participate in the study, and understood the Dutch 
language were included. Patients were followed until the start of RRT (defined as dialysis or 
renal transplantation), death, lost to-follow-up, refusal to further participate in the study 
(PREPARE-II), recovery of renal function, or the end of the study period (January 2008 for 
PREPARE-I and August 2012 for PREPARE-II), whichever came first. In PREPARE-I, patients who 
experienced kidney failure from a kidney transplant were excluded. In PREPARE-II, patients 
who experienced kidney failure from a kidney transplant that was received less than one year 
before referral to pre-dialysis care were excluded. The study was approved by the Medical 
Ethics Committee or the Institutional Review Board of the participating centers. Patients 
included in PREPARE-II gave written informed consent before study inclusion.  
Race 
Information on race was reported by medical staff during a patient’s visit to the pre-dialysis 
outpatient clinic. Whites were observed as patients originating from European countries, 
Turkey, and Morocco. Blacks were observed as patients with a sub-Saharan African origin, 
including Surinamese creoles. For the present analyses, patients with missing race data were 
considered as whites because we assumed that non-white race would have been noted (the 




Baseline was defined as the date of the first visit at the pre-dialysis outpatient clinic. Baseline 
data were collected from medical records and extracted from the hospital information 
systems. Primary kidney disease was classified according to the codes of the European Renal 
Association-European Dialysis and Transplantation Association.
20
 Cardiovascular disease was 
defined as the presence of angina pectoris, coronary artery disease, and/or myocardial 
infarction. The eGFR was calculated by using the Modification of Diet in Renal Disease (MDRD) 
formula, taking into account age, sex, black race, and serum creatinine.
21 
Follow-up data  
Follow-up time was restricted to two years because after two years the number of patients at 
risk became too small.
22
 Follow-up time was defined as the time between the first visit and 
the start of RRT or censoring (i.e. death, lost to-follow-up, refusal to further participate in the 
study (PREPARE-II), recovery of renal function, or reaching the end of the study period within 
two years of follow-up). Recovery of renal function was defined as a substantial improvement 
in renal function and was based on the clinical impression of the nephrologist. Information on 
the date of starting RRT was collected from medical records. The rate of renal function decline 
was calculated by using all available eGFR measurements during the first two years of follow-
up. 
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Statistical analyses 
Descriptive statistics are presented as mean ± standard deviation (SD) or in case of a skewed 
distribution as median with boundaries of the interquartile range (IQR), stratified in white and 
black patients. Competing risk analysis was applied to calculate cumulative incidence curves 
for starting RRT for white and black patients, with death as a competing endpoint.
23
 Because 
the cumulative incidence curves for black and white patients crossed, a time-dependent Cox 
proportional hazards analysis was used to estimate the hazard ratio (HR) and 95% confidence 
interval (CI) for starting RRT. This time-dependent model included an interaction term 
between race and time period (before and after time point of crossing curves) resulting in two 
separate HRs for each time period. A linear mixed model, including the intercept and slope as 
a random term, was used to estimate renal function decline for black versus white patients. 
This model takes into account a correlation between individual repeated eGFR measurements 
and the deviation of the individual slopes from the mean slope.
24
 Both the HRs and the slopes 
were gradually adjusted for more variables to explore underlying mechanisms. 
To maintain power and to avoid bias, missing data for baseline variables were imputed with 
standard multiple imputation techniques in PASW/SPSS (using ten repetitions). Missing values 
were predicted under the assumption of missing ‘at random’ using the patient’s available 
characteristics.
25-27
 The imputation model included the characteristics described in Table 1 
except race because this is the determinant of interest. In addition, data on starting RRT 
(yes/no) and follow-up time were included because missing baseline characteristics are often 
related to the outcome.
28
 Skewed distributed continuous variables (i.e. age, parathyroid 
hormone, proteinuria, and the time until the start of RRT) were logarithmically transformed 
before entering into the model. Significance levels were determined at p<0.05. Analyses were 
carried out with PASW/SPSS version 20.0 for Windows.  
Subgroup and sensitivity analyses 
Two subgroup analyses were performed regarding renal function decline, in which the results 
were stratified by the presence of diabetes mellitus and by proteinuria levels (above and 
below 1.5 g/24h, median value). These analyses were selected based on the high prevalence 
of diabetes mellitus and proteinuria in black patients with CKD.
1;29
  
To test the robustness of the results, several sensitivity analyses were performed. Analyses 
were repeated (1) with exclusion of patients with missing data on race; (2) with use of 
unrestricted follow-up time; (3) with stratification by PREPARE-I and PREPARE-II; (4) with 
additional adjustment for education level as proxy for socioeconomic status (available only in 
PREPARE-II) and in a separate model for pre-dialysis center as proxy for deprivation area 
(available in PREPARE-I and PREPARE-II); and (5) with use of the CKD-Epidemiology 
Collaboration (CKD-EPI) equation
30
 instead of the MDRD formula. 




In total, 1049 patients were included, of whom 663 were white, 49 were black, 54 were 
grouped as other, and 283 had missing data on race. Patients grouped as ‘other’ were 
excluded and patients with missing race data were observed as being white. Of these 946 
white and 49 black patients, 51% and 41% respectively, were from the PREPARE-I study. Of all 
patients, 75% were referred by a nephrologist and 14% by a specialist of internal medicine, 
which was similar between blacks and whites (data based on PREPARE-I). Compared with 
whites, black patients were ten years younger and more likely to have diabetes mellitus or 
glomerulonephritis as primary kidney disease. Furthermore, blacks had a higher eGFR at 
initiation of pre-dialysis care and higher levels of proteinuria (Table 1). 
Follow-up and outcomes 
With follow-up time censored at two years, Table 2 shows the median follow-up time and 
frequencies of outcomes. Follow-up time and outcome frequencies were approximately the 
same for blacks and whites. Figure 1 demonstrates that during the first 15 months of pre-
dialysis care, blacks experienced a slightly lower probability of starting RRT compared with 
whites, whereas from 15 months onward blacks had a higher probability. For blacks 
compared with whites, the crude HR for starting RRT within the first 15 months was 0.86 [95% 
CI 0.55;1.34] and from 15 months onward 1.93 [95% CI 1.02;3.68], which remained 
approximately the same after adjustment for demographic characteristics, co-
morbidities/lifestyle, and prescribed medication. After additional adjustment for eGFR and 
proteinuria at baseline, these HRs increased to 1.16 [95% CI 0.73;1.85] and 3.61 [95% CI 
1.87;7.00], respectively. After further adjustment for other laboratory measurements, these 
HRs attenuated to 1.09 [95% CI 0.67;1.75] and 3.12 [95% CI 1.56;6.23], respectively (Table 3). 
Decline in renal function 
Among whites, 6%, 19%, and 75% had one, two, and three or more available eGFR 
measurements in the first two years of follow-up, respectively. Among blacks, these 
percentages were 11%, 11%, and 78%. The median number of eGFR measurements 
(boundaries of IQR) was 4 (3-12) in whites and 4 (3-11) in blacks. In whites, the mean rate of 
renal function decline was 0.23 [95% CI 0.20;0.26] ml/min/1.73 m
2
/month and in blacks it was 
0.41 [95% CI 0.28;0.54] ml/min/1.73 m
2
/month. Table 4 shows that the faster decline in renal 
function of 0.18 [95% CI 0.05;0.32] ml/min/1.73 m
2
/month in blacks remained present after 
adjustment. Results were essentially similar when analyses were repeated with inclusion of 
imputed baseline eGFR values and somewhat stronger when we limited the analyses to 
patients with at least three measurements of eGFR (0.22 [95% CI 0.06;0.38] ml/min/1.73 
m
2
/month, adjustment model 6). 
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Age (years)  67 (52-75)  57 (42-67)  
Sex (% male) 63  49  
Body mass index (kg/m²)
1 
26 ± 5  27 ± 6  
Blood pressure (mmHg)
2
     
   Systolic 147 ± 26  150 ± 24  
   Diastolic 80 ± 13  84 ± 13  
Smoking (%)
3 
27  20  
Primary kidney disease (%)     
   Diabetic nephropathy 15  33  
   Glomerulonephritis 11  16  
   Renal vascular disease  24  14  
      Hypertension 12  12  
      Other cause 12  2  
Co-morbidity (%)     
   Diabetes mellitus
4
 24  47  
   Cardiovascular disease
5
  33  27  
Medication (%)
6
     
   ACEi/ARB   66  79  
   ESA 37  33  
Laboratory measurements
7
      
   eGFR (ml/min/1.73 m²)
8 
14.7 ± 6.2  18.4 ± 8.4  
   Proteinuria (g/24h)
 
1.5 (0.5-3.3)  2.5 (1.1-4.2)  
   Hemoglobin (g/dl)
 
11.8 ± 1.7  11.7 ± 1.9  
   Albumin (g/l) 39.9 ± 5.0  37.6 ± 6.1  
   Calcium (mmol/l)
9
 2.3 ± 0.2  2.3 ± 0.2  
   Phosphorus (mmol/l)
 
1.5 ± 0.4  1.4 ± 0.3  
   PTH (pmol/l)
 








Values are presented as mean ± standard deviation or median (boundaries of interquartile 
range) or percentage. ACEi/ARB = angiotensin-converting enzyme inhibitor and/or angiotensin-
II receptor blocker; ESA = erythropoiesis stimulating agents; eGFR = estimated glomerular 
filtration rate; PTH = parathyroid hormone. 
1
 Available for 940 patients. 
2
 Available for 973 
patients. 
3
 Defined as smoking or quit smoking <1 year before the start of pre-dialysis care.  
4
 Defined as primary kidney disease and/or as co-morbidity. 
5
 Defined as the presence of angina 
pectoris, coronary artery disease, and/or myocardial infarction. 
6
 Available for 933 patients.  
7
 eGFR, proteinuria, hemoglobin, albumin, calcium, phosphorus, and PTH available for 859, 642, 
863, 822, 820, 839, and 496 patients, respectively. 
8
 GFR estimated with the four-variable 
Modification of Diet in Renal Disease formula. 
9
 Corrected for albumin concentration. 
│Race and progression to end-stage renal disease ___________________________________ 
│116 
Table 2: Median follow-up time and outcomes of incident black and white patients receiving pre-dialysis care during 






Median follow-up time in months (boundaries of IQR) 
All patients 13.1 (5.1-24.0)  13.9 (5.3-19.5)  
Patients starting RRT 7.6 (3.8-14.6)  11.2 (5.0-15.9)  
Censored patients
1 
10.9 (5.3-16.7)  12.0 (4.0-14.7)  
Outcomes, number (%)     
Start RRT  558 (59)  30 (61)  
   Dialysis   517 (55)    29 (59)  
   Renal transplantation   41 (4)    1 (2)  
Death 67 (7)  4 (8)  
Other
2






Figure 1: Time until the start of renal replacement therapy separate for black and white patients 

















White 231 / 946 148 / 672 109 / 493 70 / 353 
Black 9 / 49 7 / 36 12 / 28 2 / 13 
 






















IQR =  interquartile range; RRT = renal replacement therapy (dialysis or renal 
transplantation). ¹ Patients who refused further study participation, were lost to-
follow-up, had a recovery of renal function, died while receiving pre-dialysis care, 
or reached the end of the study period within two years of follow-up. Excluding 
patients still receiving pre-dialysis care after two years of follow-up. ² Refused 
further study participation, lost to-follow-up, recovery of renal function, reached 
end the of the study period within two years of follow-up, or reached end of two 
years follow-up. 
The cumulative incidence curves for starting renal replacement therapy 
(RRT), with death as competing endpoint,  show the percentages of black 
and white incident patients starting RRT over time, with follow-up censored 
at two years. 
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Table 3: Hazard ratios for the start of renal replacement therapy for incident black versus white patients receiving 
pre-dialysis care, adjusted using gradually more complex multivariable models 
 
Model 
Blacks (n=49) versus 
Whites (n=946) 
(0-15 months) 





Variables included in the model 
  HR [95% CI]   HR [95% CI]   
1. Unadjusted 0.86 [0.55;1.34]   1.93 [1.02;3.68]  Race 
2.  Demographic 0.80 [0.51;1.25]  1.82 [0.95;3.46]  Model 1 plus age, sex  
3. Co-morbidities/ 
lifestyle  
0.76 [0.48;1.20]  1.81 [0.95;3.46]   Model 2 plus PKD, systolic BP, BMI, 
DM, CVD, smoking status  
4. Medication 0.79 [0.50;1.25]   1.75 [0.91;3.35]  Model 3 plus ACEi/ARB, ESA 
5. Renal function/ 
damage 
1.16 [0.73;1.85]   3.61 [1.87;7.00]  Model 4 plus eGFR at start of pre-
dialysis care, proteinuria   
6. Laboratory 1.09 [0.67;1.75]   3.12 [1.56;6.23]  Model 5 plus Hb, calcium
2
, 
phosphorus, PTH, albumin 
HR = hazard ratio; CI = confidence interval; PKD = primary kidney disease; BP = blood pressure; BMI = body mass 
index; DM = diabetes mellitus; CVD = cardiovascular disease; ACEi/ARB = angiotensin-converting enzyme inhibitor 
and/or angiotensin-II receptor blocker; ESA = erythropoiesis stimulating agents; eGFR = estimated glomerular 
filtration rate calculated with the four-variable Modification of Diet in Renal Disease formula; Hb = hemoglobin; PTH = 
parathyroid hormone. 
1 
In all six models, the HR for the time period 15-24 months is significantly different from the 
HR for the time period 0-15 months (interaction term between race and time period). 
2 
Corrected for albumin 
concentration. 
Table 4: Additional decline in renal function (ml/min/1.73 m
2
/month) for incident black versus white patients 
receiving pre-dialysis care, adjusted using gradually more complex multivariable models and with follow-up censored 
at two years 
Model Blacks versus Whites
1 
Variables included in the model 
  Additional decline² [95% CI]  
1. Unadjusted 0.18 [0.05;0.32]  Race 
2.  Demographic 0.18 [0.05;0.31]  Model 1 plus age, sex  
3. Co-morbidities/ 
lifestyle 
0.18 [0.05;0.31]  Model 2 plus PKD, systolic BP, BMI, DM, CVD, 
smoking status  
4. Medication 0.18 [0.04;0.32]  Model 3 plus ACEi/ARB, ESA 
5. Renal function/ 
damage 
0.16 [0.02;0.31]  Model 4 plus eGFR at start of pre-dialysis care, 
proteinuria   
6. Laboratory 0.16 [0.02;0.31]  Model 5 plus Hb, calcium³, phosphorus, PTH, 
albumin 
CI = confidence interval; PKD = primary kidney disease; BP = blood pressure; BMI = body mass index; DM = diabetes 
mellitus; CVD = cardiovascular disease; ACEi/ARB = angiotensin-converting enzyme inhibitor and/or angiotensin-II 
receptor blocker; ESA = erythropoiesis stimulating agents; eGFR = estimated glomerular filtration rate calculated with 
the four-variable Modification of Diet in Renal Disease formula; Hb = hemoglobin; PTH = parathyroid hormone.  
¹ Patients included with one or more eGFR measurements (850 whites and 46 blacks). ² An additional decline of 0.18 
represents a faster decline in renal function of 0.18 ml/min/1.73 m
2
/month in blacks compared with whites.  
³ Corrected for albumin concentration. 
│Race and progression to end-stage renal disease ___________________________________ 
│118 
Subgroup analyses 
Black patients with diabetes mellitus experienced a 0.43 ml/min/1.73 m
2
/month ([95% CI 
0.09;0.76], adjustment model 6) faster renal function decline than white patients with 
diabetes mellitus (0.61 versus 0.18 ml/min/1.73 m
2
/month). Furthermore, black patients with 
high proteinuria levels (≥1.5 g/24h) experienced a 0.27 ml/min/1.73 m
2
/month ([95% CI  
-0.04;0.58], adjustment model 6) faster renal function decline than white patients with high 
proteinuria levels (0.60 versus 0.33 ml/min/1.73 m
2
/month). In black versus white patients 
without diabetes mellitus and in black versus white patients with low proteinuria levels, renal 
function decline did not differ. The interaction term p-value was 0.002 for diabetes with race 
and 0.274 for proteinuria with race. 
Sensitivity analyses 
Several sensitivity analyses were performed. First, excluding patients with missing data on 
race showed similar results. Second, the crude HR with use of unrestricted follow-up from 15 
months onward was lower (HR 1.07 [95% CI 0.59;1.96]) compared with the main analyses, but 
after adjustment for the variables in model 6 blacks had a 2.21 fold higher hazard. Results 
related to renal function decline did not materially change. Third, patients in PREPARE-I had a 
lower baseline eGFR and a higher level of proteinuria than patients in PREPARE-II, but in both 
studies blacks had a higher eGFR and more proteinuria at baseline than white patients. In line 
with this, the median follow-up time was 4.6 months shorter in PREPARE-I. The fully adjusted 
HR from 15 months onward was higher in PREPARE-II (PREPARE-I: 1.82 [95% CI 0.62;5.32]); 
PREPARE-II: 7.93 [95% CI 2.97;21.22]). In both studies, renal function decline was faster in 
blacks than in whites. In PREPARE-I, renal function decline in whites was 55% of that of blacks 
(0.28 and 0.51 ml/min/1.73 m
2
/month, respectively) and in PREPARE-II 50% (0.17 and 0.34 
ml/min/1.73 m
2
/month, respectively). Fourth, additional adjustment for education level 
(available for 86% of the patients in PREPARE-II (n=425)), did not change our point estimates. 
In a separate model, additional adjustment for pre-dialysis center (available for all patients) 
also did not change our point estimates. Finally, results remained similar when the CKD-EPI 
formula was used. 
Discussion 
This study found no difference in time until the start of RRT within the first 15 months of pre-
dialysis care between black and white incident patients starting pre-dialysis care in a universal 
healthcare system. However, black patients initiated pre-dialysis care with a higher eGFR than 
whites. From 15 months onward, blacks had a 1.93 fold higher hazard of starting RRT 
compared with whites. Adjustment for differences in demographic characteristics, co-
morbidities/lifestyle, prescribed medication, proteinuria, eGFR, and laboratory measurements 
at baseline increased this HR to 2.87. Renal function decline was 0.18 ml/min/1.73 m
2
/month 
faster in black than in white patients and remained faster after adjustment. 
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Our finding that blacks have a faster progression to ESRD than whites is in line with the results 
of studies examining cohorts of patients who are insured in the healthcare system of the 
United States. 
2;31
 However, these studies have limited generalizability because of the 
selected study population. Our study presents several new findings. First, except for a small 
study from the United Kingdom showing no difference in progression to ESRD between white 
(n=24) and African-Caribbean (n=11) patients with diabetic nephropathy
32
, differences in 
progression to ESRD between blacks and whites have not been previously investigated in a 
European universal healthcare system. Second, to our knowledge, a faster progression to 
ESRD in blacks compared with whites has not been described before in patients starting pre-
dialysis care. A study from the United States, found that among patients with GFRs ranging 
from 13 to 24 ml/min/1.73 m² blacks had a 2.87 ml/min/1.73 m²/year faster renal function 
decline compared with non-blacks, but these were not incident patients starting pre-dialysis 
care.
33
 Another study in the United States found a faster decline of only 0.3 ml/min/1.73 
m²/year in blacks compared with whites who were referred to a nephrology clinic (median 
follow-up 2.8 years). However, this study included patients with CKD stages 1-5 (mean eGFR 
37.4 ml/min/1.73 m²) and thus results are not comparable to those of our study.
34
 A third 
study in the United States demonstrated that black patients with eGFR <15 ml/min/1.73 m² 
and with eGFR between 15 and 29 ml/min/1.73 m² had 1.4 and 1.8 fold higher risks of 
progression to ESRD, respectively, compared with whites. However, these results were based 
on patients admitted to the hospital with acute myocardial infarction and no eGFR 
measurements were available during follow-up. Furthermore, it was unclear whether these 
patients received specialized pre-dialysis care.
35
 Third, to our knowledge, no previous studies 
have shown that blacks are referred to pre-dialysis care with higher eGFR compared with 
whites.  
Strengths of our study include the presence of a well defined population receiving 
standardized care in a universal healthcare system, the longitudinal design, and the multiple 
eGFR measurements during follow-up. Some limitations need to be mentioned. First, the 
retrospective and the prospective cohorts of the PREPARE study were pooled, whereas the 
prospective cohort included only patients who were willing to participate in the study. This 
may have resulted in the selection of ‘healthier’ patients, as indicated by the higher eGFR at 
baseline and the slower decline in renal function in PREPARE-II versus PREPARE-I. However, 
we feel that pooling PREPARE-I and PREPARE-II is justified because both studies included 
incident patients starting pre-dialysis care in The Netherlands. The absence of a difference in 
time until the start of RRT between whites and blacks in PREPARE-I could be explained by the 
lower baseline eGFR compared with PREPARE-II (in PREPARE-I there was a shorter period to 
develop a difference). Second, patients with missing race data were considered as whites and 
race was assessed by medical staff. This may have resulted in misclassification of race. 
Nevertheless, in our opinion this has not influenced the results substantially because similar 
results were found after exclusion of patients with missing race data. Furthermore, although 
not optimal, the assessment of race/ethnicity by medical staff is considered to be suitable for 
assessing race/ethnicity.
36
 Third, data on area deprivation were lacking. Differences in area 
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deprivation could have biased our results if deprivation is associated with both race and 
progression to ESRD. However, a great strength of the universal healthcare system in The 
Netherlands is the equal access to healthcare and highly standardized care for each individual, 
minimizing area differences in CKD progression and thereby minimizing bias. Furthermore, 
adjustment for pre-dialysis center, some in a more deprived area than others, did not change 
our effect estimate. Fourth, we do not have data on the magnitude and the characteristics of 
the patient group not referred to pre-dialysis care. However, the purpose of this study was 
not to investigate progression to ESRD in patients who could have been referred to pre-
dialysis care but rather in patients who actually received specialized pre-dialysis care.  
Our finding that black-white differences in progression to ESRD exist among patients receiving 
pre-dialysis care in a universal healthcare system suggests that previously reported 
differences could less likely be completely explained by healthcare related factors.
2-4
 Our 
finding that the faster decline in renal function for black compared with white patients is 
predominantly present in patients with diabetes mellitus and in patients with high proteinuria 
levels, may suggest that in blacks diabetes mellitus leads to more extensive damage of the 
kidneys causing a faster decline in renal function. In addition, it is reported that other factors, 
such as genetic differences
7-9
, decreased production of vitamin D in blacks
37-39
, and a greater 
incidence of low birth weight in blacks
40
 may also explain the different disease progression. 
Several explanations for the higher level of renal function at the start of pre-dialysis care for 
blacks compared with whites could be postulated. Guidelines suggest that patients need to be 
referred to pre-dialysis care at least one year before the start of RRT.
41
 If healthcare workers 
are aware of the faster renal function decline among blacks, they may refer such patients 
earlier to pre-dialysis care. Furthermore, healthcare professionals may refer blacks earlier 
because of their high prevalence of diabetes mellitus as underlying kidney disease or co-
morbidity.
42;43
 Additionally, it is possible that healthcare workers do not take into account 
that blacks have a higher creatinine production than whites due to differences in muscle 
mass, metabolism, and tubular handling of creatinine.
44-46
 The different association of 
creatinine and eGFR in blacks and whites is reflected in the MDRD equation by the 
multiplicative 1.212 term.
21
 Not applying this manual correction in our black population yields 
an eGFR that is only slightly higher than the eGFR among whites (15.2 and 14.7 ml/min/1.73 
m², respectively).  
In conclusion, although the number of black patients was relatively small, this study 
demonstrated that black patients receiving pre-dialysis care in a universal healthcare system 
had a faster progression to ESRD than whites, suggesting that healthcare system factors have 
a less influential role in explaining this black-white difference. Our results may suggest that 
black patients with CKD should be referred to pre-dialysis care earlier than white patients to 
assure timely preparation for RRT. Fortunately, in The Netherlands this is already the case 
because our data showed that black patients had a higher eGFR at the start of pre-dialysis 
care than white patients. Further investigation is needed to understand the mechanisms 
underlying the faster progression to ESRD in blacks. 
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Abstract 
Background:  Studying renal function in subjects with a familial propensity for longevity may 
provide insight in (un)known mechanisms that determine the age-related decline in renal 
function of normal subjects. 
Methods:  In the Leiden Longevity Study, middle-aged offspring of non-agenarian siblings 
and their partners as environmentally matched controls were included. Information was 
collected on lifestyle, medical history, medication use, and a non-fasting blood sample was 
drawn. Renal function (estimated glomerular filtration rate, eGFR) was assessed with the 
Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula. Linear mixed models 
were used to account for familial dependencies within the offspring and all analyses were 
stratified by sex. 
Results:  eGFR was similar between female offspring and female controls (0.44 ml/min/1.73 
m
2
 [standard error (SE) 0.72] difference, p=0.54, age-adjusted). Male offspring had a higher 
eGFR compared with male controls (1.78 ml/min/1.73 m
2
 [SE 0.78] difference, p=0.022, age-
adjusted), and further adjustments for various characteristics did not materially change this 
difference. Among men with a history of hypertension, or myocardial infarction and/or 
stroke, offspring had a higher eGFR compared with controls (4.74 ml/min/1.73 m
2
 [SE 1.53] 
difference, p=0.002, age-adjusted, and 6.21 ml/min/1.73 m
2
 [SE 2.85], p=0.033, age-adjusted, 
respectively). 
Conclusion:  Middle-aged men, but not women, with a propensity for longevity have better 
renal function compared with environmentally matched controls, especially among those 
with a history of, or at risk of cardiovascular disease. 
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Introduction 
Longevity is a complex phenotype that results from genetic factors, environment (including 
lifestyle), chance, and the interaction between these factors. Studies designed to identify 
genetic determinants for familial longevity have shown that centenarians
1
 and their 
offspring
2;3
, and offspring of familial non-agenarians
4
 have a lower prevalence of diabetes 
mellitus, hypertension, and cardiovascular disease, including myocardial infarction. 
Furthermore, insulin sensitivity is preserved in centenarians
5
 and offspring of non-agenarians 
have better glucose tolerance
6
 and better peripheral insulin sensitivity
7
 than environmentally 
matched controls. These observations indicate that offspring of long-lived subjects have a 
better metabolic profile. Moreover, most parameters associated with longevity differ 
between men and women. 
Studying renal function in subjects with a familial propensity for longevity may provide insight 
in (un)known mechanisms that influence the decline in renal function of normal subjects. 
With increasing age, renal function decreases with approximately 0.4 ml/min/1.73 m
2
/year 
from the age of eighteen years onwards.
8
 This age-related decline is higher in patients with 
cardiovascular disease and diabetes mellitus, which are two important risk factors for the 
decline in renal function.
9
 Risk factors for these co-morbidities, such as body mass index 
(BMI), blood pressure, inflammation, glucose metabolism, and lipid metabolism, also 
independently accelerate renal function decline.
9;10
 Treatment of patients with renal 
insufficiency mainly focuses on these modifiable renal risk factors.
11
 
The Leiden Longevity Study was designed to identify genetic determinants of familial 
longevity.
4;12
 In this study, non-agenarian siblings and their offspring, who are genetically 
enriched for longevity, were included. The offspring and the controls, partners of the 
offspring who are environmentally matched, were used to assess whether at middle-age 
familial factors related to longevity (genetic or early environmental) influence renal function. 
Methods 
Study design and participants 
In the Leiden Longevity Study 421 families were included, with at least two alive long-lived 
siblings of 89 years or older for men and 91 years or older for women and with identical 
Dutch parents. A more detailed description of the study design has been provided 
elsewhere.
4;12
 For 1671 of the offspring of these families and 744 partners of these offspring, 
all Caucasian, non-fasting blood serum samples were drawn at baseline. Additional 
information was collected on self-reported lifestyle, information on medical history from the 
participants’ general practitioners and information on medication use from the participants’ 
pharmacies. The Medical Ethics Committee of the Leiden University Medical Center approved 
the study and written informed consent was obtained from all subjects. 
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Renal function 
Glomerular filtration rate (GFR) was estimated with the Chronic Kidney Disease-Epidemiology 
Collaboration (CKD-EPI) formula
13
, the Modification of Diet in Renal Disease (MDRD) 
formula
14
, and creatinine clearance (ml/min) was estimated with the Cockcroft Gault (CG) 
formula
15
. The CKD-EPI and MDRD formula use sex, age, black race, and serum creatinine to 
estimate GFR (eGFR, ml/min/1.73 m
2
). Compared with these formulas, the CG formula 
includes body weight and excludes black race. To compare the CG estimate with the other 
two estimates, we normalized it per 1.73 m
2
 of body surface area (BSA) using the formula of 




Creatinine levels were measured in a non-fasting blood sample by Kinetic Alkaline Picrate 
methodology. Glucose, high sensitivity C-reactive protein (hsCRP), high density lipoprotein 
(HDL) cholesterol, and triglyceride levels were measured on a Hitachi Modular P 800 (Roche, 
Almere, The Netherlands). 
Statistical analyses 
Continuous data are given as mean ± standard deviation (SD) and dichotomous data are given 
as percentages (%). hsCRP and triglyceride levels were logarithmically transformed prior to 
analyses and geometric means with their SD are reported for these transformed variables. 
Independent t-tests were used to assess differences in continuous data between offspring 
and controls and for dichotomous data chi-square tests were used.  
As primary outcome we used the eGFR calculated with the CKD-EPI formula. This formula has 




 Because renal 
function declines with increasing age
18
 and effects related to longevity often differ between 
women and men, first the mean [standard error (SE)] eGFR was calculated, stratified by sex, 
offspring/control status, and age group (<55, 55-59, 60-64, and ≥65 years). Second, 
differences in eGFR between offspring and controls (∆eGFR), stratified by sex, were assessed 
with linear mixed models to adjust for correlation of sibling relationship. Furthermore, an 
interaction term between age continuously and offspring/control status was included in the 
model to assess whether the difference in eGFR between offspring and controls changes with 
increasing age. Thereafter, ∆eGFR was further adjusted for age, history of hypertension, 
cardiovascular disease (myocardial infarction and stroke), diabetes mellitus, anti-hypertensive 
medication,  glucose-lowering medication, glucose, hsCRP, HDL cholesterol, and triglyceride 
levels, smoking (current smoker), and BMI. We made separate models instead of gradually 
more complex models during adjustment, as otherwise many patients would be excluded 
from the final model because of missing values for one or more of the variables. Finally, we 
stratified the analyses by the presence of hypertension and by the presence of myocardial 
infarction or stroke.  
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GFR was also estimated with the MDRD and CG formula and as a sensitivity analysis we 
repeated all analyses with these two measurements. Furthermore, we investigated whether 
associations remained when analyses were repeated in patients without evidence of renal 
insufficiency as indicated by an eGFR >60 ml/min/1.73 m
2
. As a final sensitivity analysis we 
imputed all missing values with multiple imputation (using five repetitions). This is a 
recommended technique where missing data for a subject are imputed by a value that is 
predicted by other known characteristics of this subject (e.g. demographic, anthropometric, 
and clinical characteristics).
19;20
 All characteristics illustrated in Table 1 were included in the 
model. Statistical analyses were done with PASW/SPSS version 20. P-values smaller than 0.05 
were considered statistically significant. 
Results 
Of the 1671 included offspring and 744 included controls, 1300 offspring and 596 controls had 
a creatinine measurement as well as information on medical history and medication use. The 
population characteristics in Table 1 show that 695 (53%) of the offspring were female and 
342 (57%) of the controls were female. The female offspring were older than the female 
controls (mean ± SD; 59.3 ± 6.5 versus 56.9 ± 6.9 years, p<0.001). The age difference between 
male offspring and male controls was smaller (mean ± SD; 59.3 ± 6.5 versus 60.9 ± 6.9 years, 
p=0.001). Despite the generally older age, offspring were less likely to have hypertension, 
myocardial infarction, and diabetes mellitus compared with controls. A difference in the 
prevalence of myocardial infarction was only present in men, 8% versus 4% (p=0.024), and the 
difference in prevalence of diabetes mellitus was most pronounced in men, 11% versus 5% 
(p=0.005). In both males and females, glucose and triglyceride levels were lower in offspring 
compared with controls. 
Table 2 and Figure 1A and 1B show the mean eGFR for female and male offspring and 
controls, stratified by age. Estimated GFR was similar between female offspring and female 
controls (75.5 ml/min/1.73 m
2
 [SE 0.52] versus 76.8 ml/min/1.73 m
2
 [SE 0.69], p=0.090) but 
higher in male offspring (82.7 ml/min/1.73 m
2
 [SE 0.53)] than in male controls (79.6 
ml/min/1.73 m
2
 [SE 0.77]) (p<0.001). In female offspring, with increasing age eGFR decreased 
0.78 ml/min/1.73 m
2
/year ([SE 0.06], p<0.001) and in female controls this was 0.73 
ml/min/1.73 m
2
/year ([SE 0.08], p<0.001) (p-value for interaction=0.63). In male offspring, 
with increasing age eGFR decreased 0.79 ml/min/1.73 m
2
/year ([SE 0.07], p<0.001) and in 
male controls this was 0.86 ml/min/1.73 m
2
/year ([SE 0.09], p<0.001) (p-value for 
interaction=0.53). These results and the results in Table 2 and Figure 1A and 1B indicate that 
at any age the eGFR difference between offspring and controls, in both women and men, was 
similar. 
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Table 1: Characteristics for the total study population, stratified by sex 










Age (years) 59.3 ± 6.5 56.9 ± 6.9 <0.001 59.3 ± 6.5 60.9 ± 6.9 0.001 
Smoking, n (%)
1
 75 (12) 45 (15) 0.26 76 (15) 37 (16) 0.68 




 25.1 ± 4.0 25.3 ± 3.7 0.37 25.7 ± 2.9 25.9 ± 3.3 0.54 
Hypertension, n (%)
2
 158 (23) 93 (28) 0.094 136 (23) 68 (27) 0.20 
Anti-hypertensive, n (%)
3
 118 (17) 78 (23) 0.024 96 (16) 58 (23) 0.015 
Myocardial infarction, n (%)
2
 6 (1) 4 (1) 0.62 23 (4) 19 (8) 0.024 
Stroke, n (%)
2
 12 (2) 9 (3) 0.32 32 (5) 7 (3) 0.10 
Diabetes mellitus, n (%)
2
 26 (4) 19 (6) 0.16 31 (5) 26 (11) 0.005 
Glucose-lowering, n (%)
4
 10 (1) 9 (3) 0.17 12 (2) 13 (5) 0.013 
Glucose (mmol/l)
5
 5.7 ± 1.2 6.0 ± 1.5 0.003 5.9 ± 1.4 6.3 ± 2.0 0.008 
hsCRP (mg/l)
5
 1.41 ± 2.95 1.52 ± 3.01 0.31 1.34 ± 2.85 1.32 ± 2.82 0.79 
HDL cholesterol (mmol/l)
5
 1.59 ± 0.45 1.56 ± 0.48 0.27 1.27 ± 0.36 1.22 ± 0.36 0.050 
Triglycerides (mmol/l)
5
 1.39 ± 1.66 1.49 ± 1.72 0.048 1.72 ± 1.71 1.83 ± 1.71 0.11 
Continuous variables are illustrated as mean ± standard deviation (SD) and as geometric mean ± SD for the 
logarithmically transformed variables high sensitive C-reactive protein (hsCRP) and triglyceride levels. 
1
 Smoking and 
body mass index were available for 1654 and 1657 subjects respectively. 
2
 Percentage of subjects with this co-
morbidity present in their medical history; hypertension, myocardial infarction, stroke, and diabetes mellitus were 
available for 1856, 1886, 1890, and 1864 subjects respectively. 
3
 All types of anti-hypertensive medication. 
4
 Insulin 
and other blood glucose-lowering medication. 
5 
Glucose, hsCRP, high density lipoprotein (HDL) cholesterol, and 
triglyceride levels were available for 1884, 1889, 1895, and 1895 subjects respectively. The p-value was obtained with 
an independent t-test, for continuous variables, or with a chi-square test. 
Table 2: Mean estimated glomerular filtration rate for offspring and controls, stratified by age and sex 
 Women    Men    
 Offspring Control  Offspring Control  


























































For each category based on sex and age, the crude mean [standard error (SE)] estimated glomerular filtration rate 
(eGFR) calculated with the Chronic Kidney Disease-Epidemiology Collaboration formula is presented. P-values were 
obtained from linear mixed models adjusted for sibling relationship. 
1
 P-values for the interaction term between age 
and offspring/control status were 0.63 for women and 0.53 for men. This indicates that the eGFR difference between 
offspring and controls remained similar with increasing age. 
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For each age category (x-axis) in women (A) and men (B) the crude mean (bar) and standard error (error bar) of the 
glomerular filtration rate (GFR) estimated with the Chronic Kidney Disease-Epidemiology Collaboration formula  
(y-axis) is presented for both offspring and controls (legend). * P-value for eGFR difference between offspring and 
controls is <0.05 and obtained from linear mixed models adjusted for sibling relationship. 
Table 3 shows the difference in eGFR between offspring and controls, stratified by sex and 
adjusted for various characteristics. Female offspring had a similar eGFR compared with 
female controls (-1.32 ml/min/1.73 m
2 
[SE 0.78], p=0.090). After adjustment for age, 
hypertension, myocardial infarction, stroke, and diabetes mellitus the difference remained 
unaltered (0.13 ml/min/1.73 m
2
 ([SE 0.75], p=0.86)). Male offspring had a significant higher 
crude eGFR compared with male controls (3.05 ml/min/1.73 m
2 
[SE 0.87], p<0.001). After 
adjustment for age, the point estimate in men changed to 1.78 ml/min/1.73 m
2
 ([SE 0.78], 
p=0.022). Further adjustment for hypertension, myocardial infarction, stroke, and diabetes 
mellitus did not affect the observed difference in men (1.83 ml/min/1.73 m
2 
[SE 0.80], 
p=0.022). Adjustment for medication use, blood parameters or lifestyle factors slightly 
attenuated the difference in men (1.63 [SE 0.77], p=0.035; 1.54 [SE 0.78], p=0.048; and 1.73 
[SE 0.83], p=0.036, respectively). 
Table 4 shows the age-adjusted difference in eGFR between offspring and controls stratified 
by sex and additionally stratified by the presence of hypertension and the presence of 
myocardial infarction or stroke. In women there was no difference between offspring and 
controls in any of the strata. In men with hypertension, offspring had a higher eGFR compared 
with controls (4.74 ml/min/1.73 m
2
 [SE 1.53], p=0.002, age-adjusted). Moreover, in men with 
a previous history of myocardial infarction or stroke, offspring had a higher eGFR compared 
with controls (6.21 ml/min/1.73 m
2
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 n ∆eGFR [SE] p-value n ∆eGFR [SE] p-value 
Crude 1037 -1.32 [0.78] 0.090 859 3.05 [0.87] <0.001 
   + age 1037 0.44 [0.72] 0.54 859 1.78 [0.78] 0.022 
   + age, HT, MI, stroke,  
      diabetes mellitus 
998 0.13 [0.75] 0.86 822 1.83 [0.80] 0.022 
   + age, anti-hypertensive  
      medication, glucose-   
      lowering medication 
1037 0.23 [0.72] 0.74 859 1.63 [0.77] 0.035 
   + age, glucose, hsCRP,  
      triglycerides, HDL 
      cholesterol 
1026 0.11 [0.73] 0.87 851 1.54 [0.78] 0.048 
   + age, smoking, BMI 898 0.36 [0.77] 0.64 747 1.73 [0.83] 0.036 
∆ estimated glomerular filtration rate (eGFR) is the difference in eGFR, calculated with the Chronic Kidney Disease-
Epidemiology Collaboration formula, between offspring and controls assessed with a linear mixed model. A positive 
number means that eGFR is higher in offspring compared with controls. The crude ∆eGFR was adjusted for sibling 
relationship. We additionally adjusted for age and the main risk factors for decline in renal function: hypertension 
(HT), myocardial infarction (MI), stroke, diabetes mellitus (DM), anti-hypertensive medication, glucose-lowering 
medication, glucose, high sensitivity C-reactive protein (hsCRP), high density lipoprotein (HDL) cholesterol, 
triglyceride levels, smoking and body mass index (BMI). hsCRP and triglyceride levels were logarithmically 
transformed. 
1
 Offspring n=695 and control n=342. 
2
 Offspring n=605 and control n=254. 
Table 4: Difference in age-adjusted estimated glomerular filtration rate between offspring and controls, stratified by 






 n ∆eGFR [SE] p-value n ∆eGFR [SE] p-value 
Hypertension
3
       
     No 725 0.27 [0.86] 0.75 589 0.35 [0.88] 0.69 
     Yes 296 0.22 [1.41] 0.87 248 4.74 [1.53] 0.002 
Myocardial infarction / stroke       
     No 1001 0.00 [0.73] 0.99 781 1.30 [0.80] 0.10 
     Yes 28 6.98 [5.46] 0.21 74 6.21 [2.85] 0.033 
∆ estimated glomerular filtration rate (eGFR) is the difference in eGFR, calculated with the Chronic Kidney Disease-
Epidemiology Collaboration formula, between offspring and controls assessed with a linear mixed model. A positive 
number means that eGFR is higher in offspring compared with controls. We adjusted for sibling relationship and age. 
1
 Offspring n=695 and control n=342. 
2
 Offspring n=605 and control n=254. 
3
 Defined as either having hypertension 
and/or using anti-hypertensive medication. 
The sensitivity analysis with GFR estimated with the MDRD or CG formula as outcome showed 
similar crude and adjusted results. Repeating the analyses in subjects with eGFR >60 
ml/min/1.73 m
2
 (offspring n=1220, controls n=556) resulted in similar differences in eGFR in 
female offspring compared with female controls (0.10 ml/min/1.73 m
2
 [SE 0.66], p=0.87, age-
adjusted), and in male offspring compared with male controls (1.59 ml/min/1.73 m
2
 [SE 0.71], 
p=0.026, age-adjusted). Multiple imputation of missing data resulted in a similar eGFR in 
female offspring compared with female controls (-0.01 ml/min/1.73 m
2
 [SE 0.72], p=0.99) and 
a non-significant higher eGFR in male offspring compared with male controls (1.39 
ml/min/1.73 m
2
 [SE 0.78], p=0.073). 
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Discussion 
Our aim was to investigate whether subjects with a familial propensity for longevity have 
better renal function compared with control subjects. We found that in the male but not in 
the female sex, middle-aged individuals with a propensity for longevity had a better renal 
function compared with environmentally matched controls. This renal function difference in 
men was predominately present in subjects with hypertension or cardiovascular disease. 
In our study three findings dependent on sex were present. First, we found that at middle-
age, women had a lower renal function compared with men. This is in line with several other 
studies
8;10;21
, showing a lower eGFR in women throughout life, and in line with the correction 




, and CG formula
15
. Second, in men the age-
associated decrease in eGFR was slightly stronger than in women. This difference may suggest 
that men are biologically older than women at a similar calendar age, which is in line with the 
evidence that men live five to ten years shorter than women.
22
 Third, women had less 
cardiovascular disease and diabetes mellitus than men. This is in line with the fact that men 
develop co-morbidities, such as cardiovascular disease
23
 or diabetes mellitus
24
, at an earlier 
age in life than women. 
In men, a difference in renal function between longevity-prone subjects and environmentally 
matched controls was observed. This difference may be explained by the lower prevalence of 
(sub)clinical hypertension and cardiovascular disease in men from long-lived families, which 
probably reflects a lower degree of atherosclerosis. Atherosclerosis is an inflammatory 
process in which inflammation has an important role in each phase of the process. 
Inflammation is involved in fat accumulation in the vessel wall, maturation of the vascular 
lesion, and eventually ruptures of the atherosclerotic plaque leading to myocardial infarction 
or stroke.
25;26
 Longevity-prone men may better handle inflammatory stress and thereby have 
less atherosclerosis and a later onset of inflammatory diseases, such as myocardial infarction 
and stroke. This better handling of inflammatory stress may furthermore reduce the negative 
consequences of inflammatory diseases, such as fibrosis of renal tissue.
27
 Our finding of a 
larger eGFR difference in male offspring compared with male controls with a previous history 
of myocardial infarction or stroke compared with male subjects without such a history may 
support this. However, our data showed that hsCRP levels were similar between male 
offspring and controls, but hsCRP may not be a good indicator for these inflammatory 
processes. 
In women we observed no difference in renal function between offspring and controls. There 
are two possible reasons to explain the absence of a difference. First, the prevalence of 
atherosclerotic disease in women aged 60-70 years is much lower than in men in the same 
age category. Moreover, the difference between male offspring and male controls was mainly 
observed in men with hypertension or cardiovascular disease. Although, we found no 
statistical significant difference in women, we did find a trend in women with a myocardial 
infarction or stroke in their history (eGFR difference of 6.98 ml/min/1.73 m
2 
[SE 5.46], 
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p=0.21). Second, the absence of a difference in renal function between women from long-
lived families and controls might be explained by the effect of sex hormones. Sex hormones 
have immuno-modulating actions often resulting in a more anti-inflammatory state.
28
 The 
genes involved in longevity leading to a better handling of inflammatory stress and less 
atherosclerosis may then play a less important role. Furthermore, our findings might suggest 
that the anti-inflammatory effects of sex hormones are less effective once myocardial 
infarction or stroke has developed. However, the exact pro- and anti-inflammatory actions of 
sex hormones need to be elucidated. 
There are some limitations to our study. First, baseline information on medical history and 
medication use were not available for all offspring and controls. However, it is unlikely that 
this selection of subjects has led to biased results because these data were only missing when 
the subjects’ general practitioner or pharmacy did not respond, which was a random process. 
Second, for our main analyses the GFR was estimated with the CKD-EPI formula. A problem 
with the CKD-EPI formula is that it sometimes overestimates the real GFR in patients with low 
renal function (<60 ml/min/1.73 m
2





only a small proportion of subjects fell in these categories and with the other two formulas, 
the MDRD and CG formula, we found similar results. Besides this, for each subject only one 
eGFR measurement was available, making it not possible to relate longevity to renal function 
decline. Third, we could not adjust for all established risk factors for decline in renal function, 
such as hemoglobin and calcium/phosphate levels because this information was lacking. 
We conclude that renal function was higher in middle-aged men with a propensity for 
longevity compared with environmentally matched controls. A possible explanation for the 
observed effect is the presence of a different strategy for inflammation and atherosclerosis in 
subjects with a familial propensity for longevity. 
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Abstract 
The achievement of treatment guidelines in patients with chronic kidney disease is poor and 
more efforts are needed to improve this. Audit-based education is a program that may 
contribute to this improvement. Therefore, de Lusignana et al investigated whether audit-
based education is effective in lowering systolic blood pressure in a primary care setting. 
Although the program is inventive and promising, several adjustments are needed before it 
can be applied as an effective strategy. 
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Hypertension is an important independent risk factor of cardiovascular events, mortality and 
renal function decline in patients with chronic kidney disease (CKD). Therefore, current 
international treatment guidelines for CKD patients recommend lowering blood pressure in 
this specific population (target: 140/90 mmHg and 130/80 mmHg for patients with >30 mg 
albuminuria/day).
1;2
 The primary recommended pharmacological therapy is the prescription 
of an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin-II receptor blocker 
(ARB). Indeed, in addition to blood pressure lowering effects, these drugs have direct 
renoprotective effects.
3
 This therapy can be combined with other anti-hypertensive drugs and 
lifestyle changes such as sodium restriction and increasing physical activity. Despite these 
treatment guidelines, guideline achievement for controlling blood pressure in patients with 
CKD is poor.
4
 A possible explanation for this could be that physicians are reluctant in 
prescribing ACEi/ARBs because of contra-indications or side effects. In addition, physicians 
might be unaware of the current treatment guidelines thereby resulting in suboptimal 
treatment of patients. Therefore, more guidance and education of physicians on the 
treatment of hypertension is necessary. Several programs to achieve this have been 
suggested but the effectiveness of these programs has not been evaluated extensively. The 
trial of de Lusignana et al.
5
 in this issue of Kidney International is one of the first, in which an 
audit-based education program was investigated. 
Audit-based education is a quality improvement intervention that provides feedback, 
education and guidance, and documents the gap between achievement and guidelines.
6;7
 For 
the auditing step, anonymised data needs to be extracted from participating practices and 
processed. After data processing several important outcome measures, such as the 
percentage of patients not reaching the recommended treatment target, are documented 
and compared between practices. Based on these results, feedback is provided for each 
practice, preferably with an accompanied target or action plan. Furthermore, local queries are 
performed to provide each physician with a list of individuals that need adjustment of their 
treatment in order to reach the targets of the current guidelines. Theoretically, audit-based 
education could be applied to improve the achievement of all recommended treatment 
targets throughout all stages of CKD, thereby including primary care practices but also 
nephrology outpatient clinics. De Lusignana et al. specifically focused on the effectiveness of 
audit-based education on systolic blood pressure lowering in a primary care setting in the 
United Kingdom. The rationale of this study was that primary care physicians feel they lack 
knowledge about and confidence in managing CKD. Therefore, the authors hypothesized that 
an audit-based education program could have a large effect on quality of care in this specific 
setting. From the 565,016 adult people that were registered in the 93 primary practices 
participating in the study, 41,183 patients were diagnosed with CKD stages 3-5 (7.3%). Of 
these CKD patients, 36,288 were not lost to follow-up. These patients were included in the 
analyses. Block randomization was used to randomize the 93 participating practices into one 
of the following arms; audit-based education (n=30), guidelines & prompts (n=32), and usual 
practice (n=31).  
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This study revealed that patients treated according to the audit-based education program 
experienced a crude additional 1.2 mmHg decrease in systolic blood pressure compared with 
patients treated according to usual practice (4.9 versus 3.7 mmHg, Figure 1). In addition, in 
the audit-based education arm 2.7% more patients reached the target of 140/90 mmHg 
compared with the usual practice arm (12.0 versus 9.3%, Figure 1). Unfortunately, it remains 
unclear why the authors chose this target and not the target of 130/80 mmHg for patients 
with albuminuria (unclear which percentage of patients has albuminuria, but this is 
approximately 70% according to the USRDS
8
). The question arises if such a reduction in 
systolic blood pressure is relevant for CKD patients in terms of clinical outcomes. In this 
respect, a reduction of 5 mmHg indeed has beneficial effects on several clinical outcomes in 
the general population.
9
 However, these study populations consisted of relatively young and 
healthy individuals, which is in contrast with the elderly CKD patients (mean age 75 years) in 
the trial by de Lusignana et al., in whom blood pressure lowering may have a different effect. 
In line with this, the effect on other clinically important outcomes in the trial of de Lusignana 
et al., such as stabilization of renal function and prevention of cardiovascular events and 
death, was less pronounced (Figure 1). Patients following the audit-based education program 
experienced a similar change in estimated glomerular filtration rate compared with patients 
following usual practice (increase of 2.0 ml/min/1.73 m
2
 during a follow-up period of 
approximately two to two-and-a-half years). Furthermore, the incidence of cardiovascular 
events and mortality was 2.4% and 5.0% respectively in the audit-based education program 
and 3.0% and 6.6% respectively during usual practice. The latter implies that approximately 
167 and 63 patients need to be treated for two to two-and-a-half years according to the 
audit-based education program in order to prevent one cardiovascular event and death 
respectively (number needed to treat = 1 / risk difference). These numbers indicate that the 
positive effect of the audit-based education program on cardiovascular events is quite small 
but that it is substantial on mortality. The effect on mortality could not be entirely explained 
by a greater switch to ACEi/ARB medication, as suggested by de Lusignana et al. Indeed, the 
percentage of patients starting with an ACEi/ARB is similar between the audit-based 
education and guidelines & prompts arm (7.0 versus 6.9%) in contrast to the incidence of 
mortality which was different (5.0 versus 7.8%, Figure 1). Therefore, it needs to be explored 
which element of the audit-based education program is actually causing the lower mortality. 
With respect to renal function stabilization and cardiovascular events, we have to keep in 
mind that the follow-up time in the trial of de Lusignana et al. may be too short to detect 
large effects on these outcomes. The above-mentioned results raised the question whether 
the clinical effects of the audit-based education program were worth the accompanying time, 
efforts, and costs. 
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Figure 1: Overview of the effect of audit-based education on clinical outcomes 
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The audit-based education program consists of several steps that can be experienced as 
burdensome, time-consuming, and costly. The step of data extraction and processing is time-
consuming for the executive authorities. Following this audit, an individualized action plan 
needs to be developed and explained to all treating physicians. To achieve this feedback and 
education, physicians need to attend workshops or meetings that can be experienced as 
burdensome. In this respect, de Lusignana et al. encountered a suboptimal attendance of 
physicians to the feedback workshops in the study. Since the adherence to treatment 
guidelines outside a clinical trial is expected to be even lower, the application of the audit-
based education program to all primary practices may lead to a lower attendance and thereby 
a smaller effect on blood pressure and cardiovascular burden. Furthermore, in the trial of de 
Lusignana et al. the local queries were excluded from the trial due to practical reasons (i.e. 
concerns about ethics and recruitment of practices). Theoretically, local queries could have 
significantly increased the effect on blood pressure because it provides a list of individuals 
that need to be targeted. However, if concerns are present about feasibility in a highly 
standardized trial, it will definitely not be feasible in real clinical practice. Altogether, the 
audit-based education program may be seen as a time-consuming and costly program, which 
is only justified when the accompanying clinical effect is substantial. 
It is indisputable that the strict implementation of treatment guidelines is necessary to 
improve quality of care, thereby leading to better clinical outcomes. The trial of de Lusignana 
et al. showed that an education-based program slightly improves the implementation of one 
treatment target guideline, namely blood pressure control. Unfortunately, it was not assessed 
whether the intervention was cost-effective and further research should therefore focus on 
this aspect. Despite the small clinical effect, the audit-based education program can still be a 
valuable tool in improving guideline achievement and thereby quality of care. By identifying 
the parts of the program that are most effective, the ineffective parts can be excluded, 
thereby reducing efforts and costs. In addition, blood pressure is not the only risk factor 
│Audit-based education and guideline achievement  _________________________________ 
│140 
poorly controlled in CKD patients. Treatment guidelines focusing on other important risk 
factors, such as lipid levels, proteinuria, potassium/sodium levels and calcium/phosphate 
levels, are also poorly achieved. Therefore, expanding the program with other risk factors 
may increase the effect on clinical outcomes (e.g. less cardiovascular events, lower mortality, 
and a slower renal function decline). In addition, improving other medical issues in CKD 
patients, such as low treatment compliance and detrimental lifestyle, can even lead to a 
greater effect. Future research focusing on these aspects can improve the program and may 
lead to a cost-effective strategy for improving guideline achievement and quality of care in 
CKD patients. 
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Abstract 
In many fields, including the field of nephrology, missing data are unfortunately an 
unavoidable problem in clinical/epidemiological research. The most common methods for 
dealing with missing data are complete case analysis – excluding patients with missing data –, 
mean substitution – replacing missing values of a variable with the average of known values 
for that variable –, and last observation carried forward. However, these methods have 
severe drawbacks potentially resulting in biased estimates and/or standard errors. In recent 
years, a new method has arisen for dealing with missing data called multiple imputation. This 
method predicts missing values based on other data present in the same patient. This 
procedure is repeated several times, resulting in multiple imputed datasets. Thereafter, 
estimates and standard errors are calculated in each imputation set and pooled into one 
overall estimate and standard error. The main advantage of this method is that missing data 
uncertainty is taken into account. Another advantage is that the method of multiple 
imputation gives unbiased results when data are missing at random, which is the most 
common type of missing data in clinical practice, whereas conventional methods do not. 
However, the method of multiple imputation has scarcely been used in medical literature. We 
therefore encourage authors to do so in the future when possible. 
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Introduction 
Missing data are a problem that is often encountered when performing clinical studies. In any 
study design, such as a randomized controlled trial, a cohort study, and a case-control study, 
missing data can occur. Especially, in studies with routinely collected data, missing values are 
unfortunately unavoidable. Even after the introduction of statistical software allowing more 
sophisticated procedures, the methods most often used to deal with missing data are 
complete case analysis, mean substitution, and last observation carried forward (LOCF). 
In a complete case analysis, patients with missing data are excluded from the statistical 
analyses. Consequently, only patients with complete data will contribute to the results. Mean 
substitution is a method in which missing observations for a certain variable are replaced by 
the average of observed data for that variable in other patients. However, both these 
methods have severe drawbacks. Performing a complete case analysis not only leads to a 
smaller sample size and therefore may reduce statistical power but can also lead to biased 
results. These biased results can occur when the patients excluded from the analysis have 
different patient characteristics compared with those who were included. Mean substitution 
will maintain the original sample size, but can still lead to biased results when the patients 
with missing data have different patient characteristics compared with those with available 
data. Furthermore, the variances obtained with mean substitution are biased downwards 
because the substituted values are treated as ‘real’ observed values although they are all 
centered on the mean, resulting in a narrower distribution of values. LOCF is a method 
frequently used with missing longitudinal data, such as trials and cohort studies. This method 
replaces missing values with the last observation measured before the one that is missing. In 
this way data are kept constant over time and the method will lead to biased results when in 
reality data change over time. 
In recent years, a new method for dealing with missing data called multiple imputation has 
arisen. However, in medical literature the application of this method is quite uncommon but 
has been rising during the last few years.
1;2
 In this educational article we provide a brief 
introduction to the method. We will not go into details of the technical or practical aspects of 
the multiple imputation method. For those details we refer to other literature.
3-6
 Our goal is 
to describe the different types of missing data, for what types of missing data the multiple 
imputation method can be used, and explain why this new method is preferred over other 
conventional methods for dealing with missing data. 
Types of missing data 
Missing data can roughly be classified into three types: missing completely at random 
(MCAR), missing at random (MAR), and missing not at random (MNAR) (Box 1). With MCAR, 
the underlying reasons for data being missing are independent of known and unknown 
patient characteristics. In other words, subjects with missing values are a completely random 
subset of the study population and patient characteristics will therefore be similar between 
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subjects with and without missing data. An example of data being MCAR is when a tray with 









The underlying reasons for data being missing in clinical research, however, are often related 
to several known patient characteristics. This type of missing data is called MAR, as 
conditional on the known patient characteristics data are missing randomly. An example of 
this type of missing data is the higher probability that a blood sample could not be drawn 
before the start of dialysis in patients who started dialysis acutely. It is highly likely that 
patient characteristics of subjects starting dialysis acutely are different compared with 
subjects not starting acutely. In that case, patients with missing blood samples are not a 
random subset of the study population, and their true laboratory values are probably 
different from those for whom a blood sample was available. However, it could be possible to 
predict from the available data which patients are acute starters and therefore have missing 
blood samples. Conditional on these prediction characteristics, meaning within the different 
strata, subjects with a missing blood sample do constitute a random subset, and therefore 
this type of missing data is called MAR. 
The third type of missing data, MNAR, is the most complicated type of missing data, as here 
the underlying reasons for data being missing are related to unknown patient characteristics. 
For example, subjects with a low education are more likely to skip a question about their level 
of education in a questionnaire. The level of education depends on many characteristics, 
which may not all be measured. Neither conventional methods nor the multiple imputation 
method are suitable when missing data are MNAR. There are some other methods available, 
but these methods are very complex and subject to many assumptions, and are therefore 
outside the scope of this article.
7
 It is common in clinical practice that the missing data type 
MNAR coexists with the other two types (MCAR and MAR). For example, when quality of life 
data are missing, some patients have not filled in the questionnaire because their pencil 
broke (MCAR), some because of clinical characteristics – like age – which are measured 
(MAR), and some patients because they have a low quality of life for reasons unrelated to 
Box 1: Types of missing data 
• Missing completely at random (MCAR) – The underlying reasons for data being missing are independent of 
known and unknown patient characteristics. An example is when a tray with blood samples is accidentally 
broken, resulting  in missing laboratory values. 
• Missing at random (MAR) – The underlying reasons for data being missing are related to known patient 
characteristics. An example is the higher probability that a blood sample could not be drawn before the start 
of dialysis in patients who started acutely. 
• Missing not at random (MNAR) – The underlying reasons for data being missing are related to unknown 
patient characteristics. An example is that subjects with a low education are more likely to skip a question 
about their level of education in a questionnaire. 
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measured patient characteristics (MNAR). When the MNAR type is rare in this mixture of 
different missing data types, multiple imputation can be used. 
In the next section we will describe the conventional methods of complete case analysis, 
mean substitution, and LOCF and indicate for which types of missing data, MCAR and MAR, 
these methods give unbiased results. 
Conventional methods: when to use them? 
To illustrate when a complete case analysis, mean substitution, and LOCF can be used, we 
simulated a situation where data were missing. In this example, the mean [standard error] 
serum urea level at the start and end of pre-dialysis care, and the change [standard error] of 
urea, were measured in 1500 incident patients starting pre-dialysis care. Standard compute 
commands in PASW/SPSS version 20 were used for data simulation. The first urea 
measurement at the start of pre-dialysis care (U1) was simulated by taking a random subset 
of 1500 patients from a normal distribution (mean 20 mmol/l, standard deviation 6, 
computed with the random variable function rv.normal). The second urea measurement at 
the end of pre-dialysis care (U2) had a mean of 24 and a standard deviation of 6. The 
correlation between U1 and U2 was specified at 0.75. Table 1 shows the mean [standard 
error] U1, U2, and change of urea (U2-U1) for these 1500 patients from the main analysis of 
our simulation. The increase in urea (U2-U1) during pre-dialysis care was 4.0 [0.11] mmol/l, 
with a urea level of 20.0 [0.15] mmol/l at the start of pre-dialysis care and 24.0 [0.15] mmol/l 
at the end. 
Table 1: Simulation study: results of conventional and multiple imputation method when data is missing completely 
at random (MCAR) 















Mean [SE] U1 20.0 [0.15] 20.0 [0.17] 20.0 [0.15] 20.0 [0.15] 20.0 [0.15] 
Mean [SE] U2 24.0 [0.15] 24.0 [0.17] 24.0 [0.14] 23.3 [0.16] 24.0 [0.15] 
Mean [SE] U2-U1 4.0 [0.11] 4.0 [0.12] 4.0 [0.12] 3.3 [0.11] 4.0 [0.11] 
 
U2 was made MCAR for ~20% of the subjects, computed with the random number function 
uniform(n), resulting in the missing data type MCAR. Now, for only 1218 patients both U1 and 
U2 were measured. A complete case analysis in these 1218 patients resulted in an increase in 
urea of 4.0 [0.12] mmol/l, U1: 20.0 [0.17] mmol/l and U2: 24.0 [0.17] mmol/l. All values were 
similar to the values from the main analysis. The standard errors were somewhat higher due 
to the lower sample size (n=1218). When performing the mean substitution method we found 
an increase in urea of 4.0 [0.12] mmol/l, U1: 20.0 [0.15] mmol/l and U2: 24.0 [0.14] mmol/l. 
Again all values were similar to the values from the main analysis. However, the standard 
error of U2 is biased downwards because all substituted data had the same value, resulting in 
less variance. Although the method of LOCF is not justified when only two data points are 
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present in a study we applied this method to our simulated situation for illustrative purposes. 
Using LOCF when data were MCAR resulted in an increase in urea of 3.3 [0.11] mmol/l, U1: 
20.0 [0.15] mmol/l and U2: 23.3 [0.16] mmol/l. The mean value for U2 and thereby the 
increase in urea were biased downwards. 
What results would the conventional methods give if data were MAR? We therefore 
simulated U2, using the uniform(n) function, with a 1% higher chance of being missing for 
each mmol/l higher U1 . In Table 2, the results of the conventional methods are presented. In 
the complete case analysis the values U1 (19.6 [0.17] mmol/l) and U2 (23.7 [0.17] mmol/l) 
were biased downwards. This finding can be explained by the fact that subjects with a high 
mean U1 have a higher chance of having missing data for U2. In a complete case analysis, 
these subjects are excluded from the analysis, resulting in a lower mean U1. The mean U2 is 
also lower because a high correlation was specified between U1 and U2 (0.75). Had this 
correlation been lower, the resulting value of U2-U1 would have been even more biased, as 
the mean U2 would move towards the mean of the main analysis. In the mean substitution 
analysis the values of U2 (23.7 [0.13] mmol/l) and thereby also U2-U1 (3.7 [0.12] mmol/l) 
were biased downwards. Again this is explained by the fact that subjects with a high U2 have 
a higher chance of having missing data. Therefore, substitution of the mean U2 will result in 
an underestimation. LOCF again resulted in biased values for U2 and U2-U1, 23.2 [0.15] 
mmol/l and 3.2 [0.11] mmol/l, respectively. 
Table 2: Simulation study: results of conventional and multiple imputation method when data is missing at random 
(MAR) 















Mean [SE] U1 20.0 [0.15] 19.6 [0.17] 20.0 [0.15] 20.0 [0.15] 20.0 [0.15] 
Mean [SE] U2 24.0 [0.15] 23.7 [0.17] 23.7 [0.13] 23.2 [0.15] 24.0 [0.15] 
Mean [SE] U2-U1 4.0 [0.11] 4.1 [0.12] 3.7 [0.12] 3.2 [0.11] 4.0 [0.11] 
 
The simulation studies presented above clearly demonstrate that the conventional method of 
complete case analysis gives unbiased estimates and standard errors – only slightly higher 
due to a smaller sample size and thereby loss of power – when data are MCAR, but not when 
data are MAR. With mean substitution the standard errors are biased downwards in both 
types of missing data due to a higher number of values centered on the mean. Loss of 
statistical power and/or biased results makes neither method the method of choice. 
Furthermore, it is likely that in clinical research the two types of missing data are mixed and it 
is very difficult to assess which type is (most) present. When using the method of LOCF, urea 
levels were kept constant between the start and end of pre-dialysis care. The analysis thereby 
resulted in a too small increase in urea in both types of missing data and is also not the 
preferred method. This dilution would be less prominent when more data points were 
available, so that missing urea values at the end of pre-dialysis care can be replaced by a value 
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measured at a closer data point. It can be concluded that all three conventional methods have 
limitations and are not preferred for handling missing data. In the next sections, we discuss 
the method of multiple imputation and when this method can be used. 
Multiple imputation: explanation of the method 
Multiple imputation is a method in which missing data are predicted based on known data 
and on the pattern of missing data.
8
 In our view, this method builds on and improves the idea 
of mean substitution. When using mean substitution, missing values are replaced with the 
overall mean and imputed values are treated as ‘real’ observed values. Obviously, this 
approach is too simplistic and generally leads to biased results as in reality some patients 
have higher values than the mean and other patients have lower values. The overall mean is 
therefore not the best estimate for all of them. An improvement on simple mean substitution 
could be made by stratifying by age, for example, and substituting the mean among young 
patients for missing values among young patients and that among old patients for missing 
values among old patients. This line of reasoning can be followed further, by stratifying by 
more relevant variables, and substituting a variety of mean values in a multitude of 
subgroups. In principle, the method of multiple imputation thus makes strata based on the 
variables known by creating a prediction model for the missing variable. Each patient falls 
within a stratum based on his or her known characteristics. A patient’s missing value is then 
replaced by the mean of that stratum. However, in reality there is variation around the mean, 
even in small strata. If you impute the same value for all patients within a stratum, the 
variation will be too low. Therefore, a random error component should be added to the 
imputed mean value. This error component should be randomly drawn from the error 
distribution (i.e. from the residuals) from the prediction model. In the above example, in 
patients on pre-dialysis care with missing U2, their missing U2 would be replaced by a 
predicted value of U2 based on the available U1. Usually, it is possible to predict the missing 
U2 values based on more variables, such as age and sex. If the patients with missing U2 are 
also old and male, it makes sense to replace their missing value with a value similar to that of 
old male patients. It is very important to think about the known variables you want to include 
in the model to predict the missing value of interest. There are several strategies you can 
follow in this respect
6
, but generally all variables (continuous or categorical) used for your 
final analyses should be included. Inclusion of the outcome is also necessary because reasons 
for missing data are usually related to the outcome status.
9
 It is important to keep in mind 
that depending on the statistical software used, difficulties can arise when continuous 
variables are not normally distributed – which can be solved with transformation – or when 
categorical variables need to be imputed. Another important thing to keep in mind is that the 
imputation model will not always perform better and may even lead to biased results when 
including large numbers of variables, especially, when these variables have many missing 
values themselves. For a more in-depth description of these two important computational 
issues we refer to other literature.
10;11
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 Performing the imputation procedure only once is not to be recommended. With single 
imputation, imputed values are treated as ‘real’ observed values and, as mentioned earlier, 
the standard error will be underestimated. Single imputation resembles mean substitution 
conditional on other known data, and therefore will have the same problem with 
underestimating standard errors. The imputation procedure should be repeated several times 
resulting in multiple imputation data sets. Each imputation takes a random draw from the 
error distribution, and adds this to the predicted mean value. How many times this procedure 
should be repeated depends on the rates of missing data. It has been claimed that 3-10 
imputations are sufficient to obtain an adequate efficiency.
12;13
 Only when the percentage of 
missing data is very high (>30%) more imputations are recommended. After performing 
multiple imputations, the analyses of interest are performed within each individual 
imputation set. The obtained estimates and standard errors of each imputation set are then 
pooled together into one overall estimate and standard error. For the overall estimate the 
average is taken of all separate estimates. The overall standard error consists of the within- 
and between-imputation variance, based on Rubin’s rules.
12
 With multiple imputation, the 
uncertainty of the separate imputations is taken into account by incorporating the between-
imputation variance, which when compared with mean substitution or single imputation 
results in a less biased standard error. The combination of predicting missing values, based on 
other known information, and taking into account imputation uncertainty does not support 
the term ‘data creation’ introduced by critics of the method. Figure 1 presents a more 
graphical representation of the method of multiple imputation. 
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Multiple imputation: when to use? 
In this section, we demonstrate how multiple imputation affects the results when data is 
either MCAR or MAR. We used the same example of urea levels during pre-dialysis care (U1 
and U2) as described before. In this example missing U2 values were imputed based on 
known U1 values (n=1500). We performed five imputations because U2 data were only 
missing for ~20% of the patients. Tables 1 and 2 show that multiple imputation resulted in the 
same values and standard errors when compared with the main analysis, for both MCAR and 
MAR. Our simulation results show that multiple imputation performs well in both types of 
missing data, and is therefore the preferred method in clinical practice where mixtures of 
missing data types are common. 
Multiple imputation in the field of nephrology 
Studies performed in the field of nephrology often aim to estimate the association of a 
determinant with an outcome, such as the start of dialysis or mortality. Unfortunately, quite 
often the outcome cannot be established for all patients due to study drop-out or reaching 
the end of the study period. A complete case analysis is not the preferred method because of 
power problems and possible biases. Time-to-event analysis estimates an incidence rate and 
can handle these missing outcomes through censoring.
14
 All patients can be included in this 
analysis because follow-up time until the event of interest or the moment of censoring is 
taken into account. If time-to-event data are not available, or the assumption of non-
informative censoring is violated, multiple imputation could be used to impute these missing 
outcomes. Deo et al.
15
 investigated how many trials performed in patients on renal 
replacement therapy without time-to-event data available, reported a method to impute 
missing outcome data, which they found were only 5 of the 110 trials (5%). However, none of 
these studies used the technique of multiple imputation. 
Furthermore, when routinely collected data are used, which is often the case in the field of 
nephrology, the determinant of interest or the confounders you want to adjust for can have 
missing values. The reason for these missing data is often based on other known patient 
characteristics. For example, when data from a national registry of patients on dialysis are 
used to develop a prediction model for the risk of mortality, it is not surprising that many 
patients have missing data on co-morbidities and laboratory values. Wagner et al.
16
 found 
that patients with missing data (~50%) have a higher risk of mortality, were older, more likely 
to be white, and had more often an uncertain diagnosis of primary kidney disease, resulting in 
missing data type MAR. Excluding these patients from the analyses can lead to biased results. 
Therefore, the authors of this article performed multiple imputation as a sensitivity analysis. 
Another article, by Collier et al.
17
, also used the technique of multiple imputation as a 
sensitivity analysis to check the robustness of their main complete case analysis. They 
investigated the association of co-morbidities with survival in patients on renal replacement 
therapy. The association found when using the method of multiple imputation was less strong 
compared with the association found when using a complete case analysis. This dilution is 
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probably due to the fact that patients excluded from the main complete case analysis had 
more co-morbidities. 
In summary, only a few years ago the multiple imputation method was scarcely used in the 
field of nephrology as shown by Deo et al. Currently, a full text search of ‘multiple imputation’ 
on the website of Nephrology Dialysis Transplantation resulted in seven hits between 2006 
and 2008. However, this number has been rising during the last few years as there were 
eighteen hits between 2009 and 2011. And although it has been applied as a sensitivity 
analysis in the study of Wagner et al. and Collier et al., hardly any study uses it in its main 
analyses with full attention to the imputed results. We recommend to present results the 
other way around, so multiple imputation results as main analysis and complete case results 
as a sensitivity analysis. This and other important recommendations on how to report 




We can conclude that the multiple imputation method gives unbiased estimates and standard 
errors provided that data are either MCAR or MAR, and the prediction model specification is 
adequate, which may require the help of a statistician. The conventional method complete 
case analysis only gives unbiased results – and a somewhat higher standard error due to the 
loss of power - when data are MCAR. In both types of missing data, mean substitution and 
LOCF give biased results. In clinical practice, combinations of missing data types are most 
common and it is difficult to assess which type(s) is present for which patient. We can only 
theoretically imagine which types are present. However, overall multiple imputation performs 
better than the conventional methods and is therefore the method of choice. In the field of 
nephrology, multiple imputation is not used very often, and we encourage authors to do so in 
the future. Especially, because the method is relatively easy to perform in many statistical 
packages, such as recent versions of PASW/SPSS, STATA, and SAS. One problem about 
multiple imputation is that some people feel that the method is making up data, which is not 
scientifically ethical. With this educational article, we hope to have demonstrated that the 
multiple imputation method predicts data based on known variables with the incorporation 
of missing-data uncertainty, which will lead to estimates closest to the truth. 
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Dear Editor, 
In the article of Brown et al.
1
 a clinically relevant question was addressed. They investigated 
whether in non-diabetic chronic kidney disease (CKD) patients (stages 3-5) obesity is related 
to the rate of progression of CKD, defined as the start of renal replacement therapy (RRT) and 
estimated glomerular filtration rate (eGFR) decline. The authors concluded that a high body 
mass index (BMI), either analyzed as a continuous or dichotomous variable, was not 
associated with the progression of CKD. However, we believe that the used statistical analyses 
are insufficient to draw a reliable conclusion. 
First, it can be questioned whether comparing obese patients (BMI ≥30 kg/m
2
) to a broad 
reference group (BMI <30 kg/m
2
) is correct. Previous studies performed in the general 
population and in dialysis patients showed that subjects with a low BMI (<20 kg/m
2
) have a 
higher risk of mortality
2;3
 compared with those with a BMI between 20 and 25 kg/m
2
. 
Therefore, a reference group excluding patients with a low BMI would be more appropriate, 
to prevent underestimation of the effect of obesity. Second, Table 2 shows a higher eGFR 
decline in non-obese patients, except for stage 5 where the decline is lower in non-obese 
patients. Therefore, we believe it is not justified to combine all stages of CKD in the 
subsequent analyses. Third, not controlling for important confounders, such as smoking, age, 
and co-morbidities, and inappropriate control for biological effects of obesity, such as 
hypertension, may result in bias. In line with this, the association of BMI with the rate of 
starting RRT should be investigated with a multivariable Cox Regression model. With this 
model, crude incidence rate ratios can be statistically tested and adjusted for confounders. 
For the eGFR decline a linear mixed model would be an appropriate method.
4
 This type of 
model calculates individual slopes and takes its deviation from the mean slope into account. 
This is useful when limited measurements per individual are available as is the case in this 
study. Fourth, the stratified analysis presented in Table 5 may introduce bias. The eGFR 
decline is compared between obese and non-obese patients who started RRT, died, or 
reached end of study. Obesity and eGFR decline are competing risk factors for mortality. 
Therefore, if a patient dies it may be either because of obesity, or because of eGFR decline. 
Consequently, the results of Table 5 improperly suggest that non-obese patients who died 
have a faster eGFR decline than obese patients who died.
5
 
In conclusion, we invite the authors to perform further analyses to give a reliable insight into 
the effect of obesity on progression of CKD in non-diabetic patients with CKD stages 3-5. 
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Introduction 
Chronic kidney disease (CKD) has become a major public health problem worldwide.
1-4
 The 
increasing prevalence of patients with CKD
1;5;6
 can be explained by the growing elderly 
population and lifestyle changes. Renal function has an age-related natural decline
7
, leading 
to a moderately reduced renal function at older age
5
. Lifestyle changes, such as high-fat diets 
and low physical activity, have led to an increasing prevalence of hypertension
8
 and type 2 
diabetes mellitus
9
. These morbidities are known to accelerate renal function decline, thereby 
increasing the risk of developing CKD. CKD is defined by a progressive loss of renal function 
which may eventually lead to the need for renal replacement therapy (RRT, starting dialysis or 
receiving a kidney transplant; also defined as end-stage renal disease, ESRD).
10
 Ideally, 
progression towards the start of RRT is slowed down in early stages of the disease process, in 
which renal function is normal or mildly reduced and albuminuria/proteinuria is present (CKD 
stages 1 and 2). However, in most patients CKD only becomes symptomatic when renal 
function deteriorates and drops below 30-60 ml/min/1.73 m
2
 (CKD stages 3-5).
11
 Screening 
strategies based on albuminuria/proteinuria to identify patients in earlier stages of the 
disease process are unfortunately not optimal yet. At this moment, no consensus has been 
reached regarding the appropriate type of test, which thresholds to use, which patient 
populations to screen and whether a screening strategy is cost-effective.
4;12-14
 Therefore, 
treatment to slow down the disease progression is mainly performed in more advanced CKD 
stages and guidelines for this population are important. In The Netherlands young patients 
(<65 years) with a renal function below 60 ml/min/1.73 m
2
 (CKD stages 3-5) should be 
referred to a nephrologist and treated according to guidelines.
10;15
 Elderly patients should 
only be referred when this moderately reduced renal function coincides with the presence of 
proteinuria (>1 g/24h) or a progressive loss of renal function (>3 ml/min/1.73 m
2
/year). When 
renal function deteriorates even further (<30 ml/min/1.73 m
2
, CKD stages 4-5), both young 
and elderly patients are referred to an outpatient clinic for multidisciplinary pre-dialysis care. 
Treatment guidelines for this specific population have been developed in The Netherlands.
16
 
However, these guidelines are mainly based on studies performed in early- to middle-stage 
CKD patients and mainly focus on the objectively assessed outcome renal function decline. 
Studies in the pre-dialysis population are therefore needed to make these guidelines more 
evidence-based. Therefore, the main goal of this thesis was to investigate the effect of several 
risk factors on objectively assessed disease progression, defined as renal function decline and 
time until the start of RRT, and subjectively assessed disease progression, defined as disease-
related symptoms and health-related quality of life, in patients on specialized pre-dialysis 
care. We furthermore tried to explore (un)known mechanisms that determine renal function 
decline in pre-dialysis patients. For both aims data were used from the PRE-dialysis PAtient 
REcord (PREPARE) study. We also explored (un)known mechanisms of the age-related renal 
function decline in the general population and for this aim the Leiden Longevity Study was 
used. This study consists of subjects with a propensity for longevity and environmentally 
matched controls without this propensity.
17;18
 The exploration of (unknown) mechanisms may 
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unravel new treatment targets for pre-dialysis patients. A summary of our main findings are 
presented in the following paragraphs and in Table 1. 
Summary of main findings 
Outcome: renal function decline 
In chapters 2, 4, and 5 we used renal function decline as outcome. Renal function was 
expressed as glomerular filtration rate (GFR) and we used serum creatinine-based formulas to 
estimate the GFR (eGFR). These chapters provide evidence that current treatment targets for 
controlling blood pressure (systolic below 130 mmHg and diastolic below 80 mmHg, when 
proteinuria is present), proteinuria (below 0.3 to 1.0 g/24h) and lipid levels (low density 
lipoprotein (LDL) cholesterol levels below 2.5 mmol/l and triglyceride levels below 2.25 
mmol/l
16
) are clinically well defined regarding the outcome renal function decline. Patients on 
pre-dialysis care with levels below these targets experience a slower renal function decline 
compared with patients having levels above the treatment target. For all three important risk 
factors a dose-response relation was found, indicating that higher levels were associated with 
a faster renal function decline. Clinically relevant increases of these risk factors (10 mmHg 
increase in systolic and diastolic blood pressure, 1 g/24h increase in proteinuria, and 1 mmol/l 
increase in LDL cholesterol and triglyceride levels) resulted in a 0.04 to 0.06 ml/min/1.73 
m
2
/month faster renal function decline. On a yearly basis this represents a 0.48 to 0.72 
ml/min/1.73 m
2
 faster decline in renal function. This additional decline is quite large 
considering the relatively low renal function at the start of pre-dialysis care (~15 ml/min/1.73 
m
2
). To illustrate the clinical impact of these findings, 17% of all pre-dialysis patients have a 
systolic blood pressure above 180 mmHg, resulting in a 2.4 ml/min/1.73 m
2
/year faster renal 
function decline compared with patients with their blood pressure on target. For proteinuria, 
25% of the patients have levels above 3.8 g/24h, leading to a 1.7 ml/min/1.73 m
2
/year faster 
renal function decline compared with patients with a level of 0.3 g/24h, which is the lower 
target boundary. Lowering blood pressure, proteinuria, and lipid levels may therefore slow 
down the rate of renal function decline. Several large randomized controlled trials indeed 
showed a slower renal function decline when blood pressure and proteinuria were lowered 
with an angiotensin-converting enzyme inhibitor (ACEi) and/or an angiotensin-II receptor 
blocker (ARB).
19;20
 Lowering lipid levels with statins showed an absent or very small effect on 
renal function decline.
21-24
 However, we have to keep in mind that these randomized 
controlled trials mainly included patients with moderate CKD (stage 3) instead of patients 
with advanced CKD (stages 4-5) or used renal endpoints that are very robust (e.g. start of RRT 
and doubling of serum creatinine). 
Outcome: start of renal replacement therapy 
For proteinuria, chapter 4 showed that higher levels resulted in an earlier start of RRT, which 
is consistent with the outcome renal function decline. Per each 1 g/24h increase, there was a 
6% higher rate of starting RRT. This consistency was also present for systolic (≥180 versus 140-
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159 mmHg) and diastolic (≥100 versus 80-89 mmHg) blood pressure in young (<65 years) pre-
dialysis patients (1.9 and 1.7 fold higher rate, respectively, chapter 3). However, chapter 3 
showed contradictory findings with respect to renal function decline in elderly (≥65 years) 
patients. Low systolic (<120 versus 140-159 mmHg) and diastolic (<70 versus 80-89 mmHg) 
blood pressure were associated with an earlier start of RRT in elderly patients (2.8 and 1.6 
fold higher rate). This finding may indicate that in clinical practice indications are present to 
start RRT, that do not influence renal function decline. Congestive heart failure is a 
complication often seen in CKD patients
25
 and leads to a reduction in cardiac output. This 
disease, especially in CKD patients, is often accompanied by volume overload. Fluid overload 
is one of the most important indications to start RRT. Moreover, a reduced cardiac output will 
also result in hypo-perfusion of the kidneys and thereby a lower renal function. The loop 
between cardiac dysfunction and progressive loss of renal function is also called the cardio-
renal syndrome.
26
 The presence of the renal part of this syndrome is not supported by the 
results presented in chapter 3, showing a similar renal function decline in elderly patients 
with low compared with normal blood pressure. However, it could be that congestive heart 
failure leads to a sudden drop of renal function followed by an immediate start of RRT. Such a 
drop may not be detected when calculating renal function decline with multiple 
measurements over time. 
Outcome: symptoms and health-related quality of life 
Chapters 6 and 7 focused on disease-related symptoms and/or health-related quality of life, 
which are considered subjectively assessed outcome measures. As compared with other 
medical fields, such as the field of cardiovascular disease
27
, in the field of nephrology these 
outcome measures are not clearly incorporated into clinical guidelines
16
. This is probably 
caused by the lack of consensus between investigators and clinicians on the meaning, 
importance, assessment, and interpretation of health-related quality of life
28
 and symptoms, 
implicating the need for more research. During the last years more research has been 
performed on health-related quality of life in CKD patients. Several studies showed that 
health-related quality of life deteriorates when renal function declines.
29-31
 This could be 
explained by the fact that disease-related symptoms become more present when kidney 
function decreases. Together with treatment choices that have to be made, the mental and 
physical well-being of an individual can be affected. Furthermore, health-related quality of life 
is a good predictor for mortality and progression to ESRD throughout all stages of CKD.
32
 
These findings have changed the thought about health-related quality of life and more studies 
are now focusing on this outcome. Results from chapter 6 provide further support for the 
importance of subjectively assessed outcome measures, by showing an increase in symptoms 
and a decline in health-related quality of life during pre-dialysis care with the sharpest change 
in the last 6-12 months before starting dialysis. Furthermore, each additional symptom and 
each 3-point lower physical and mental health-related quality of life score were associated 
with a respectively 7%, 2%, and 3% higher risk of starting dialysis within the subsequent six 
months. Besides these changes during pre-dialysis care, it has been shown that in anemic CKD 
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patients, targeting hemoglobin levels of 11-12 g/dl (recommended target) improves health-
related quality of life.
33
 However, a debate is ongoing whether targeting higher (≥13 g/dl) 
hemoglobin levels has more beneficial effects. Evidence supporting this idea is lacking, 
especially in the specific population of patients on pre-dialysis care. Chapter 7 showed that 
only in young (<65 years) patients treated with anemia-medication (an erythropoiesis 
stimulating agent and/or an iron supplement), high compared with recommended 
hemoglobin levels (11-12 g/dl) were associated with a better physical and mental health-
related quality of life (8.5 and 6 points respectively, 3-5 points are considered clinically 
relevant
34
). In elderly (≥65 years) patients treated with anemia-medication, no effect of higher 
hemoglobin levels on health-related quality of life was present. 
Risk factors: explore (un)known mechanisms 
To identify new treatment strategies for slowing down renal function decline, exploration of 
(un)known mechanisms that determine renal function decline should be performed. Several 
studies have shown that black CKD patients who are not dialysis-dependent, experience a 
faster renal function decline
35
 and progression to ESRD
36;37
 than whites. The results described 
in chapter 8 are in line with this. In this chapter we tried to explore which underlying 
mechanism(s) is (are) responsible for the faster decline in blacks (additional decline of 0.16 
ml/min/1.73 m
2
/month). In The Netherlands, a universal healthcare system is present, leading 
to equal access and comparable quality of care for all patients. Healthcare system related 
factors could therefore not be the complete explanation for the faster decline found in blacks. 
Furthermore, results did not change after adjustment for demographic characteristics, co-
morbidities/lifestyle, medication, renal damage, renal function, and laboratory values. 
Therefore, these factors could also not explain the difference in renal function decline 
between blacks and whites. However, the faster decline in renal function in blacks when 
compared with whites was only present in patients with diabetes mellitus or proteinuria. This 
finding could indicate that diabetes mellitus in black patients has more severe consequences 
for the kidneys than in white patients. Chapter 9 indicated that at middle-age renal function is 
higher in men with a propensity for longevity compared with men without such a propensity 
(eGFR difference of 1.78 ml/min/1.73 m
2
). This finding may implicate that subjects from 
longevity families are less susceptible to risk factors, such as hypertension and cardiovascular 
events, that further accelerate the age-related natural renal function decline (0.4 ml/min/1.73 
m
2
/year from the age of eighteen years
7
). An even stronger renal function difference was 
found in men with a history of hypertension or myocardial infarction/stroke (6.98 and 6.21 
ml/min/1.73 m
2
, respectively), which may implicate a better handling of systemic 
inflammation in male longevity subjects. Further research should focus on finding the specific 
underlying mechanism causing a faster renal function decline in blacks and a lower renal 
function in middle-aged subjects with a propensity for longevity. By identifying the genetic 
pathways responsible, our understanding of how the kidneys work increases and new 
treatments can be identified.
38
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Table 1: Pre-dialysis guidelines: evidence from the PREPARE study 
Progression factor / 
complication 
Target Outcome Associations present in 
PREPARE study 
Hypertension Blood pressure <130/80 
mmHg 
Renal function decline, 
start of RRT 
Below target, <65 years: 
- Slower renal function  
  decline 
- Later start RRT 
Below target, ≥65 years: 
- Earlier start RRT 
Proteinuria  Urinary protein excretion 
<1 g/24h 
Renal function decline, 
start of RRT 
Below target: 
- Slower renal function  
  decline 
- Later start RRT 
Hyperglycemia  HbA1c <7%   
Anemia Hemoglobin 6.8-7.4 
mmol/l, avoid ≥8.0 
mmol/l, serum ferritin 
100-500 µg/l 
Health-related quality of 
life 
Above target, <65 years: 
- Better physical and    
  mental health-related  
  quality of life 
Mineral bone disorders Calcium 2.1-2.37 mmol/l, 
phosphate 0.7-1.3 
mmol/l, PTH ~2-7 pmol/l 
  
Metabolic acidosis Serum HCO3 20-22 mmol/l   
Hyperkalemia Potassium <5.5 mmol/l   
Hyperlipidemia LDL <2.5 mmol/l, non-HDL 
<3.4 mmol/l, HDL >1 
mmol/l, triglycerides 2.25-
4.5 mmol/l 
Renal function decline Below target, LDL: 
- Slower renal function  
  decline 
Lifestyle factors Stop smoking, balancing 
nutrition and physical 
activity 
  
RRT: renal replacement therapy; HbA1c: hemoglobin A1c; PTH: parathyroid hormone; HCO3: bicarbonate; LDL: low 
density lipoprotein; HDL: high density lipoprotein. 
Strengths and limitations of the PREPARE study 
A great strength of the retrospective PREPARE-1 and prospective PREPARE-2 cohort study is 
the inclusion of incident instead of prevalent patients in multiple academic and peripheral 
centers. By following incident patients from the moment of referral, a reliable course of 
disease progression during pre-dialysis care can be obtained. Furthermore, including 
prevalent patients may lead to biased results. The chance to be included in a prevalent 
population not only depends on the occurrence of an event – in this study receiving pre-
dialysis care – but also on the duration of the event. Therefore, ‘healthier’ patients receiving 
care for a longer period will have a higher chance to be included in a prevalent population. 
This may lead to selection bias and results cannot be generalized to the entire population of 
patients on pre-dialysis care. Including patients from multiple centers, both academic and 
peripheral, results in a good representation of the total pre-dialysis population in The 
Netherlands and thereby a high generalizability of the results. In the PREPARE-1 study this 
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generalizability is even more pronounced because data were retrospectively extracted from 
medical records and thereby all consecutive patients could be included. 
The strength of the PREPARE-2 over the PREPARE-1 study is the availability of repeated 
measurements. In addition to baseline – start of pre-dialysis care – during every six-month 
interval demographic, anthropometric, and clinical data were collected. Furthermore, health-
related quality of life and illness perception questionnaires were filled in by patients. Data on 
functional status could not be obtained in the PREPARE-1 study due to the retrospective 
design of the study. With these repeated measurements, changes in clinical factors during 
pre-dialysis care can be illustrated. Furthermore, changes over time can be related to clinical 
outcomes on pre-dialysis care, such as the start of RRT or death. 
Besides the above mentioned strengths, the PREPARE-1 and PREPARE-2 study have three 
important methodological limitations, which are discussed in the following three paragraphs. 
Confounding 
Confounding is a bias that arises when the exposure and the outcome share a common 
cause.
39
 The causal diagram in Figure 1A represents the structure of confounding, depicting 
two pathways between exposure (E) and outcome (O). The first pathway is the causal effect 
of exposure on outcome (E  O) and the second pathway between exposure and outcome is 
via a common cause CC (E  CC  O). If the common cause did not exist the only pathway 
present would be the causal effect of exposure on outcome. However, the common cause 
results in an additional association that confounds the causal effect between exposure and 
outcome. Conditioning on the common cause will block the additional association between 
exposure and outcome and eliminate confounding. Therefore, all variables that block 
additional pathways after being conditioned on are called confounders. Confounding is often 
encountered when answering causal questions in observational studies. In such studies, a 
causal contrast for the exposure of interest is made – for example high versus low blood 
pressure – and outcome frequencies – for example mortality rate – are compared. Blood 
pressure and mortality share many common causes that can confound the causal effect 
between the two. Elderly patients for example often have a high blood pressure and mortality 
rates are rising with increasing age. So, when an association is found between high blood 
pressure and a high mortality rate, this association can be confounded by age. In other words, 
the higher mortality rate in the high blood pressure category is not completely caused by 
blood pressure but also by the higher age. Therefore, the analysis should be conditioned on 
the common cause age to block this additional association. In all chapters of this thesis we 
used multivariable models to adjust for confounding. Unfortunately, it is difficult to define 
and measure all common causes (confounders). Residual confounding is therefore 
unavoidable in observational studies. The optimal method to demonstrate whether a causal 
relation exists is an interventional randomized controlled trial. Randomization leads to an 
equal distribution of all (un)known and (un)measured confounders between the trial arms, if 
the randomization procedure is performed correctly and the sample size is large enough. Only 
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the assigned intervention will be different between the groups compared. In our example of 
blood pressure, prescribing anti-hypertensive medication is a possible intervention. However, 
we have to keep in mind that the results of this trial will tell us something about the causal 
effect of prescribing anti-hypertensive medication on mortality and not about the causal 
effect of blood pressure. Most probably, this causal effect of anti-hypertensive medication 
will act via the lowering of blood pressure, but maybe not entirely. However, for clinical 
purposes we are more interested in how to treat high blood pressure and what the causal 
effect is of this treatment than we are interested in the causal effect of blood pressure itself. 
The prescription of anti-hypertensive medication can be easily randomized and blinded. 
However, not all exposures in the field of nephrology are easily randomized – such as 
conservative treatment versus renal replacement therapy – or blinded – such as starting 
dialysis versus not starting dialysis. A correctly performed observational study is often a good 
alternative to answer such questions. Furthermore, observational studies are very suitable for 
answering unintended effects, such as side effect of certain therapies.
40
 
Figure 1: Causal diagrams, structure of confounding and selection bias 
E
CC
A   Confounding
O
E
B   Selection bias
O CE
 
CC: common cause, E: exposure, O: outcome, CE: common effect, 
square: conditioned on this variable. 
Selection of patients 
Patients with CKD often die of (cardiovascular) complications before reaching pre-dialysis care 
or ESRD.
41
 Therefore, patients who reach the start of pre-dialysis care are a selection of 
survivors. By conditioning on the start of pre-dialysis care, independent indications to start 
are then artificially associated with each other. In our study for example, low health-related 
quality of life and the presence of hypertension are independent indications to start pre-
dialysis care. If a physician refers a patient with low blood pressure to an outpatient clinic for 
specialized pre-dialysis care, the chance that this patient has a low health-related quality of 
life – another indication for referral – will be greater. We indeed found this association in the 
PREPARE-2 study (data not shown in thesis), which could be explained by this form of 
selection bias
42
, sometimes called index-event bias. Conditioning on a common effect of 
exposure and outcome is often encountered in scientific literature (chapter 11) and the 
causal structure of this selection bias is represented in Figure 1B. We cannot account for this 
problem in our statistical analyses, but we have to keep this in mind when interpreting 
results. However, many of the chapters in this thesis did not investigate an association 
between two indications for referral. Only the results in chapter 7 – investigating the 
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association of hemoglobin levels with health-related quality of life on each time point during 
pre-dialysis care – could be biased because of conditioning on the start of pre-dialysis care. 
Patients treated for anemia towards a high hemoglobin level may be referred to pre-dialysis 
care because they have a low health-related quality of life. However, if this type of bias plays 
a role, than our results are an underestimate of the real association.  
Missing data 
Missing data are a problem that we encountered in every chapter of this thesis. This problem 
is often encountered in observational studies – cohort or randomized – with routinely 
collected data. In chapters 2-4, 8 and 9, factors at baseline – start of pre-dialysis care – were 
associated with renal function (decline) and/or time until the start of RRT. In these studies, 
the exposure – blood pressure, proteinuria, race, and longevity – and/or potential 
confounders we want to adjust for were missing in some individuals.  When performing a 
complete case analysis, patients with missing data on either the exposure or a confounder are 
excluded from the analysis. This leads to loss of power due to a smaller sample size and 
selection bias can occur. Results can be biased if for example the reason of data being missing 
depends on the prognosis of the patient (i.e. missing data type missing at random). In 
chapters 5-7, factors during pre-dialysis care were associated with renal function (decline), 
time until the start of RRT, and/or health-related quality of life. A method for dealing with 
missing follow-up data is the method of last observation carried forward. This method can 
only be used with repeated measurements because it replaces a missing value of a patient 
with the last measurement before that time point. However, biased results can occur because 
the assumption is being made that factors stay constant over time. Especially during pre-
dialysis care, this is an assumption that is clinically not very plausible. Therefore, both 
standard methods for dealing with missing data, complete case analysis and last observation 
carried forward, are not preferred for the analyses in this thesis. 
In this thesis, the method of multiple imputation is used, in which missing values for an 
individual are predicted based on known data for that individual.
43;44
 Chapter 10 describes the 
theory behind this method and when to apply. In short, strata are being made based on all 
variables (baseline and/or follow-up measurements) included in the imputation model. Each 
individual patient can be categorized into one of these strata based on their patient 
characteristics. The mean value – of the variable you want to impute – in that stratum is than 
imputed. Prediction uncertainty is taken into account by adding a random error component 
and by repeating the imputation procedure several times. We believe that this method results 
in an imputed value that lies closest to the true value. However, it is important to keep in 
mind that unknown and unmeasured variables that can predict the missing value very well, 
cannot be included in the imputation model. Furthermore, the prediction variables included 
in the imputation model cannot have too much missing values themselves.  
In chapters 2-4, 8 and 9 all patients with available baseline data on the exposure were 
included in the analyses. We chose the method of multiple imputation to impute missing 
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baseline confounders because patients with missing confounder data had somewhat different 
baseline characteristics compared with patients with all data available. Besides loss of power 
due to a smaller sample size, a complete case analysis would have led to selection bias in this 
case. Only in chapter 4 the exposure, proteinuria, was missing in a considerable number of 
patients (~20%). Furthermore, the patients with missing data on proteinuria had somewhat 
different baseline characteristics compared with the patients with available data. Therefore, 
we performed a sensitivity analysis in which proteinuria was additionally imputed to check 
whether the results of our primary analysis were biased. The analyses presented in chapters 
5-7 have missing baseline and follow-up measurements. For dealing with these missing 
follow-up measurements we used a linear mixed model.
45
 Patients with at least one available 
exposure and outcome measurement during pre-dialysis care can be included in such a linear 
mixed model, leading to the exclusion of patients with no data available (varying from 20% to 
30% of the total population). Missing baseline confounders were again imputed with multiple 
imputation to maintain power and avoid selection bias after adjustment. The main reason for 
not including all patients in the imputation model and thereby not imputing missing baseline 
and follow-up measurements in these patients is as follows. Including all patients and/or all 
follow-up measurements would have resulted in prediction variables with too many missing 
values themselves. It is known that an imputation model does not perform well in such cases. 
However, if the exclusion of patients leads to selection bias, the not optimal performing 
imputation model may be preferred. Fortunately, baseline characteristics were very similar 
between patients with and without at least one exposure and outcome measurement, which 
excludes the possibility of selection bias. Therefore, excluding patients with no available 
exposure and outcome data and applying linear mixed models to account for the remaining 
missing data is in our opinion the preferred method. 
Objective versus subjective outcome measures 
In this thesis we aimed to find factors that influence the disease progression of patients on 
specialized pre-dialysis care. But how can we define disease progression in these patients? 
The most objective manner agreed upon to define progression is by assessing decline in renal 
function (eGFR) in each individual patient. Renal function is important for defining CKD stages 
3-5
10
 and is used as a parameter in the decision when to start with dialysis
16
. So, the decline of 
this parameter reflects progression quite well. But how can we measure renal function? The 
gold standard for measuring renal function is based on injecting a substance in the blood 
stream which is freely filtered by the glomerulus and neither secreted nor reabsorbed by the 




. After injection, renal function (in ml/min) is 
determined by measuring the substance concentration in blood and urine at certain time 
points. Unfortunately, this is an invasive, time-consuming, and expensive procedure. 
Therefore, several formulas have been developed to estimate renal function based on serum 




, and Cockcroft Gault formula
50
. These 
formulas experience much inter-variability within and intra-variability between populations
51-
53
, for example between age categories and CKD stages. This variability may be explained by 
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the fact that all formulas are based on serum creatinine levels, a waste product of muscles. 
Serum creatinine levels are not only influenced by the filtration capacity of the kidneys but 
also by muscle mass, which varies with age, weight, and sex.
54
 For example, it is known that 
patients experiencing cachexia break down their muscles leading to higher serum creatinine 
levels and thereby a lower estimated renal function than in reality. In contrast, patients who 
are underweight because of malnutrition will have a low muscle mass, leading to lower serum 
creatinine levels and thereby a higher estimated renal function than in reality. Moreover, 
creatinine levels only start rising when a substantial loss of renal function has taken place. 
Therefore, the formulas will experience more bias in patients with lower creatinine levels.
55
 
Efforts are made for developing formulas based on other markers of renal function, such as 
Cystatin-C. However, formulas based on this marker experience similar biases as creatinine-
based formulas.
52
 So, the estimation of renal function with formulas is perhaps not as 
objective as we think. 
Another outcome used in this thesis is the start of RRT. This outcome is more subjective than 
the outcome renal function decline. Besides renal function, other factors – such as co-
morbidities or other clinical parameters (e.g. hyperkalemia, fluid overload), physicians’ or 
patients’ preference, patients’ physical or mental status – influence the decision when to start 
RRT.
56
 The actual time until the start of RRT is therefore very subjective to variation. Imagine 
two patients with a similar renal function at the start of pre-dialysis care (20 ml/min/1.73 m
2
), 
a similar time until the start of RRT (1 year), but a different renal function when starting RRT 
(10 versus 5 ml/min/1.73 m
2
). With regard to the outcome RRT, disease progression is similar, 
namely one year. However, in the patient with a renal function of 10 ml/min/1.73 m
2
 at the 
start of RRT, renal function decline is slower (10 versus 15 ml/min/1.73 m
2
/year). The decision 
to start at a higher renal function is probably based on other reasons, such as those 
mentioned before. However, time until the start of RRT is clinically very important because 
the goal of specialized pre-dialysis care is to postpone the start. According to known factors 
that accelerate RRT initiation
56
, postponement of the start of RRT can be achieved either by 
the application of therapies that slow down the rate of renal function decline, by regulating 
clinical parameters/complications, or by improving patients’ physical and mental status. For 
clinical purposes and guideline development, the outcome start of RRT is therefore just as 
objective as the outcome renal function decline. Research focusing on disease progression 
should therefore investigate both outcome measures if possible. 
Disease-related symptoms and health-related quality of life, both physical and mental, are 
outcome measures rarely published in the field of nephrology. These outcomes are often 
classified as subjectively assessed measures and therefore of less value. However, it may well 
reflect the disease or health status of an individual. Several studies showed that health-
related quality of life deteriorates with decreasing renal function.
29-31
 Furthermore, it is well 
established that health-related quality of life at the start of dialysis influences survival, 
independently of other important risk factors.
57-59
 Dialysis patients with a low physical 
(analyzed categorical, <20 points versus >50, and continuously, per each 10 point increase) 
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health-related quality of life score experienced respectively a 48% and 22% higher rate of 
dying. For mental health-related quality of life (analyzed categorical, <30 points versus >50, 
and continuously, per each 10 points increase) these numbers were 97% and 22% 
respectively. This effect is also present in CKD patients who are not dialysis-dependent.
32
 
These studies show that the subjectively assessed health-related quality of life correlates well 
with objective outcomes. This correlation makes health-related quality of life an objective 
outcome measure as well. 
We believe that for clinical practice all outcome measures used in this thesis are important. 
During pre-dialysis care, patients should be treated according to guidelines to slow down 
decline in renal function, decrease symptoms, and improve health-related quality of life, 
thereby postponing the start of RRT. 
Elderly patients 
Over the last decades the prevalence and incidence of elderly patients (≥65 years) with CKD 
or ESRD have increased and these numbers will continue to increase over the coming years.
5
 
Due to this increasing elderly population, research in the field of healthy ageing becomes 
more important. Several studies in the field of geriatrics have shown that known risk factors 
for renal function decline – such as blood pressure, cholesterol, and body mass index – 
behave differently in the geriatric population.
60-62
 In the general population it is known that 
these risk factors increase the risk for mortality and accelerate renal function decline. 
However, in the geriatric population a protective effect has been found. It could be 
hypothesized that decreasing body weight, cholesterol, and blood pressure levels are 
indicators for a declining cardiovascular and cognitive health (e.g. declining nutritional status 
or increasing prevalence of congestive heart failure).  Such a different association may also be 
present in elderly CKD patients because the prevalence of malnutrition and congestive heart 
failure is high in this population. Nowadays, pre-dialysis treatment guidelines
16
 are based on 
studies performed throughout the entire range of age. Therefore, we advocate obtaining 
more evidence for this specific growing elderly population on pre-dialysis care. 
In our pre-dialysis cohort, a less pronounced negative association was found for high systolic 
and diastolic blood pressure with the start of RRT in elderly (≥65 years) compared with young 
(<65 years) patients (chapter 3). The association between high hemoglobin levels and 
improved health-related quality of life was also less pronounced in elderly (≥65 years) 
patients treated with anemia-medication (chapter 7). Furthermore, elderly (≥65 years) 
patients with low systolic and diastolic blood pressure experienced an earlier start of RRT 
(chapter 3), which is a complete opposite association as seen in young (<65 years) pre-dialysis 
patients. Therefore, our results indicate that some risk factors for renal function decline show 
a different association with disease progression in elderly (≥65 years) patients on pre-dialysis 
care. 
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Several methodological explanations for these contradictory associations in elderly patients 
on specialized pre-dialysis care can be postulated. First, it is a highly selected population of 
elderly patients with CKD. Only patients surviving until the start of pre-dialysis care were 
included.  Second, the presence of competing risks may lead to beneficial effects on the short-
term but negative effects, as seen in the general population, on the long-term.
63
 Third, 
reverse causation can be an issue, meaning that just before the start of RRT, for example 
blood pressure decreases. In other words, low blood pressure may be a marker of the 
impending start of RRT. 
Of course, only based on our results we do not advocate discontinuing the prescription of 
anti-hypertensive medication or anemia-medication in elderly patients on pre-dialysis care. 
This recommendation cannot be made solely based on observational data. Future studies 
should proof whether the associations we found are indeed causal. For example, randomized 
controlled trials in the near future should specify in their study protocol that they want to test 
the intervention separate for young and elderly patients. Another option would be to pool all 
available trials on these medications in a meta-analysis and perform subgroup analyses by 
age. 
Risk factors for renal function decline not only behave differently in elderly patients, but also 
in dialysis-dependent patients. Opposite or absent associations as compared with the general 
population have been found for cholesterol and body mass index.
63;64
 It could therefore well 
be hypothesized that such an opposite or absent association is already present in patients on 
pre-dialysis care, who are in the transition phase from early CKD stages to being dialysis-
dependent. However, we found a faster renal function decline in patients with high levels of 
LDL cholesterol or triglycerides (chapter 5), which is comparable with the associations seen in 
the general population. 
Conclusions 
Chapters 2 and 3: Young (<65 years) patients on pre-dialysis care with low blood pressure 
levels experience a slower renal function decline and later start of RRT. Elderly (≥65 years) 
patients with a low blood pressure experience an earlier start of RRT, but a comparable renal 
function decline. 
Chapter 4: Proteinuria is an important dose-dependent risk marker for CKD progression, 
defined as a faster renal function decline and an earlier start of RRT, in patients on pre-dialysis 
care. 
Chapter 5: In patients on pre-dialysis care, high levels of LDL cholesterol and triglycerides are 
associated with a faster renal function decline, independent of the prescription of lipid-
lowering medication. 
Chapter 6: During pre-dialysis care the prevalence of disease-related symptoms increase and 
both physical and mental health-related quality of life decrease over time, with the sharpest 
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change during the last 6-12 months before starting dialysis. This is supported by the finding 
that patients who report a high number of symptoms and/or a low health-related quality of 
life experience a higher risk of starting dialysis within six months. 
Chapter 7: High hemoglobin levels (≥13 g/dl) in young patients (<65 years) treated with 
anemia-medication are associated with a higher physical and mental health-related quality of 
life. However, this association is absent in elderly (≥65 years) patients. 
Chapter 8: Black patients on pre-dialysis care experience a faster renal function decline and 
earlier start of RRT compared with white patients, which may be explained by the greater 
negative consequences of diabetes mellitus and proteinuria on the kidneys in black patients. 
Chapter 9: Middle-aged men with a propensity for longevity have a better renal function 
compared with men without such a propensity, especially in men with a history of 
hypertension or cardiovascular disease. A better biological handling of systemic inflammation 
and atherosclerosis in men from longevity families may be an explanation for this difference. 
Chapter 10: When data is missing at random, a correctly specified multiple imputation model 
is preferred over other conventional methods, such as complete case analysis, mean 
substitution, or last observation carried forward.  
Clinical implications and future research 
Chapters 2-4 showed that high baseline blood pressure levels (especially in young (<65 years) 
patients), proteinuria, and high lipid levels can be useful in predicting the disease progression 
of patients starting pre-dialysis care. Furthermore, these results indicate that timely referral 
and well-controlled blood pressure, proteinuria, and lipid levels at the start of pre-dialysis 
care are important. So, multidisciplinary guidelines and treatment in the phase before pre-
dialysis care is just as important. Unfortunately, patients with earlier stages of CKD are 
difficult to identify due to the absence of clinical symptoms
11
 and the lack of appropriate cost-
effective screening strategies
4;12
. Randomized controlled trials performed in the specific 
population of patients on pre-dialysis care are needed to proof whether the lowering of blood 
pressure, proteinuria, or lipid levels is causally related to a slower disease progression. 
The course of symptoms and health-related quality of life during pre-dialysis care is described 
in chapter 6. Currently, a large debate is ongoing about when to start with dialysis. Consensus 
has been reached that making this decision solely based on renal function is not optimal.
65
 In 
clinical practice, other measures, such as disease-related symptoms and health-related quality 
of life, are taken into account. However, these measures are not sufficiently incorporated into 
clinical guidelines because of the lack of knowledge how and when to use them. The results 
from this study showed that the increase of symptoms and decrease of both physical and 
mental health-related quality of life was mainly present during the last 6-12 months before 
starting dialysis. This implicates that these measures could be used in making the decision 
when to start. They are not useful when the course stays rather stable in the last phase of 
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pre-dialysis care. Furthermore, the number of symptoms and a low physical and mental 
health-related quality of life were associated with a higher risk of starting dialysis within six 
months. Unfortunately, no information was present regarding the exact reasons for starting 
dialysis in each individual patient. Therefore, we do not know whether the high number of 
symptoms and low score of health-related quality of life were markers of the underlying 
indications to start or the actual indications to start. Future research should focus on this 
relation and follow-up should be continued also after the start of dialysis. In this way, patients 
can be divided into different groups based on their indications to start; for example four 
groups based on combinations of high/low renal function and high/low functional status (i.e. 
symptoms and health-related quality of life). Thereafter, mortality rates during the complete 
period after referral to pre-dialysis care can be compared between these groups. With this 
extended follow-up data other clinical factors during pre-dialysis care can also be related to 
clinical outcomes on dialysis. Such a study, the European QUALity Study on when to start 
dialysis (EQUAL Study)
47
, has been designed and started. The results from the EQUAL study 
may be used to develop a risk score indicating when to start dialysis for the guidance of 
nephrologists in this difficult decision. 
The results from chapter 7 implicate that young anemic pre-dialysis patients treated towards 
higher hemoglobin levels (≥13 g/dl) experience a better health-related quality of life 
compared with patients treated towards optimal hemoglobin levels (11-12 g/dl). Anemia 
guidelines were changed in 2007, indicating that the optimal hemoglobin target level is 11-12 
g/dl and that targeting high hemoglobin levels (≥13 g/dl) should be avoided.
66
 This 
amendment has been made because several trials showed an increased risk of mortality and 
morbidities when targeting high hemoglobin levels.
67
 These guidelines are applied to all CKD 
patients, irrespective of age. Our results implicate that these guidelines may indeed be 
optimal for elderly patients (≥65 years) but need to be adapted for young patients. In clinical 
practice, a well-considered decision should be made for the best hemoglobin treatment 
target in each individual patient. This decision should be made by nephrologists together with 
the patient and should be based on the balance of negative effects – poorer survival – and 
positive effects – better health-related quality of life – for that individual patient. It could well 
be that the risk of mortality and morbidities is lower in young patients (<65 years), which 
would even more advocate targeting high hemoglobin levels in this population. Therefore, 
future randomized controlled trials investigating the causal effect of targeting high 
hemoglobin levels in pre-dialysis patients should make subgroups by age and should focus on 
the balance of negative and positive effects. 
Unraveling (un)known biological mechanisms determining renal function decline or time until 
the start of RRT is important for a better understanding of CKD progression. Additional studies 
are necessary to investigate whether the finding in chapter 3 is causal or whether low blood 
pressure is a marker for complications/mechanisms (e.g. congestive heart failure) that are 
indications to start RRT. For example, by measuring proBNP, a marker of congestive heart 
failure, this can be further elucidated. Furthermore, the underlying mechanism explaining the 
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faster renal function decline in blacks compared with whites (chapter 8) and the lower 
susceptibility to risk factors that accelerate renal function decline in men with a propensity for 
longevity (chapter 9) should also be explored. In both studies we could not find the exact 
underlying mechanism, but additional information on this may reveal new treatment targets.  
We believe that future research should invest more effort in defining subgroups for which 
certain interventions are most beneficial. Age is an easy and important factor on which these 
subgroups could be defined. This individualized care is important because the population of 
patients on pre-dialysis care is very heterogeneous. Furthermore, not all focus should be on 
performing interventional randomized controlled trials to optimize treatment guidelines for 
pre-dialysis patients. Research to explore (un)known biological mechanisms that determine a 
faster renal function decline or an earlier start of RRT may unravel new targets for treatment. 
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Het aantal patiënten met chronische nierinsufficiëntie is de afgelopen jaren sterk 
toegenomen en verwacht wordt dat dit aantal zal blijven stijgen. Redenen voor deze toename 
zijn de vergrijzing en het vaker voorkomen van de belangrijke risicofactoren hypertensie en 
diabetes door met name veranderingen in onze leefstijl. Chronische nierinsufficiëntie wordt 
gedefinieerd als progressief verlies van de nierfunctie. Als de nieren hun functie hebben 
verloren zullen patiënten moeten starten met dialyse of een niertransplantatie moeten 
ondergaan. Om de start van deze nierfunctie vervangende therapieën zo lang mogelijk uit te 
stellen, maar ook om patiënten voor te bereiden op deze naderende start zijn pre-dialyse 
poliklinieken ingericht. Patiënten met een sterk verminderde nierfunctie en een progressief 
verlies worden verwezen naar deze poliklinieken. Door een multidisciplinair team van artsen, 
verpleegkundigen, diëtisten en maatschappelijk werkers wordt zorg verleend aan deze 
specifieke groep. 
Meer dan 1000 patiënten die starten met gespecialiseerde pre-dialyse zorg zijn geïncludeerd 
in de ‘PRE-dialysis PAtient REcord’, PREPARE, studie en van deze patiënten is informatie 
verzameld tot aan de start van nierfunctie vervangende therapie. De PREPARE studie bestaat 
uit twee cohorten: PREPARE-1 (547 patiënten, inclusie 1999-2001, informatie terug gezocht in 
medische dossiers) en PREPARE-2 (502 patiënten, inclusie 2004-2011, patiënten gevolgd over 
de tijd). Tijdens het gehele pre-dialyse traject zijn van deze patiënten klinische en 
demografische gegevens, maar ook labwaarden en kwaliteit van leven scores verzameld. Deze 
gegevens zijn gebruikt voor bijna alle onderzoeken beschreven in dit proefschrift. 
Uit dit onderzoek is gebleken dat pre-dialyse patiënten met bloeddruk, lipiden waarden in 
bloed en eiwit waarden in urine, die voldoen aan de huidige behandeldoelen een langzamere 
nierfunctie achteruitgang hebben dan patiënten waarbij deze waarden niet voldoen aan de 
behandeldoelen. Echter, in contrast met deze bevindingen starten oudere pre-dialyse 
patiënten (65 jaar of ouder) met een lage bloeddruk juist eerder met nierfunctie vervangende 
therapie. Misschien is deze lage bloeddruk een marker van een ziekteproces dat nierfunctie 
achteruitgang niet versnelt maar wel een indicatie is om te starten met nierfunctie 
vervangende therapie (bijvoorbeeld hartfalen). Bovenstaande resultaten impliceren dat het 
verlagen van bloeddruk, lipiden waarden in bloed en eiwit waarden in urine (bijvoorbeeld 
door middel van medicatie en/of specifieke dieetvoorschriften) voor en tijdens pre-dialyse 
zorg belangrijk is om de ziekteprogressie te vertragen. Verder onderzoek is nodig om uit te 
zoeken of het tegenstrijdige resultaat gevonden in ouderen causaal is. Met andere woorden, 
leidt een lage bloeddruk in ouderen tot een eerdere start van dialyse of wordt de eerdere 
start verklaard door een onderliggend ziekteproces? 
Verder kwam uit dit onderzoek naar voren dat tijdens pre-dialyse zorg de kwaliteit van leven 
van deze patiënten afneemt, zowel fysiek als mentaal, en dat de aanwezigheid van 
ziektegerelateerde klachten toeneemt. De sterkste verandering vindt plaats tijdens de laatste 
zes maanden van pre-dialyse zorg en is geassocieerd met een eerdere start van dialyse. Beide 
determinanten kunnen dus mede gebruikt worden om het juiste moment voor de start van 
dialyse te definiëren. Ook is aangetoond dat hemoglobine waarden in bloed sterk 
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geassocieerd zijn met de kwaliteit van leven. Bij patiënten jonger dan 65 jaar met 
bloedarmoede die behandeld worden met medicatie werd een associatie gevonden tussen 
hoge hemoglobine waarden en een betere kwaliteit van leven. Bij oudere patiënten (65 jaar 
of ouder) werd deze associatie niet gevonden. In de klinische praktijk is het daarom belangrijk 
om leeftijd mee te nemen bij de keuze tussen het nastreven van een normale of hoge 
hemoglobine waarde. Voor deze keuze moet bij ieder individu de negatieve effecten  
– verhoogde kans op overlijden en ziekte – en positieve effecten – verbeterde kwaliteit van 
leven – van het verhogen van hemoglobine waarden worden afgewogen. 
De verschillende analyses in dit proefschrift ondersteunen of kunnen bijdragen aan het 
aanscherpen/aanpassen van de huidige behandelrichtlijnen voor patiënten op pre-dialyse 
zorg. In de toekomst is het bijna onvermijdelijk om in analyses en richtlijnen geen onderscheid 
te maken tussen oude en jonge patiënten. Dit omdat verscheidene analyses hebben 
aangetoond dat een aantal risicofactoren niet hetzelfde effect hebben in deze groepen. Het 
streven zou dan ook moeten zijn om in de toekomst meer naar de geïndividualiseerde zorg 
toe te gaan omdat de pre-dialyse populatie erg heterogeen is. Verder zullen er meer 
gerandomiseerde onderzoeken uitgevoerd moeten worden om huidige behandelstrategieën 
te onderbouwen en waar nodig te veranderen. Daarnaast moet er ook meer focus komen te 
liggen op het exploreren van (on)bekende biologische processen om zo nieuwe 
behandelstrategieën te ontdekken. Hier is al een begin voor gemaakt in twee onderzoeken in 
dit proefschrift. Zo hebben we mogelijke aanwijzingen gevonden voor biologische 
mechanismen die kunnen verklaren waarom de nierfunctie achteruitgang sneller is in 
negroïde versus kaukasische patiënten en waarom de nierfunctie hoger is in langlevende 
versus niet langlevende families. Er kan geconcludeerd worden dat voor het verbeteren van 
de zorg voor pre-dialyse patiënten nog veel onderzoek moet worden verricht, waaraan dit 
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jullie ook altijd om afleiding te zoeken in sporten en gezellige uitjes, waarvoor bedankt. Ad en 
Hans, grote broers, bedankt voor jullie interesse en alle gezelligheid. Ook veel dank aan mijn 
lieve vriendinnetjes, Leonie en Anieke. Wat was het fijn om tijdens het genot van een wijntje 
en hapje mijn promotietraject te bespreken. Maar natuurlijk ook over hele andere dingen dan 
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